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In almost all instances of adult angiogenesis, the growth of new vessels is associated with 
inflammation. An inflammatory infiltrate composed mainly of monocytes and 
neutrophils precedes or accompanies angiogenesis. Once inside the wound environment· 
monocytes migrate through the temporary scaffold provided by the fibrin clot, and 
differentiate into macrophages. In this study the interaction between peripheral blood 
monocytes and two angiogenic growth factors was investigated. 
Angiopoietin-2 (Ang-2) is a growth factor originally identified as playing a critical role in 
vessel remodeling during angiogenesis. It was recently shown to be a component of the 
endothelial cell Weibel-Palade bodies, suggesting involvement in vascular homeostatic 
responses such as coagulation and inflammation, which are central to wound healing. 
Platelet-derived growth factor-BB (PDGF-BB) is a member of the pleiotrophic family of 
PDGFs, and is a known component of the a.-granules of platelets. Both these growth 
factors are therefore temporally and spatially co-expressed during the formation of the 
fibrin clot, and the arrival of the monocyte infiltrate. 
In this study we show that the co-administration of Ang-2 and PDGF-BB to peripheral 
blood monocytes in, vitro causes a significant upregulation in monocyte fibrin clot 
invasion through fibrinolysis~ This, heightened invasion was dependent on both serine 
proteases and matrix metalloproteinases (MMPs) , and the combination of Ang-2 and 
PDGF-BB upregulated urokinase plasminogen-activator receptor (uPAR) expression, as 
well as MMP9 and membrane type 1 MMP (MT1-MMP). 
No expression of the Ang-2 receptor, Tie-2, was seen on the peripheral blood monocytes 
under experimental conditions. Instead, Ang-2 was seen to signal to the cells through the 
leukocyte-specific integrin tho Furthermore, the occupancy of integrin ~2 with Ang-2 was 
seen to increase the integrin's association with uPAR, while the inhibition of integrin ~2 
removed the Ang-2IPDGF-BB-dependent upregulation of MMP9 and MT1-MMP. 
PDGFR-fl was poorly expressed on untreated monocytes, however treatment with Ang-2 
(with or without PDGF-BB) significantly raised the expression of the receptor. This 
suggests that one of the ways in which Ang-2 and PDGF-BB interact is through the Ang-












The Ang-2IPDGF-BB-dependent upregulation of fibrin invasion was seen to extend to 
monocytes from different species, as determined by rat and baboon peripheral blood 
monocytes. This fibrin invasion, however, did not extend to other cell types, such as 
endothelial cells, smooth muscle cells and fibroblasts. This suggested that the 
association of Ang-2 to integrin ~2 is critical for the Ang-2IPDGF-BB action. 
Proteolytic events at the cell surface. such as cell migration, are of interest because of 
their potential to affect cellular functions immediately (Seiki 2002), and the finding of 
elements of the angiogenic cascade affecting monocyte fibrinolytic functioning is of 
importance. In this project the interaction between monocytes and members of the 
angiogenic cascade are studied in terms fibrinolytic potential. These data give further 
credence to the concept of Ang-2 as a key regulator of several essesntial phases of wound 
healing, as well as emphasizing the role of PDGF-BB in the process. It also provides an 
initial analysis of the manner in which Ang-2 and PDGF-BB act in a cooperative manner 
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1.1 Angiogenesis and Inflammation 
1.1.1 Angiogenesis and Wound Healing 
Angiogenesis is a key process in wound healing (Carmeliet 2000), during which blood vessels 
are formed through a highly controlled sequential process (Davis 2002; Mariotti 2006). The 
angiogenic process is also responsible for the successive remodeling of blood vessels formed 
during embryonic vasculogenesis, pruning vessels into the highly developed adult vascular 
system, and in the maintenance of the female reproductive cycle (Carmeliet 2000; Conway 
2001; Kampfer 2001). As angiogenesis plays a significant role in many pathological diseases, 
such as cancer, understanding and controlling the angiogenic process remains an area of 
intensive research (Carmeliet 2000). 
Initiation of angiogenesis scenarios is accompanied by hyper-permeability of the vasculature 
(Dvorak 1995), which leads to plasma exudation and deposition of plasma proteins (Hiraoka 
1998). Fibrinogen, a major component of plasma, polymerises in the presence of tissue factor 
(TF) and/or platelet degranulation, leading to formation of a fibrin clot (Hiraoka 1998). This 
establishment of haemostasis by the fibrin clot is vital for the progression of healing, and the 
clot is believed to further serve as a temporary matrix which supports the migration of cells 
involved in the formation of a new vessel sprout (Dvorak 1995; van Hinsbergh 2001). 
The angiogenic process is controlled by a number of different angiogenic and anti-angiogenic 
factors, and recent studies have already identified a number of key players in the angiogenic 
cycle, such as vascular endothelial growth factor (VEGF) - a critical driver in vessel 
remodeling, and mediator of initial vessel hyper-permeability (Davis 2002; Mariotti 2006). 
The complex array of factors necessary for effective angiogenesis are tightly regulated 
(Conway 2001), and are produced by a variety of different sources. While a number of 
angiogenic signals are produced by endothelial cells, many others come from cells in nearby 
tissues, such as keratinocytes, corneal fibroblasts, synovial fibroblasts, monocytes and 
macrophages (Jackson 1997). In addition, as cells migrate out of existing vessels, they 











factors normally sequestered in the matrix (Conway 2001). Some of the major classes of 
molecules involved in angiogenesis are detailed in the table below. 
Clus of Molecule Involved 
Growth Factors and Growth factor receptors 
Adhesion molecules of the integrin and cadherin families 
Extracellular matrix (ECM) proteins 
Remodeling and morphogenic molecules and their 
receptors 
Proteases 
Intracellular signaling molecules 
Transcription factors and regulators 
Examples" 
Vascular endothelial growth factor (VEGF) A, B, C, D 
and E and VEGF receptor (R) 1, 2 and S 
Fibroblast growth factors (FGFs) and FGFRs 
Platelet derived growth factors (PDGFs) and 
PDGFRs 
Fibronectin, collagens and lammms 
von Wille brands factor (vWF) 
Anpopoietms and Tie receptors, EpbJephrins 
MMP2, MMP9, plasminogen activators (uPA and tPA) 
and the inhibitors TlMPs and PAIs 
Protein kinases (Raf and mitogen" activated protein 
kinase (MAPK», proteinase kinase A, B. and GTPases 
such as Rac and Rho) 
Hypoxia inducible factor (HIF)-I-a, inhibitors of 
differentiation (Id1l3), nuclear factor (NF)-KB and 
homeobox gene products (HoxD3 and BS) 
Table 1. Summary of major classes of molecules involved in angiogenesis (adapted from (Ruegg 2004». 
In a system such as angiogenesis, where many factors contribute to each stage of the 
processes, VEG F (see table 1) maintains its position as the most potent of the growth factors 
involved in vascular formation, and is vital both in vasculogenesis and angiogenesis (Mariotti 
2006). The angiopoietins are thought to be among VEGF's most important partners, 
controlling the stability of the vasculature. Other growth factors, including members of the 
fibroblast growth factor (FGF) , the platelet derived growth factor (pDGF) and the 
transforming growth factor 13 (TFG (3) families also have important roles in modulating a 
number of different processes (Davis 2002; Mariotti 2006). 
Membrane-bound factors (see table 1) also play an important in angiogenesis, and integrins, 
cadherins and ephrins have all been shown to be involved in vessel regeneration. Integrins, 
in particular, as cell adhesion molecules, have emerged as critical mediators and regulators 











migration and positioning, and the induction of signaling events essential for cell survival, 
proliferation and differentiation (Mariotti 2006). 
The factors and compounds detailed in Table 1 differ not only in cell specificity, but also in 
the mechanisms by which they induce the growth of new blood vessels. Furthermore, many 
of the factors are pleiotropic, and are involved in a number of different processes specific to 
. certain cell types. The recent studies of angiogenic factors increasingly indicate that the 
simplistic model of an invading capillary sprout is not sufficient· to appreciate the whole 
spectrum of morphogenic events that are required to form a neovascular network (Augustin 
2001). Many molecules that orchestrate angiogenesis control a number of functionally and 
molecularly related processes which remain poorly understood, such as vessel assembly, 
vessel maturation and extracellular matrix: assembly and acquisition of vessel identity 
(Augustin 2001). Thus, it is becoming increasingly apparent that the angiogenic processes 
rely on both temporal and spatial coordination of the involved molecules in order to ensure 
successful vessel regeneration. 
1.1.2 .. Inflammation and Angiogenesis 
A recent study by Martin et al showed that tissue repair in immune-compromised mice (PU.1 
null) was not dependent on inflammatory cells (Martin 2003). These data are some of the 
flrst that challenges the proposal of angiogenesis and chronic inflammation as co-dependent 
processes, involving both augmentation of cellular inffitration and proliferation, and 
overlapping roles of regulatory growth factors and cytokines (Jackson 1997). 
While a question-mark hangs over the nature of the communication between the two 
processes, that damage to neonatal and adult tissues always incites an influx: of 
inflammatory cells cannot be avoided (Jackson 1997; Martin 2003; Lemieux: 2005). Indeed, 
post-natal angiogenesis has previously been associated with numerous inflammatory 
conditions, such as atherosclerosis, arthritis, retinopathy and tumour growth (Lemieux: 
2005), while during tissue repair, pathological remodeling or tumoral growth, an 
inflammatory inflltrate, composed mainly of neutrophils and monocytes precedes or 
accompanies angiogenesis (Jackson 1997; Croll 2004; Matias-Roman 2005; Moldovan 2005). 
These cells are recruited from the circulating blood in response to molecular changes in the 
surface of endothelial cells lining the capillaries at the wound site (Martin 1997). They 











enzymes which together contribute towards the regulation of angiogenesis (Loskutoff 2000; 
Lemieux 2005). 
Therefore, research into the role of inflammatory cells in angiogenesis - be they vital or not -
continues. The complexity of the possible involvement of immune and inflammatory cells in 
angiogenesis has led to research in number of different areas of influence. These include: i) 
influence between leukocytes and endothelial cells, ii) angiogenic molecule modulation of 
leukocyte functions, and iii) chemokine recruitmetlt of leukocytes and stimulation of 
endothelial cells. As leukocytes are also known to generate pro- and anti-angiogenic factors, 
their contribution towards angiogenesis, as dependent upon their temporal and spatial 
expression of these modulators, is also under investigation (Mariotti 2006). 
1.1.3 HaemQstasis and Tissue Repair 
Tissue repair is initiated by the re-establishment of haemostasis, the physiologic process 
whereby bleeding is halted (Martin 1997). Haemostasis begins with vasoconstriction, which 
minimizes vessel diameter and slows bleeding. During primary haemostasis platelets bind 
to collagen in the exposed walls of the damaged blood vessel to form a haemostatic plug 
within seconds after injury. Coagulation forms the second phase of haemostasis, and 
involves cellular and serine protease mechanisms. It is commonly divided into two different 
pathways: the intrinsic and extrinsic pathways. Both constitute of a series of zymogen 
activations which ultimately result in the activation of thrombin. This enzyme is known to 
convert fibrinogen into fibrin while also activating factor XIII, which crosslinks the fibrin 
into the fibrin clot at the site of injury. 
Secondary haemostasis also involves the degranulation of platelets (Gawaz 2005). In 
addition to establishing haemostasis, de granulating platelets also release a number of potent 
inflammatory and mitogenic substances into the local microenvironment (Martin 1997; 
Gawaz 2005), including PDGF-BB, TGF-(:J, and VEGF (Siegbahn 1990; Ernofsson 1996). 
These growth factors attract monocytes, endothelial cells and fibroblasts (Epstein 1999; 
Gawaz 2005), all of which utilize the fibrin clot as a provisional matrix for their migration 
into the wound (Epstein 1999). 
Platelet aggregation and degranulation are accompanied by endothelial activation 
(Matsushita 2004), a two stage process involving the rapid exocytosis of pre-formed Weibel-











subsequent slower synthesis and expression of adhesion molecules (Matsushita 2004). A 
number of different molecules involved in rapid vascular responses related to haemostasis 
Of 
and inflammation have been identified in Weibel-Palade bodies. These include von 
Willebrand's factor (vWF) , P-selectin, CD36, tissue-type plasminogen activator (tPA) , and 
interleukin 8 (Fiedler 2004; Matsushita 2004). Interestingly, Ang-2 has also recently been 
identified as a Weibel-Palade body molecule (discussed later in 1.4.2.2) (Fiedler 2004; Fiedler 
2006). 
Exocytosis of Weibel-Palade bodies causes rapid translocation of P-selectin from within 
granules to the endothelial surface, where P-selectin then interacts with P-selectin 
glycoprotein ligand-1 on the surface of leukocytes, triggering leukocyte rolling, the first step 
in leukocyte trafficking (Fiedler 2004). vWF, another Weibel-Palade protein, mediates 
platelet rolling along the endothelium, and binds to a number of cells and molecules involved 
in the coagulation cascade. Thus exocytosis of Weibel-Palade bodies is a critical early step in 
vascular inflammation and thrombosis (Matsushita 2004). 
Platelets are increasingly seen to represent an important linkage between inflammation, 
thrombosis and angiogenesis (Gawaz 2005), and indeed, have been shown to affect, and be 
affected by, all three processes. For example, platelets contribute to angiogenesis through 
the secretion of angiogenic factors on activation, yet the stimulation of endothelial cells with 
VEGF promotes adhesion and activation of platelets (Verheul 2000). Furthermore, the 
coagulation factor, thrombin, is required for platelet adhesion, but is also known to affect 
cytokine production or inflammatory cell apoptosis (Esmon 2001; Levi 2004). Other studies 
have demonstrated a variety of mechanisms by which coagulation, particularly the 
generation of thrombin, factor Xa, and the tissue factor-factor Vila complex, can augment 
acute inflammatory responses, many of which are due to the activation of one or more of the 
protease activated receptors, and that anti-coagulants can limit the inflammatory response 
in wound healing situation (Esmon 2001; Levi 2004). 
Clot formation and platelet degranulation during hemostasis are followed by the 
reorganization of intravascular clots by several cellular processes including the covering of 
the surface exposed to blood with monocytes, and the penetration of these cells into the clot 
(Moldovan 2003). Over following days, inflammatory cells, and then fibroblasts and 
capillaries invade the clot to form contractile granulation tissue that draws the wound's 











nitric oxide, VEGF and bFGF (Epstein 1999), revascularizing and regenerating the wound 
area. 
1.2 Fibrinolysis and Cell Invasive Behaviour 
During wound healing the fibrin matrix serves as a structural support for 
neovascularization. Its highly cross-linked structure, however, presents a major barrier to 
cell movement (Hiraoka 1998), and fibrinolysis is essential for ingressing cells to be able to 
penetrate the deposited fibrin. In addition to wound healing scenarios, the fibrinolytic 
system also plays a vital role in the removal of fibrin from the circulation, as well as in 
several other biological processes including ovulation, embryogenesis, intima proliferation, 
angiogenesis, tumorigenesis, and atherosclerosis (Lijnen 2002). 
Fibrinolysis occurs through two major groups of proteases: serine proteases and matrix 
metalloproteinases (M:MPs) (Lijnen 2002). While the serine protease plasminogen/plasmin 
pathway is generally assumed to be the dominant pathway, increasing evidence suggests 
that MMPs may play a more important role in fibrinolysis than previously anticipated 
(Ronfard 2001). Indeed, it is possible that MMP- versus plasmin-dependent fibrinolytic 
processes may be dictated by the repertoire of proteases available to the invading cell 
population (Hiraoka 1998). 
1.2.1 Fibrinolysis 
Figure 1. Schematic representation of 
plasminogenlplasmin and WP fibrinolytic 
systems. 
In the plasminogen/plasmin system the 
proenzyme, plasminogen, is converted to the 
active plasmin by tPA and uP A. Plasmin 
degrades fibrin and al!!O converts many pro-
MMPs into active MMPs. These in tum degrade 
the ECM and fibrin. Activation is al!!O regulated 
by positive feedback in which MMPs can activate 
pro·MMPs. Solid lines, :::: activation, dotted lines 











1.2.1.1 The PlasminQlenJPlasmin Cascade 
The main components of the plasminogen/plasmin cascade are detailed in the schematic 
diagram above (figure 1). It comprises of several serine proteases: a proenzyme, 
plasminogen, which is proteolytically converted to the active enzyme plasmin via the action 
of t-PA and urokinase-type plasminogen activator (uPA) (Lijnen 2002; van Hinsbergh 2006). 
Several inhibitors of the serpin superfamily (PAl-I, PAl-2, <l2-AP) regulate activation of 
plasminogen, activity of plasmin, and stepwise degradation of fibrin and other substrates 
(Dobrovolsky 2002). The fibrinolytic activity of the plasminogen/plasmin cascade depends on 
the activity of the enzyme plasmin. In addition to fibrin, however, this protease is known to 
have wide specificity and directly cleaves blood coagulation factors VNa and VIIINIIIa, some 
growth factors, MMPs and other extracellular matrix components. It can also catalyze the 
degradation of plasmin-resistant matrix proteins, such as natural collagens, through 
activation of inactive zymogens of collagenases (Ellis 1997; van Hinsbergh 2006). Thus, due 
to its multifarious substrates, the plasminogen/plasmin cascade is thought to play a 
dominant role in extracellular proteolysis throughout the body (parfyonova 2002). 
The precise timing and location of adequate extracellular proteolysis is provided by multiple 
mechanisms, among which the regulation of expression of plasminogen activators and 
inhibitors is especially important. A wide spectrum of hormones, growth factors, and cell 
environment factors are involved in the regulation of expression of the genes of plasminogen 
activators and of their inhibitors. The expression of uPA, for example, is activated by various 
inflammatory factors such as cytokines (Besser 1996), growth factors (Reid 1999), and 
tumour promoters (Stoppelli 1986). Conversely, anti-inflammatory agents, such as 
glucocorticoids have been seen to inhibit its expression (parfyonova 2002). The regulation 
usually occurs on the level of gene transcription, but can also occur on the level of translation 
and protein secretion. Once secreted by the cells, members of the cascade are able to enter 
circulation. Table 2 demonstrates the components of the plasminogen/plasmin system, and 











Component Molecular Mean Halt-life Fu.nction 
:ma8skDa plumaconc 
Plasminogen 90 0.2 mglml 50 hours Pro-enzyme 
tPA 70 5-10nglml 2-3min Plasminogen activator 
uPA 65,31 1 nglml 3-6min Plasminogen activator 
PAl-l 60 60nglml 5-7min Inhibitor of tPA and uP A 
PAl-2 70 < 5 nglml 5-7min Inhibitor of uP A and tPA 
Oll-antiplasmin 70 0.07 mglml 60 hours Plasmin inhibitor 
Table 2. Components of the nlasmjnogenlplgmin fibrinolytic system Adapted from (Collen 2001; Dobrovolsky 
2002). 
Although the activators tPA and uPA are products of two different genes, they have in 
common the same substrate, plasminogen, and two specific inhibitors: plasminogen activator 
inhibitors 1 and 2 (pAI·l and ·2) (parfyonova 2002). In their manner of expression, however, 
they have been seen to differ considerably, in that tPA is expressed in relatively few tissues 
or cell types, its primary source probably beilig the endothelium, while uP A is expressed by 
many cell types in a variety of tissues (Ellis 1997). tPA usually functions as a secreted 
enzyme, and is involved in general fibrinolysis needed to maintain vessel patency 
(parfyonova 2002). Although there have been reports of tPA binding to the cell surface of 
SMCs (Grobmyer 1993; Ellis 1997), uPA is usually considered to be the primary plasminogen 
activator involved in pericellular proteolysis due to its binding to the cell surface by a 
membrane-bound uPA receptor (uPAR) and the generation of cell-bound 
plasminogen/plasmin (Ellis 1997; Lijnen 2002{Ellis, 1997 #674). 
uPAR is a GPI·receptor, and lacks both cytoplasmic and transmembrane domains. This 
allows it a high degree of lateral mobility in the cell membrane - its location and therefore 
that of the urokinase bound to it are very mobile and closely associated with the functional 
state of the cell. Thus, in migrating cells, the uPAR is seen to cluster on the leading edge, 
focusing the proteolytic potential on the cell-substrate and cell-cell contact sites necessary for 
directed cell movement (Parfyonova 2002). uPA-uPAR is therefore thought to be mainly 
involved in cell migration (Collen 2001), suggesting that it is a key factor in physiological and 












In invading leukocytes, for example, a complex containing uPA, uPAR, and integrins has 
been recognized as vital for cell adhesion and invasion (Simon 1996; Pluskota 2003; Tarm 
2003; Pluskota 2004; van Hinsbergh 2006), and in vivo, uPAR·deficient mice show 
significantly reduced leukocyte recruitment to inflamed areas (prager 2004). An increase in 
functional uPA-uPAR has been detected at the cell surface of the leading edge of migrating 
leukocytes, allowing the substrate, plasminogen to be cell-associated, and focused on the 
leading edge of the migrating cell (Murphy 1999). The repetitive activation of the 
uPAlplasmin system at adhesion sites enables migrating leukocytes to tunnel through 
fibrinous matrices. This interaction can be on the cell surface, but also between uP AR and 
integrins on another cell, suggesting that the uPAR-integrin interaction facilitates cell-
matrix and even cell-cell interactions (Tarui 2003; van Hinsbergh 2006). Indeed, uPAR's 
ability to interact with proteins other than uPA has lead to the discovery of its role as a 
multifunctional receptor. uPAR has been observed to be involved in several different, yet 
often related biological events in addition to cell-associated proteolysis, such as cell adhesion, 
chemotaxis, cell migration, and proliferation (Montuori 2002). 
While the plasminogen/plasmin system is known to be an important fibrinolytic mechanism, 
the recent discoveries of the multifunctional nature of some of the elements of this system, 
such as plasmin and uPAR, suggest that the activation of the plasminogen/plasmin system 
cannot be seen simplistically in terms of fibrinolysis. In addition, fibrin-rich tissues in 
plasminogen-null animals are infiltrated efficiently by normal as well as neoplastic cell types 
despite significant defects in intravascular fibrinolysis (Hotary 2002). These observations 
suggest the presence of alternate proteolytic systems that would allow cells to infiltrate 
fibrin matrices via plasminogen-independent processes (Hotary 2002). 
1.2.1.2 Matrix MetaUoproteinases 
MMPs are a family of over 20 zinc-dependent endopeptidases involved in matrix degradation 
and remodeling (Johnson 1998; McCawley 2001). MMPs have a wide range of substrates, 
including matrix components such as cross-linked fibrin, collagen, gelatin, and elastin 
(Johnson 1998). They have been shown to regulate developmental growth as well as many 
remodeling processes, such as angiogenesis, arterial remodeling and fetal development, cell 
migration and invasion, and wound healing (Johnson 1998; McCawley 2001; van Hinsbergh 
2006). MMPs also play an important role in the cleavage and activation of various growth 











functioning is controlled by a delicate balance between the MMPs and natural tissue 
inhibitors of metalloproteases (TIMPs) and other MMP inhibitiors (Chang 2001; Baker 2002). 
All MMPs are synthesized as inactive zymogens (Van 1990) and activated in situ by 
enzymatic means. This activation occurs through the enzymatic breakage of the "cysteine 
switch", which opens the active site (Van 1990; Worley 2003; van Hinsbergh 2006). MMPs 
can be categorized depending on their position as active enzymes and can be classed as either 
soluble or membrane type MMPs (MT-MMP), While all soluble MMPs are secreted in the 
latent form and activated in the extracellular environment, MT·MMPs are activated 
intracellularly by furin-like enzymes and anchored to the plasma membrane (Cowell 1998; 
Lafleur 2001; Murphy 2002; van Hinsbergh 2006). 
All MMPs demonstrate very low activity in normal tissue (Shapiro 1998; van Hinsbergh 
2006), but are upregulated and/or activated during inflammation and physiological 
remodeling processes in response to specific stimuli, including cytokines, growth factors and 
extracellular matrix interactions (Murphy 1995; Johnson 1998). In these situations, MMPs 
are synthesised by endogenous connective tissue cells, as well as some types of 
haematopoietic cells (Murphy 1995). Indeed, recent investigations have demonstrated that 
the extracellular matrix can directly influence its remodeling and repair via regulation of the 
production of MMPs by resident inflammatory cells through enzyme- and substrate-specific 























































Pro·MMP9, gelatin, elastin 
Gelatin, elastin 
Pro·MMPl, Pro·MMP7, Pro-MMP8, Pro·MMP9, Pro· 
MMP13, aggrecan, matrix components (incl fibrin) 
Aggrecan, fibronectin 
Pro-MMP2, Pro-MMP13, Helical. collagen, matrix 
components (incl fibrin) 
Fibronectin, aggrecan 
Collagen m, gelatin, fibronectin 
Unknown 
Pro·MMP9, aggrecan, matrix components (incl 
fibrin) 




Table S. Detailing members of the MMP familv. Fibrin is degraded by MMP3, MMP7, MMP9, MMP12 and MTl·MMP. 
MMPs share significant sequence homology, and common multi-domain structure including a 
pro-peptide, a catalytic domain, a hinge and a haemopexin-like (PEX) domain (Johnson 1998; 
Seiki 2002). Some MMPs vary from this structure with additional insertions that 
presumably contribute to the functional difference between MMP types. As detailed in the 











substrate: collagenases, gelatinases, stromelysins. and membrane-type (Johnson 1998), 
however all MM:Ps are known to display overlapping but distinct substrate specificities and 
cell-specific expression (Shapiro 1998). Indeed, specific MM:P knockout in transgenic animals 
has not been observed to affect the viability, development, fertility or life-span of the 
homozygous animals - indicating enough overlap of function within the MM:P family to 
compensate for the loss of activity of a single member (Johnson 1998). 
As a family of enzymes, the MM:Ps have been implicated in the remodeling of the ECM and 
the penetration of both normal and tumour cells through tissue barriers. Due to the high 
level of redundancy, however, it has been noted that no definitive single mechanism can be 
ascribed to all situations (Murphy 1999). 
1.2.1.2.1 MTI-MMP and Other Fibrinolytic MM:Ps 
A fine-tuned spatio-temporal regulation of the proteolytic activity is required for focused 
degradation of the ECM during extravasation, and membrane-anchored MM:Ps especially 
suited for pericellular proteolysis (Matias-Roman 2005). Following intracellular activation 
by furin-like enzymes, MT1-MMP is presented as an active enzyme anchored on the cell 
surface (Collen 2003). This apparatus restricts the function of these MM:Ps to the cells that 
produce them and causes them to regulate cellular functions in the tissue directly (Seiki 
2002) - unlike most other MMPs, which, as secreted enzymes (Collen 2003), diffuse into the 
tissue cavity away from the producer cells. 
MTI-MMP displays a wide range of proteolytic activities, including degrading cross-linked 
fibrin, fibrillar collagen, laminin-1, laminin-5, aggrecan, fibronectin and vitronectin. It has 
been seen to be important in tumour angiogenesis, development, bone formation and matrix 
degradation (Murphy 1995; Hiraoka 1998; Collen 2003; van Hinsbergh 2006). It is also 
known as the activating mechanism for pro-MM:P2 (in the presence of TIMP-2) and pro-
MM:P13 (Cowell 1998; Lafleur 2001; Shankavaram 2001; Worley 2003). Furthermore, MTl-
MM:P processes cell adhesion molecules CD44 and pro-o.v integrin and tissue trans-
glutaminase (van Hinsbergh 2006). 
The membrane-bound proteolytic mechanisms of MTI-MM:P and uPA-uPAR have much in 
common, and the membrane-anchored MM:Ps, specifically MTI-MMP, have been shown to be 
required during endothelial tubulogenesis within a fibrin matrix (Lafleur 2002). Like uPA-











suggesting an interaction between MTI-MMP and the actin cytoskeleton (van Hinsbergh 
2006). Furthermore, VEGF-dependent activation of the uPAR-bound uPA activation was 
shown to be dependent on a change in integrin affinity as well as MT1·MMP·bound MMP2 
activity on endothelial cells (prager 2004). 
The recent generation of MTI-MMP-deleted mice has provided much insight into its 
functions (Homlbeck 1999; Zhou 2000). It is interesting to note from experiments done in 
these mice that an additional subset of membrane-anchored MMPs, including MT2-MMP 
and MT3-MMP but not MT4-MMP allow cells to transverse fibrin matrices independently of 
MTI-MMP (Hotary 2002). These findings suggest a triad of MT·MMPs whose expression, 
alone or in combination, is sufficient to confer fibrin-invasive activity. 
Other MMPs known to degrade fibrin inClude MMP3 and MMP7. MMP3 is also known as 
stromelysin-l, and its other substrates include fibronectin, laminin, collagens III, IV, IX, and 
X, and cartilage proteoglycans (Lijnen 2002). MMP7, also known as matrilysin, in addition 
to fibrin also degrades aggrecan, fibronectin, laminin, collagens III, IV, IX, and X, and 
cartilage proteoglycans. (Wilson 1997). Additionally, it has been shown that intestinal 
tumorigenesis is suppressed in mice lacking the metalloprotinase matrilysin (Wilson 1997). 
Both MMP3 and MMP7 are thought to be involved in wound repair, progression of 
atherosclerosis, and tumor initiation. Interestingly, both. MMPs are known to activate pro-
MMP9 (Lijnen 2002). 
1.2.1.2.2 Gelatinases 
A number of studies including gene deletions in mice have pointed to the essential role of 
MMP2 (gelatinase A) and MMP9 (gelatinase B) during the onset of angiogenesis in tumours 
and in development, bone formation and matrix degradation (Brooks 1998; ltoh 1998; 
Homlbeck 1999; Bergers 2000; van Hinsbergh 2006). They degrade a number of other 
proteins in the ECM, including gelatin and elastin. Although MMP2 and MMP9 were 
origninally thought not to have direct fibrinolytic potential (Bini 1999), recent investigations 
have contradicted this observation (Hiraoka 1998; Lelonght 2001). One study, for example 
(Lelonght 2001), showed that in MMP9-null mice anti-glomerular basement membrane 
nephritis was accelerated, as attested by the extent of the fibrin deposits. These data 











of these fibrin-induced glomerular lesions, through clearance or degradation of fibrin 
(Lelonght 2001). 
Gelatinases also affect the release of some non-matrix substrates, including cell· surface and 
matrix-bound growth regulators which they release from ECM-sequestered stores (Chang 
2001; van Hinsbergh 2006). Thus, the coordinated regulation of these MMPs and TIMPs has 
been seen to govern the cleavage and release of many important growth factors and cell 
surface receptors, such as TGF-f:3 activation by MMP2 and 9, as well as FGFR·1 by MMP2 
(Chang 2001). These findings further emphasise that during angiogenesis, MMPs can have 
both a pro-angiogenic role, by releasing matrix-bound pro-angiogenic factors, and also an 
anti-angiogenic role, by cleaving the ECM components into anti-angiogenic factors (Chang 
2001; Mott 2004). 
The switch from vascular quiescence to angiogenesis during carcinogenesis has recently been 
shown to involve MMP9-dependent release of VEGF-A from an extracellular reservoir 
(Bergers 2000; Mott 2004), suggesting that MMP9 is a component of the angiogenic switch 
(Bergers 2000). Notably, however, angiogenesis was observed to still occur when MMP9 was 
absent or functionally interfered with, which indicates that alternative regulatory 
mechanisms exist. Immunohistochemistry revealed that the MMP9 was expressed by a 
small number of cells in close apposition to the vasculature. These cells displayed features 
characteristic of infiltrating, inflammatory cells (Bergers 2000). 
Immune cells, specifically macrophages, recruited to sites of allergic inflammation were seen 
to express MMP9 (Corry 2004) in mice. In studies done with MMP2 and MMP9 knockout 
mice, the researchers showed that despite similar levels of characteristic allergic and 
obstructive features, knockout and double knockout mice showed significantly reduced cells 
in total bronchoalveolar lavage, specifically eosinophils and neutrophils (Corry 2004). Lack 
of either MMP2 or MMP9 therefore did affect inflammatory cell trafficking and egression 
into the airway (Corry 2004; Greenlee 2006). It is proposed that both MMP2 and MMP9 are 
broadly implicated in inflammation by the establishment of multiple transepithelial 
chemokine gradients (McQuibban 2000; Greenlee 2006). These observations correlated with 
results obtained in a study of lavage fluid and sputum from patients with asthma where 
MMP9 expression was increased in patients with severe asthma, and the expression 











The release of pro-MMP9 by monocyte cell lines (THP-l and U937 cells) into conditioned 
media increased under the action of recombinant single-chain urokinase. This effect occured 
on both transcription and translational levels, yet was not accompanied by proteolytic 
activation of MMP9 (Menshikov 2004). This coupling of MMP9 expression to an element of 
the plasminogen/plasmin pathway further suggests that MMP9 expression is linked to 
fibrinolytic cascade. 
The recent observations involving MMP9 have suggested that its function may be of 
significant importance in angiogenesis as well as aspects of inflammation, and may have 
effects over and above the degradation of specific substrates. 
1.2.1.3 MMPs and PlasminoleWPlasmin 
A complex interrelationship between the uPAIplasmin and the MMP systems is not only 
suggested by the fact that a number of MMPs (MMP1, 2, 3, and 9) depend on plasmin for 
their activation (van Hinsbergh 2006), but also by the fact that MMPs can control 
plasminogen activation by uPA-uPAR at the cell surface (Ugwu 1998; Collen 2003). This 
suggests that impairment of one protease system influences the activity of the other system. 
Indeed, it is thought that MMP versus plasmin-dependent fibrinolytic processes may be 
dictated by the repertoire of prot eases available to the invading cell population (Hiraoka 
1998). Increasingly, MMP activities are being shown to play crucial roles in proteolysis and 
cell migration. Endothelial cells at the leading edge of a new blood vessel concomitantly 
express components of both protease systems, and their expression is regulated by the same 
growth factors and cytokines (Collen 2003). 
Extracellular proteolysis by the plasminogen/plasmin system and MMPs are required for 
tissue injury in autoimmune and inflammatory diseases (Liu 2005). In a study of bullous 
pemphigoid (BP) , for example, the autoimmune disease which is characterized by dermal-
epidermal separation, Liu et al (Liu 2005) showed that the plasminogen cascade IS 
synergized with MMP9. Interestingly, mice deficient in MMP9 were resistant to 
experimental BP, while plasminogen-deficient, uPA-deficient. and tPA-deficient mice showed 
delayed onset BP. This suggests that, in this situation, the plasminogen/plasmin system is 
epistatic to MMP9 activation and BP onset. 
Using plasminogen-deficient mice, Hiraoka et al demonstrated that the plasminogen/plasmin 











MMP was essential (Hiraoka 1998). This, however, is not consistent in other cell types, as 
keratinocytes, smooth muscle cells, and inflammatory cells all display major defects in their 
ability to invade or degrade fibrin deposits in plasminogen-deficient states in vivo (Hiraoka 
1998). It would appear, thus, that different cell types rely variably on fibrinolytic 
mechanisms available. 
These, and many other excellent studies suggest that the plasminogen/plasmin cascade and 
the MMP family of proteases cannot be considered as entirely separate systems, and that a 
hitherto unrealized amount of interaction exists between the two. 
1.2.2 Intecrins and Cell Adhesion 
In addition to the vital role it plays in wound healing, cell migration also plays pivotal parts 
in a number of other biological events, including morphogenesis and tumour metastasis 
(Murphy 1999). The molecular mechanisms involved in effective cell migration include 
interactions between the cell and the ECM, cytoskeletal changes, cell signaling and gene 
regulation. Because of the wide range of processes involved, cell migration is therefore 
influenced not only by the cell type, but also by variables such as their origin, adhesion 
receptor function and environment, including the nature of the ECM (Murphy 1999). The 
complex response of cell migration requires the coordination and cooperation of multiple cell 
surface receptors, including sensory receptors that detect migratory stimuli, adhesion 
receptors that mediate interactions of migrating cells with the ECM, and protease receptors 
that facilitate movement of cells through their extracellular environment (pluskota 2003). 
As transmembrane glycoproteins, integrins can bind ECM components and trigger signal 
transduction cascades (Clark 2003). On the cell surface integrins ligands include growth 
factors and MMPs, while inside the cell integrin-triggered signal pathways integrate with 
those emanating from growth factor ligation. Integrins are heterodimeric cell surface 
adhesion receptors formed by two non-covalently associated subunits, a and ~ (Hynes 1992; 
Hynes 1999; Stupack 2002; Ruegg 2004), which mediate cell-cell and cell-matrix adhesion 
(Ahlen 2004). These subunits form a~ combinations with unique binding specificity and 
signaling properties (Demetriou 2004). Integrins connect extracellular matrix fibers with the 
actin cytoskeleton at focal adhesion sites, and integrate and govern interacellular signaling 
events (Ahlen 2004). They have been shown to recognize ECM proteins, such as fibronectin, 
laminins, collagens or vitronectin, and allow the cell to sense the ECM environment. 











migration and differentiation, as well as blood clotting and tissue organization (Ruegg 2003; 
Demetriou 2004; Ruegg 2004). 
Importantly, integrins are known to be promiscuous, and one integrin can bind to several 
different ligands, while, conversely, a number of different integrins can bind the same ligand 
(Ruegg 2004). Redundancy may be an advantage when the cellular response (such as 
survival or migration) in. a particular context is more important than the identity of the 
particular ECM protein eliciting the response (Hynes 1992; Ruegg 2004). This is important 
in situations such as wound healing or tissue remodeling, when resident and infiltrating cells 
have to rapidly react and adapt to changes in the composition of the ECM. As integrins have 
no intrinsic enzymatic activity, signal transduction depends on the recruitment of 
cytoplasmic structural and signaling proteins and the assembly of characteristic structures 
named focal contacts and focal adhesions (Ruegg 2004). Importantly, many of these 
signaling pathways that are activated by integrins are also known to be activated by growth 
factor receptors, and cross-talk between these two elements is believed to provide enhanced 
specificity and control over many different cellular events (Ruegg 2004). Integrins stimulate 
4 major pathways that are involved in angiogenesis: the mitogen activated protein kinase 
(MAPK) pathway, the phosphoinositide 3-kinase (PI-3-K)-PKB/Akt pathway, Rho family 
GTPases and NF'KB (Ruegg 2004). 
Both serine and metalloproteinases have been implicated in the complex integrated events 
underlying cell migration but no defInitive single mechanism has emerged (Murphy 1999). 
The molecular mechanisms behind the various cellular strategies employed are being 
analysed at all levels, from interactions between the cell and its extracellular matrix, 
cytoskeletal changes, cell signaling, and gene regulation. The efficient integration of these 
processes is a key determinant of different cell migration patterns and a major challenge to a 
rational understanding of events. 
1.3 Monocvtes and Macrophages 
1.3.1 Monocyte Morphology and General Characteristics 
Circulating monocytes are mononuclear phagocyte precursors to tissue-resident 
macrophages, as well as to other specialized cells, such as dendritic cells and osteoclasts 
(Satchura 1989; Shannon 2003; Gordon 2005). They are derived from multipotent stem cells 
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Increased in Activated Monocytes 
Size 
Phagocytosis for Cab & IgG-coated particles 
Secretion of gelatinases, collagenases, elastase 
and plasminogen activators (uPA I tPA) 
Prostaglandin release 
Rate of spreading 




02 radical release 
Decreased in Activated Monocytes 
Mannose-fucose receptor sites 
Leukotrieneproduction 
Plasmalemmal 5'nucleotidase 
Secretion of apolipoprotein E 
Table 4. Major alterations in the functipning pf activated monocvtes; Adapted from (Ross 2002). 
During activation, monocytes experience enhanced cellular metabolism, mobility, lysosomal 
enzyme activity and cytocidal capacity (Ross 2002). This is usually accompanied by 
increased elaboration of important products of mononuclear phagocytes, including lysosomal 
neutral proteases, acid hydrolases, complement components, enzyme inhibitors, binding 
proteins, interleukin (IL)-l, and factors promoting haematopoiesis. 
Recent cell surface phenotyping studies have suggested that distinct sub-populations of 
macrophages exist (Duffield 2005). Depending on expression of receptors, such as CD163, 
two forms of inflammatory macrophages have been proposed: the classically and the 
alternatively activated macrophage (Gordon 1999; Duffield 2005), although these 
classifications may still be a simplification of the in vivo functions of macrophages. 
Alternatively activated macrophages produce anti-inflammatory cytokines, including IL-lO 
and TGF-/:l. When cultured with myofibroblasts, alternatively activated macrophages 
promote complex matrix deposition. Classically activated inflammatory macrophages, on the 
other hand, play crucial roles in ,bringing about matrix destruction through the production of 
MMPs (Duffield 2003). This matrix degrading proteolytic activity is thought to allow cell-
killing monocyte/macrophages to migrate easily through matrix structures, where they are 
essential for the first phase of wound healing through the containment and clearance of 
debris. 
Monocytes are recruited to non-immune sites of inflammation following metabolic and other 











cell types to migrate into the fibrin clot (Henderson 2003; Moldovan 2005) - within the first 
two hours of inflammation - responding rapidly to signals produced in situ at the site of 
inflammation (Henderson 2003), such as thrombin (Bar-Shavit 1983). This recruitment in 
response to activating and chemotactic factors is thought to be a key event during the 
inflammatory response (Henderson 2003; Matias-Roman 2005). Interestingly, while the 
rapid recruitment of inflammatory monocyte migration is accompanied by neutrophil 
migration, these processes have been shown to be independent or each other (Henderson 
2003). 
Despite being known to release a number of agents that assist in the degradation of the 
matrix, and although in almost all instances of adult angiogenesis the growth of new vessels 
is associated with inflammation (Dvorak 1995), the precise role of monocyte/macrophages at 
the site of injury remains unclear due to conflicting experimental results (Duffield 2005). 
Some studies have shown monocyte depletion from the angiogenic environment resulting in 
impaired angiogenesis, suggesting interdependence between monocyte inflammation and 
angiogenesis (Leibovich 1975; Jackson 1997; Croll 2004; Moldovan 2005). Indeed, activated 
monocytes and/or macrophages alone were sufficient to induce angiogenesis in the avascular 
cornea, probably through the elaboration of growth factors and cytokines known to regulate 
angiogenesis (Jackson 1997). 
A study done with L-selectin and intercellular adhesion molecule-l (ICAM-1) knockout mice 
showed delayed wound healing manifested by decreased wound leukocyte 
(monocyte/macrophages and neutrophils) accumulation (Nagaoka 2000). L-selectin is 
constitutively expressed by most leukocytes and mediate leukocyte capture and rolling along 
the endothelium (Tedder 1995), while ICAM-l is expressed by ECs and is involved in 
leukocyte-endothelial cell adhesion (Dustin 1986). These results suggest that leukocyte 
infiltration into the wound is necessary for healing. Treatment of the wounds with PDGF 
normalized delayed wound healing in ICAM-l'/' mice, but not in L-selectinlICAM-l'/' mice. 
Other investigations, however, have recently raised the suggestion that the steroid 
treatment in some of the depletion studies may have knocked down more than just 
leukocytes at the wound site. Wound healing studies in the PU.l null mouse (Martin 2003), 
which is genetically incapable of raising the standard inflammatory response because it lacks 
macrophages and functioning neutrophils, have shown that these mice are capable of scar-
free wound repair in similar time to wild-type mice. These results suggest that the 











CDllb-DTR transgenic mice, in which macrophages could be selectively depleted, suggested 
that macrophage depletion during advanced liver fibrosis resulted in reduced scarring and 
fewer myofibroblasts. In contrast, monocyte depletion during recovery led to a failure of 
matrix degradation. This study suggested that distinct sub-populations of macrophages exist 
in the same tissue and play different roles in both injury and repair (Duffi~ld 2005). It is of 
importance however, that in these studies, despite the convincing wound healing data, it 
must be noted that the level of angiogenesis was not investigated under the experimental 
conditions. 
That the inflammatory macrophage is able to mediate the destruction of the matrix and 
mediate apoptosis, yet also possesses the ability to aid cell proliferation and secrete new 
matrix components, suggests that the role of monocyte/macrophages in wound healing is 
complex (Duffield 2003). The recent discovery of different sub-populations of inflammatory 
macrophages also suggests more diverse roles than previously suspected (Duffield 2003; 
Duffield 2005) 
1.3.2 Monocyte Fibrinolysis and Invasive Behaviour 
Despite the ambiguous role of monocytes in wound healing, during tissue repair, pathological 
remodeling or tumoural growth, an inflammatory infiltrate, composed mainly of 
monocytes/macrophages, precedes or accompanies angiogenesis (Moldovan 2005). Monocytes 
are recruited in response to many different stimuli. One of the major cytokines known to 
influence monocyte chemotaxis is VEGF (Croll 2004; Murdoch 2004). Monocyte chemotactic 
protein-1 (MCP-1), TGF-a. and TGF-~ are also known to modulate monocyte infiltration 
(Moldovan 2005). 
Upon extravasation from the vasculature, monocytes encounter the extracellular matrix, 
which leads them to adopt an angiogenic phenotype (White 2001; Levi 2004). In partiCUlar, 
fibronectin has been shown to be a potent inducer of angiogenic activity in monocyte 
(signaling via the integrin (IOP1). Accompanying endothelial transmigration, monocytes must 
traverse tissue barriers composed of distinct structural proteins (Moldovan 2003; Matias-
Roman 2005), and a provisional matrix of fibrin deposited during vascular injury. Therefore, 
invasion into the wound area necessitates that the ability to degrade the ECM is an essential 
requirement for monocyte transmigration, and requires the proteolytic action of specific 
enzymes (Matias-Roman 2005). The major fibrinolytic pathway involves the activation of 











Monocytes possess fibrin(ogen) receptors and migrate intravascularly to sites of fibrin 
deposition during the inflammatory response (Simon 1996). 
In plasminogen-deficient mice, however, plasmin-independent mechanisms may account for 
up to 33% of clot lysis (ploplis 1995; Simon 1996). These plasmin-independent fibrinolytic 
pathways in leukocytes also include both the extracellular release of fibrinolytic proteases 
(Simon 1996; Moldovan 2000) and the phagocytosis of fibrin (Loscalzo 1996; Simon 1996). 
MMP studies conducted by Moldovan et al (Moldovan 2000) have described 
monocytes/macrophages traveling through fibrin in a manner which they describe as 
''MMP12-dependent-tunnelling''. It has been suggested that these "tunnels" form pathways 
for endothelialization by later migrating endothelial cells (Moldovan 2000). Other MMP 
studies have shown monocytes to produce MMP1, MMP3, MMP9, MMP10, MT1-MMP, 
MMP19 and MMP25 (Bar-Or 2003), of which MMP3 and MT1-MMP are important 
fibrinolytic MMPs. Fibrin degradation has also been seen to occur by way of Ii proteolytic 
system within the macrophage lysosome that does not involve plasmin. This alternate 
pathway involves first the binding of fibrin(ogen) to the surface integrin IXvlh (CDllb/CD18) 
followed by internalization of the complex into the lysosome where the protease cathepsin D 
degrades the protein (Loscalzo 1996). Furthermore, in an interesting study, Ciano et al 
demonstrated that the occurrence of tunnels in fibrin gels was dependent on the density of 
the fibrin matrix, and monocytesimacrophages were able to push apart the fibrin strands in 
lax gels, thereby moving through the fibrin gel without fibrinolysis (Ciano 1986; Lanir 1988). 
1.3.2.1 Monocvtes and the PlasminoleniPlasmin System 
Fibrinolytic factors, in particular uPA and uPAR, may modulate the inflammatory response 
by their effect on inflammatory cell recruitment and migration (Levi 2004). uPAR is known 
to mediate leukocyte adhesion to the vascular wall or ECM components, and the expression 
of uPAR on leukocytes is strongly associated with their migratory and tissue-invasive 
potential (Blasi 1997). In migrating monocytes uPAR is expressed in the microenvironment 
of the leading edge, producing a "front" of proteolysis that facilitates degradation of fibrin 
thrombus or ECM, and the expression of uPAR on leukocytes is strongly associate with their 
migratory and tissue-invasive potential (Blasi 1997; Levi 2004; Murdoch 2004). Indeed, the 
recruitment of mononuclear cells to infarcted areas in patients with myocardial infarctions is 
connected with enhanced uPAR expression on the surface of these cells. The underlying 
mechanism by which uPAR and uPA affect cell migration may be related to ECM 











Human monocytes are also known to produce tPA, PAl-I, PAl-2 in addition to uPA and 
uPAR (Loscalzo 1996; Pierleoni 2003). 
Studies in knockout mice have also shown monocyte-expressed uPAR to exert protease-
independent properties, involving transmembrane signal transduction after interaction with 
proteins or receptors, which leads to cytokine and growth factor production (Blasi 2002; Levi 
2004). In those models, observations suggest that the function of uPAR in chemotaxis was 
independent from its interaction with uPA, and interference of uPAR binding to ligands or 
modulation of uPAR-dependent cell signaling were seen to affect leukocyte recruitment and 
invasion in inflamed tissue areas as a result of infarction (Levi 2004). The extensive 
involvement ofuPAR in signaling has lead to the suggestion that the type of ligand for uPAR 
determines gene expression by this receptor in monocytes (Rao 1995). 
uPAR is known to be a multifunctional protein capable of not only promoting peri-cellular 
proteolysis and matrix attachment, but also effecting cysteine- and MMP expression during 
macrophage differentiation (Rao 1995). Indeed, uPAR is thought to be one of the markers of 
monocyte activation (Pierleoni 2003). In addition, uPA not only promotes pericellular 
proteolysis, but can also directly influence the expression of cathepsin-B and MMP9 mRNA 
and protein during macrophage differentiation (Menshikov 2004). These results extend the 
cooperation seen among distinct classes of proteases at the macrophage cell surface to 
regulation of their gene expression (Rao 1995). 
1.S.2.2 Monocytes and MMPs 
In a 2003 study, Bar-Or et al utilized quantitative real time PCRto systematically analyse 
the expression of all 23 MMP members in subsets of leukocytes isolated from the blood of 
normal individuals. In monocytes MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-lO, MT1-
MMP, MMP-19 and MMP-25 were all significantly represented. Interestingly, MMP-2 and 
MTI-MMP were both upregulated in patients with multiple sclerosis, suggesting their 
involvement in monocyte transmigration (Bar-Or 2003). 
MT1-MMP is known to be involved in monocyte migration (Matias-Roman 2005) and has 
been observed to be regulated through the cell's interaction with fibronectin or the 
endothelium. MTI-MMP clustering was observed at motility-associated membrane 
protrusions of MCP-l-stimulated monocytes migrating. In addition, upregulation of MTl-











dependent on integrins 04~1 and U5PI. These observations suggest that MT1-MMP has a key 
role in monocyte recruitment during inflammation. 
It has been suggested that freshly isolated monocytes produce primarily serine proteinases, 
but become predominantly MMP-producing cells when cultured on plastic in the presence of 
serum in vitro (Lepidi 2001). Indeed, the up regulation of MMP9 expression is commonly 
taken as a marker associated with monocyte differentiation (Menshikov 2004). Furthermore, 
the analysis of the temporal pattern of MMP expression during the healing of skin wounds in 
the mouse showed that after an initial outburst of more common collagenases and of their 
inhibitors, the later stages of healing were characterized by macrophage-specific MMP 
(MMP-12) expression. It was observed that this expression was dominant when the cells 
were clustered around vascular structures (Anghelina 2002; Moldovan 2005). 
1.3.2.3 Mopocrtes and Iptelrins 
Integrins are surface receptors which interact with the cytoskeleton, and integrate the 
extracellular environment with the cell interior, while also able to induce functional changes 
in the .cell by activating intracellular biochemical signaling cascades (Reyes-Reyes 2002). 
They have been found to participate in many aspects of the inflammatory response, 
especially in cell migration, adherence and activation (Petty 2002). 
Members of the P2 integrin family are the dominating integrins expressed on leukocytes, 
known to play major roles in leukocyte cell-cell and cell-matrix adhesions during 
inflammation and other immune responses (nib 2000). One of the earliest events in P2 
signaling is the activation of non-receptor tyrosine kinases, which in turn trigger 
downstream activation of various signaling pathways that affect different functional 
responses of the cell. These non-receptor tyrosine kinases include the src family, Syk, focal 
adhesion kinase (FAK), and fakB, Rac and Rho (Eliceiri 2001). 
In addition to the ~2 integrin family, monocytes also express a number of other integrins, 
including the PI integrins (Arnaout 1990; Reyes-Reyes 2002). While P2 integrins mediate cell-
cell interactions that are important for migration through the endothelium, and also for 
phagocytosis, the PI family mediates adhesion to extracellular matrix proteins, which results 
in a strong induction of immediate early genes that are important in inflammation (Reyes-
Reyes 2002). Therefore it is evident that the PI and ~2 families of integrins regulate different 











the PI and P2 integrin families, while sometimes resulting in the same outcome, activate 
different signaling pathways (Reyes-Reyes 2002). For example. adhesion of human blood 
monocytes to ECM proteins as well as ligation of the Pl integrins with antibodies results in 
activation of the nuclear transcription factor NF-KB through PI-3K (Reyes-Reyes 2002), 
which is required for the transcription of inflammatory genes. P2 integrins, on the other 
hand, while also able to activate NF-l'CB, did not use the PI-3K pathway to do so (Reyes-Reyes 
2002). 
Interestingly, many of the signaling pathways and effectors which are activated by integrin 
ligation are also activated after growth factor stimulation (Eliceiri 2001). Growth factor-
induced cell proliferation, adhesion and migration in cultured cell models involving factors 
such as PDGF, bFGF, VEGF, and endothelial growth factor (EGF) often depends on specific 
integrins (Miyamoto 1996; Eliceiri 2001; Grundstrom 2003). In cooperation with aggregated, 
ligand-bound integrins, these growth factors produced a marked, transient activation of the 
extracellular signal-regulated kinase (ERK) class of MAP kinase (Miyamoto 1996). 
Interestingly, the growth factor receptors were induced to aggregate transiently by integrin 
ligand-coated beads in a process requiring both aggregation and occupancy of integrin 
receptors, but not necessarily the presence of growth factor ligands (Miyamoto 1996). Thus, 
the assembly of integrins and growth factor receptors into large signaling and cytoskeletal 
complexes, after matrix contact involving both integrin aggregation and occupancy, could 
explain the synergy observed when effectors and substrates are transiently concentrated 
together at a local site for greater mutual interaction (Miyamoto 1996). 
The plasma membrane receptors known to physically interact and functionally cooperate 
with integrins includes uPAR and PDGF receptor-~ (pDGFR-P)(Plopper; Sundberg 1996; 
Petty 2002), resulting in signaling pathways converging within focal adhesion complexes 
(plopper 1995). Multiple signaling molecules, including PI-3K, involved in both integrin and 
growth factor receptor signaling pathways became associated with the cytoskeletal 
framework of the focal adhesion complex after integrin ligand adhesion (plopper 1995). 
Tyrosine kinase receptors were also recruited to the focal adhesion complex, and tyrosine 
phosphorylation was enhanced (Plopper 1995; Reyes-Reyes 2002). Interestingly, recent 
investigations have also shown cell-surface association between MMPs and P2 integrins was 
seen to influence neutrophil migration and cancer progression (Stefanidakis 2006), 
suggesting that leukocyte motility is dependent on both P2 integrins and the gelatinases 











The P2 integrins (also known as the CDll/CD18 family) consists of three different receptors 
which all share a common P2 unit, while having different a units (Arnaout 1990; nib 2000). 
The family includes integrin aL~2 (CDllalCDI8), which is present on all leukocytes, integrin 
aMP2 (Mac-I, CDllb/CDI8) and integrin axP2 (CDllc/CD18), which are restricted to 
monocytes, macrophages, neutrophils and natural killer cells (Arnaout 1990). The 
expression of these integrins is dependent on the cell type and the state of cell activation and 
differentiation (Arnaout 1990). In resting monocytes, for example, the expression of aLP2 is 
roughly equivalent to that of aMP2, and both are greater than ax~2. Upon activation, the cell 
surface expression of these integrins increases from the translocation of intracellularly-
stored pools. 
The multivalent binding properties of the leukocyte integrin aMP2 allows this receptor, 
amongst other things, to regulate alternative pathways of fibrin degradation (Simon 1996). 
Indeed, as mentioned above, after activation integrin aMP2 is able to bind fibrin(ogen) (Altieri 
1986), which facilitates the internalization and degradation of fibrin via cathepsin D (Simon 
1993; Loscalzo 1996). Interestingly, the ligation of integrin aMp2 to fibrin also results in the 
release of neutrophil elastase, which has fibrin degrading properties (Weitz 1987). 
Furthermore, integrin aMp2 and uPAR have been shown to form a functional unit on 
monocyte cells (Simon 1996). Together they mediate complementary functions and promote 
the degradation of fibrin(ogen) and confer adhesive properties on the cells (Simon 1996; 
Sitrin 1996). In this situation, uPAR occupancy by uPA inhibits integrin aMp2-mediated 
fibrin degradation by monocytes. Thus, it has been suggested that where relatively large 
amounts of fibrinolytic activity could be expected, aMP2 function appears to be downregulated. 
Conversely, under conditions where little plasmin is being generated by uPAR, the receptor 
functions to promote aMP2 activity (Simon 1996). These results imply a functional coupling of 
aM~2 and uPAR, which operates to regulate the interaction between monocytic cells and the 
components of the fibrinolytic cascade. In addition, aM~2-mediated adhesion to fibrinogen is 
dependent on uPAR (Sitrin 1996; Zhang 2003), and adhesion is increased by occupancy of 
uPAR with uPA. Phosphorylation of FAK and MAPK was increased by the interaction of 
uPAR with aMP2. 
Direct phosphorylation of integrin cytoplasmic stalks can mediate platelet aggregation (Law 
1999). Human monocytes adhere to activated platelets, and form platelet-monocyte 
complexes (PMC) (da Costa Martins 2006), in an P-selectin- and P-selectin glycoprotein 
ligand-l (PSGL-l)-dependent manner. Monocytes within these PMC have increased 











2006) that the P-selectin-PSGL-1 interaction induced increased expression and activity of 
The formation of these PMC also increased monocyte 
transendothelial migration. These data suggested that by binding to platelets, monocytes 
displayed increased adhesion to the activated endothelium, and were in a higher state of 
activation (da Costa Martins 2006). 
1.4 Angiogenic Cvtokines 
Cytokines are soluble non-immunogloblin (glyco)proteins which are released by living cells, 
and act non-enzymatically in pico-molar to nano-molar concentrations to regulate host cell 
function. They make up the fourth major class of soluble intercellular signaling molecules, 
alongside neurotransmitters, endocrine hormones and autacoids (Nathan 1991). Cytokines 
play central roles in a number of different processes, including the (re)modeling of tissues, 
angiogenesis and inflammation. The two cytokines focused on in this study - Ang-2 and 
PDGF-BB are discussed in detail below. These two factors were chosen for their spatio-
temoral co-expression with monocytes during early wound healing. 
1.4.1 Platelet-Derived Growth Factor-BB (PDGF-BBl 
1.4.1.1 Overview of Functions 
Members of the PDGF family are a family of polypeptide growth factors that affect a number 
of cell types (Antoniades 1979; Hoyle 1999). They were originally characterized as the 
predominant mitogen in serum, (Antoniades 1979; Hoyle 1999; Hoch 2003), and have since 
been shown to drive cellular responses including proliferation, survival, migration and the 
deposition of ECM. and tissue remodeling factors (Schwartz 1990; Bornfeldt 1994). The 
severity of the various PDGF and PDGFR knockout mice phenotypes indicate pleiotrophic 
involvement in development, and it is only through the use of conditional gene ablation 
transgenics that some roles ofPDGF and PDGFR could be elucidated (Hoch 2003). 
The PDGF family is made up of four ligands: PDGF-A - D. and two tyrosine kinase receptors: 
PDGFR-a, and PDGFR-p. All PDGFs can function as secreted, disulfide-linked homodimers, 
while PDGFA and B can also form functional heterodimers (Siegbahn 1990; Hoch 2003). 
Upon ligand dimer binding, the receptors dimerize, activate, and initiate signal transduction 











One of the sources of serum-derived PDGF-BB are megakaryocytes, and PDGF-BB is stored 
(along with other PDGFs and other substances) in the a-granules of human platelets (Hoyle 
1999), and released upon degranulation (Hosgood 1993; Beer 2000). It is also produced by a 
number of cell types, including macrophages, epithelial, endothelial, mesenchymal, and 
neuronal cells (Hosgood 1993; Hoyle 1999) 
In order to maintain the ability to elicit pleiotrophic effects, expression of the PDGF family is 
tightly controlled. Although there are slight differences between the signaling molecules 
activated by the a and 13 receptors, major differences between the functions of the receptors 
derive from their expression patterns (Funa 2003). Cellular responses to PDGFs have also 
been seen to differ at distinct times or locations during development, and it is possible that 
other signals influence PDGF-mediated responses (Boch 2003). This suggests that not only 
the expression of PDGF receptors and ligands, but also the cell differentiation state of the 
cell and local signaling environment play factors in determining PDGF-mediated responses. 
As the PDGF family has also been seen to interact with other cytokines (Bornfeldt 1994), 
such as bFGF (Russo 2002), the growth factors present in the extracellular milieu contribute 
to the effect of PDGF on cells. 
1.4.1.2 PDGF-BBlPDGFR=§ and Accessory Factors 
Following receptor ligation by," PDGF·BB, the PDGFR-P dimerizes, undergoes 
autophosphorylation, and recruits a diverse set of at least 10 SH2 domain-containing 
proteins that then activate multiple downstream cascades which serve to control a number of 
different cellular functions (DeMali 1999; Lehti 2005). Independent of this action, PDGF-
BIPDGFR-~ effector function can be further modulated by interactions with accessory factors 
including growth factors and cell adhesion molecules (Schneller 1997; DeMali 1999; Lehti 
2005). 
The PDGF family is known to associate with a number of different integrins, which has lead 
to the suggestion that integrin-mediated signaling processes synergize with growth factor 
responses. Integrin av~3, for example, associates with activated insulin and PDGFR·13 and 
potentiates the biological activity of PDGF in fibroblasts (Schneller 1997). Also in fibroblasts, 
PDGF-BB has been shown to modulate membrane motility of ~l integrins (Ahlen 2004). 
In monocyte cell lines RhoA and integrin clustering were activated by GM·CSF, MCP·1 and 











mediated by the association. Treatment of VSMC with PDGF-BB significantly increased 
binding to human monocytic THP-l cells and to peripheral blood monocytes, and was 
inhibited by antibodies to monocyte Pi and P2 integrins (Cai 2004). This effect was shown to 
involve Src, PI-3-K, and MAPK. 
A number of studies have been conducted on PDGF-BB interaction with elements of the 
fibrinolytic cascades. For example, a study by Lehti et al using MTI-MMP-deficient mice 
determined that MTI-MMP is a PDGF-BB-selective regulator of PDGFRfJ dependent signal 
transduction and mural cell function. Catalytically active MTI-MMP associates with 
PDGFR-~ in membrane complexes that support the efficient induction of mitogenic signaling 
by PDGF-BB in an MMP inhibitor-sensitive fashion, facilitating chemotaxis and proliferation 
as well as ERK1I2 and Akt activation (Lahti 2005). Furthermore, it was observed that 
PDGF-BI PDGFR-fJ function can be further modulated by interactions with accessory factors 
ranging from non-PDGF peptide growth factors and sphingolipids in addition to the cell 
adhesion molecules (DeMali 1999; Lehti 2005). While fibrinolysis was not investigated in 
these studies, it is highly possible that PDGFR-fJ, associated as it is with MTI-MMP, would 
influence mural cell fibrinolysis. 
uPAR activation in VSMC by uPA induces its association, with PDGFR-fJ. The interaction 
results in PDGF-independent PDGFR-fJ activation and dimerization, and the mediation of 
uPA-induced downstream signaling relating to migration and proliferation (Kiyan 2005). 
Furthermore, PDGFand bFGF have also been shown to increase uPA expression in VSMC 
(padro 20(2), and uPA, in turn, mediates the mitogenic activity of the growth factors in a 
catalytic-do main-dependent manner. 
Interestingly, a correlation has been established between PDGF·BB expression and lung 
fibrosis in both human disease and in animal models (Hoyle~ 1999), Pdgfb transgenic 
overexpression in the lung gave rise to emphysema in adult mice, and these animals display 
thickened septa, enlarged saccules, severe inflammation and fibrosis. Knockout and 
transgenic studies showed that overexpression of PDGF·BB resulted in localized areas of 
fibrosis that exhibited increased cellularity and ECM deposition. The focal nature of the 
fibrosis, however, suggested that PDGF-BB overexpression by itself could not produce 












The pleiotrophic effects of the PDGF family, and the observations that PDGF and PDGFR 
influenced, and influence, the activity of varjous elements of the fibrinolytic system, suggest 
that PDGF may be more closely involved in fibrinolysis than previously thought. 
1.4.1.3 PDGF and Inflammation 
PDGFR-fl has previously been reported to be expressed on monocytes (Kumagai 2001), and 
chemotaxis studies in uitro have shown PDGF-BB to be chemotactic for monocytes (Siegbahn 
1990; Kohno 2004). Indeed, in transgenic mice overexpressing PDGF under the lung-specific 
surfactant protein·C promoter, inflammation composed mainly of monocyte/macrophages and 
eosinophils was always observed within or adjacent to fibrotic regions in the lung - an 
observation consistent with the findings from human intersititallung disease, and in other 
animal models (Hoyle 1999). 
PDGF-BB delivery into chronic non-healing wounds has been seen to exaggerate the 
inflammatory and proliferative/matrix deposition phases of repair (Pierce 2001). 
Additionally, PDGF-BB has also been seen to interact with other elements of the wound 
healing process. For example, PDGF-BB and MCP-l have been observed to induce TF 
expression in human peripheral blood monocytes (Ernofsson 1996), the initiator of the 
clotting cascade. This observation suggests a PDGF-BB-dependent link between 
haemostasis and inflammation. 
1.4.2 Angiopoietin-2 (Ang-2) 
1.4.2.1 AnI-2 and Angiolenesis 
Angiopoietin-2 (Ang-2) was first identified by Maisonpierre et al in 1997 using homology 
screening (Maisonpierre 1997). It is a growth factor belonging to the angiopoietin family 
(composed of Ang-1 to Ang-4), and is structurally related to Ang-l, with which it shares the 
tyrosine kinase receptor Tie-2 (Lemieux 2005). 
Tie-2 was initially thought to be an endothelial-specific receptor, however recent 
investigations have shown its presence on a variety of other cells (Koh 2002; Iurlaro 2003; 
Lemieux 2005). Tie-2 is unique among receptor tyrosine kinases in that its extracellular 
ligands, the angiopoietins, appear to have opposing actions on endothelial cells, despite 











ligand that induces phosphorylation of Tie-2 and promotes endothelial cell survival, vascular 
impermeability (Fiedler 2006) and integrity (Jones 2003). Ang-l is also known to play both 
anti-permeability and anti~inflammatory roles by decreasing both adhesion of leukocytes to 
the endothelium, as well as strengthening cell junctions through the localization of PECAM· 
1 (platelet-endothelial cell adhesion molecule-I) (Jones 2003). Ang-2, on the other hand, acts 
as a steric inhibitor of Ang-l's action on Tie-2 (Maisonpierre 1997). 
By binding to Tie-2, and blocking its Ang-l-mediated activation, Ang-2 causes the 
destabilization of the endothelium and vessel disruption (Kampfer 2001; Fiedler 2006). 
Through the mediation of the endothelium into a more plastic state, Ang-2 is believed to 
potentiate the actions of pro-angiogenic growth factors, such as VEGF and bFGF (Labov 
2002; Visconti 2002; White 2003). Indeed, exogenous Ang-2 has been shown to enhance 
VEGF-mediated corneal neo-vascularization (Labov 2002; Asahara 2003), while ectopic over-
expression of Ang-2 in cancer cell lines produced larger, more vascular tumours in mice. 
Ang-l is constitutively expressed at low levels in the quiescent adult vasculature (White 
2003). In contrast, Ang-2 appears to be expressed only at sites of active angiogenesis, such 
as the ovary, vascularized tumours and sites of injury (Maisonpierre 1997; Kampfer 2001). 
While matrix-associated Ang-l is thought to act in a paracrine agonistic manner, Ang-2 
appears to primarily act in a diffuse, autocrine antagonist regulatory manner to control 
endothelial cell quiescence and responsiveness (Fiedler 2004; Dallabrida 2005). In keeping 
with the observation that Ang-2 i  expressed only at sites of active angiogenesis 
(Maisonpierre 1997), a number of different angiogenic inducers are known to up regulate 
Ang-2 expression. These include hypoxia, cyclooxygenase-2 (COX-2), VEGF, bFGF, TNF-a, 
leptin, prostaglandins (PGEz and PGb) (Pichiule 2004), HIF-1a, the von Hippel-Lindau gene, 
angiotensin II, oestrogen, and HER2 (Koh 2002; Jones 2003). The diversity of these inducers 
seems to suggest that the upregulation of Ang-2 might be a common pathway by which 
different angiogenic inducers act (Koh 2002; Cai 2003). 
Transgenic studies have shown the essential role of Ang-l in vascular (re)modeling (Jones 
2003), and Ang-1-null mice die at embryonic day 12.5 showing defects in their vasculature. 
Studies using Ang-2-knockout mice, however, show that loss of the gene and function is 
compatible with life (Gale 2002). Ang-2-deficient mice are born relatively normal with only 
minor abnormalities in the vascular system, which do not affect function. Interestingly, 
however, in some strains of Ang-2-deficient mice (129/J), newborn pups die at l4d from 











vessels and kidney cortical peritubular capillaries (Jones 2003; Fiedler 2006). In contrast, 
mice transgenically overexpressing Ang-2 have an embryonic lethal phenotype, which is 
similar to both Ang-1- and Tie-2-deficient phenotypes (Sato 1995; Suri 1996; Maisonpierre 
1997). 
Studies with transgenic mice do however suggest that Ang-2 functions cannot be limited to 
an Ang-l antagonist, and Ang-2 has been observed to act as a Tie-2 agonist in postnatal 
remodeling events. In vivo studies using either the rabbit corneal pocket assay (Asahara 
2003) or the murine papillary membrane (Lobov 2002) also show that Ang-2 can act as a pro-
angiogenic factor. This suggests that the function of Ang-2 may be more dependent on the 
context in which it is found than has previously been understood. Furthermore, in vitro 
research has shown Ang-2 to be able to activate Tie-2, stimulate EC migration, and stimulate 
EC capillary-like tube formation in vitro (Mandriota 1998; Teichert-Kuliszewska 2001; 
Lemieux 2005). It has also been seen to stimulate migration and tube-like structure 
formation of murine brain capillary endothelial cells through c-Fes and c-Fyn (Mochizuki 
2002). 
When acting in the absence of VEGF. however, Ang-2 has been shown to stimulate apoptosis 
and vascular regression in capillary endothelial cells (Lobov 2002) - in contrast to its 
migratory and proliferatory roles in the presence of VEGF (Mandriota 1998). Furthermore, 
the inhibition of Ang-2 by nuclease-resistant RNA aptamers in rat corneal angigogenesis 
inhibited bFGF-mediated neo-vascularization, indicating that specific inhibitors of Ang-2 can 
act as anti-angiogenic agents (White 2003). 
It is therefore possible that Ang-2, as an autocrine-acting antagonist, acts in a context-
dependent manner as either an agonist or antagonist of Tie-2 signaling, and is dependent on 
the presence of pro-angiogenic activity (Fiedler 2004). In keeping with this observation, the 
angiopoietins have been associated with a number of different diseases, including vascular 
malformation, diabetes, pulmonary hypertension, arthritis, psoriasis, infertility and 
tumours. 
These seemingly contradictory results strongly suggest that Ang-1 and Ang-2 are context-
dependent modulators of angiogenesis and highlight the importance of targeting these 
factors in an appropriate spatial and temporal context (Iurlaro 2003; White 2003), in which 
the concentration, the duration of treatment and the accompanying factors together 











1.4.2.2 Ang-2 as a Homeostatic Contributor 
The opposing effects of Ang-l and Ang-2 support a model of constitutive Ang-1frie-2 
interactions controlling vascular homeostasis as a default pathway, and Ang-2 acting as a 
dynamically regulated antagonizing cytokine (Fiedler 2004). This model is supported by the 
recent identification of Ang-2 as a component of Weibel-Palade bodies, co-localized with vWF 
(Fiedler 2004; Fiedler 2006). As mentioned previously, Weibel-Palade bodies are found in 
endothelial cells, and play a dual role in blood coagulation haemostasis and inflammation. 
The two major constituents of Weibel-Palade bodies are vWF, a multimeric protein involved 
in blood coagulation, and P-selectin, which binds passing leukocytes to the endothelium and 
subsequently facilitates transmigration across the endothelium. While Ang-2 and P-selectin 
storage in Weibel-Palade bodies was mutually exclusive (Fiedler 2004; Fiedler 2006), vWF 
was required for the trafficking of Ang-2 into the Weibel-Palade bodies (Fiedler 2004). 
Through the storage of these, and other, biologically active constituents, Weibel-Palade 
bodies provide a dynamic storage compartment whose contents can be regulated depending 
on the presence of inflammatory mediators in the vascular micro-environment (Rondaij 
2006). The release of Weibel-Palade bodies is tightly regulated, and feedback mechanisms 
have been identified that prevent excessive release of bioactive components from this sub-
cellular organelle (Rondaij 2006). 
The few number of molecules identified in Weibel-Palade bodies, and the fact that they are 
all involved in controlling rapid vascular responses related to coagulation and inflammation 
(Fiedler 2004) suggests that Ang-2 also has important roles in these processes. As vascular 
morphogenetic programmes are primarily considered slow, transcriptionally-driven 
processes, the identification of Ang-2 as a stored, rapidly available molecule of endothelial 
cells therefore puts Ang-2 conceptually in a totally different biological context to its earlier 
roles, and raises a number of critical questions for the functional consequences of Weibel-
Palade body-stored Ang-2 (Fiedler 2004; Fiedler 2006). 
Experiments with endothelial cells showed that intracellular pools of Ang-2 can recover 
rapidly upon challenge, and that stored Ang-2 has a long half-life of more than 18 hours, and 
can be secreted within minutes of stimulation by PMA (phorbol-12 myristate l3-acetate), 
thrombin and histamine (Fiedler 2004). This identification of Ang-2 as a stored, rapidly 











system beyond the established roles during angiogenesis likely to be involved in rapid 
vascular homeostatic reactions such as inflammation and coagulation (Fiedler 2006). 
1.4.2.3 Ang-2 and Inflammation 
While Ang-1 has been reported to have anti-inflammatory properties, Ang-2 is thought to be 
pro-inflammatory (Fiedler 2004; Lemieux 2005; Roviezzo 2005; Fiedler 2006; Imhof 2006), 
and it has been proposed that it should be considered as an acute, pro~inflammatory 
mediator which may contribute to the initial steps of pathological angiogenesis (Lemieux 
2005). 
During inflammatory cell recruitment the entry of a pathogen induces the secretion of 
cytokines and chemokines, which activates neighbouring endothelial cells and attracts 
leukocytes. Leukocytes then move from blood to tissue by leukocyte r lling, activation, fIrm 
adhesion, and extravasation from the vasculature. This cascade occurs in a highly regulated 
manner, in which inflammatory cytokines such as TNF-a prompt upregulation of the 
adhesion molecules ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) on endothelial 
cells. These adhesion molecules interact with leukocyte integrins to promote leukocyte 
adhesion and extravasation. Thus the expression of ICAM-1and VCAM-l during the early 
inflammatory response calibrates the outcome of the local immune reaction (Imhof 2006). 
In a series of experiments, Fiedler et al showed that Ang-2 sensitizes endothelial cells to 
TNF-a and has a crucial role in the induction of inflammation (Fiedler 2006). Mice defIcient 
in Ang-2 could not elicit an inflammatory response to immune challenge, while recombinant 
Ang-2 restored the inflammation defect (Fiedler 2006). Cellular experiments show that Ang-
2 promotes adhesion of leukocytes to endothelial cells by sensitizing endothelial cells towards 
TNF-a and modulating TNF-a-induced expression of endothelial cell adhesion molecules 
ICAM-1 and VCAM-l. Together these fIndings identify Ang-2 as an autocrine regulator of 
endothelial cell inflammatory responses (Fiedler 2006). Ang-2 thereby acts as a switch of 
vascular responsiveness, exerting a permissive role for the activities of pro-inflammatory 
cytokines. 
As mentioned previously, Tie-2 was initially thought to be an endothelial cell-specifIc 
receptor, however, recent investigations have shown its expression on a number of different 
cell types including endothelial precursor cells (Sato 1998; Ikeda 2004). Furthermore Tie-2 











that the Tie-2 receptor is maintained during the commitment of the hematopoietic progenitor 
cells. Angiopoietins were seen to modulate pro-inflammatory activities such as neutrophil 
adhesion onto endothelial cells and neutrophil migration (Lemieux 2005; Sturn 2005), 
suggesting that the angiopoietins might be instrumental in promoting acute recruitment of 
neutrophils, thus contributing to the facilitation of vascular remodeling and angiogenesis 
(Lemieux 2005). 
Endothelial progenitor cells (De Palma 2005; Modarai 2005) are hematopoietic precursors 
which are proposed to potentially give rise to a number of different cell lineages, such as 
monocytes, endothelial cells and neutrophils (Schmeisser 2001). The identification of Tie-2 
on endothelial progenitor cells (Sato 1995; Sato 1998) has led to the proposal that the Tie-2 
receptor may be maintained by a number of cell types during differentiation. This includes 
the monocyte cell type, where current thinking is tending towards viewing monocytes as a 
collective term for a number of different sub-populations (including s me expressing Tie-2) 
(Venneri 2007). These observations suggest that Ang-2 may be more involved in the 
regulation of the inflammatory response than previously anticipated. 
1.4.2.4 Alternative Signaling pathways 
An increasing number of reports suggest that the angiopoietins are able to interact directly 
with cells in the absence of Tie-2. In vitro studies show that human umbilical vein 
endothelial'eells (HUVECs) adhere to both Ang-1 and Ang-2, as do fibroblasts, which do not 
express the Tie receptors, and show similar adhesion through integrin as (Carlson 2001). 
This suggests that angiopoietins can interact directly with members of the integrin family 
(Jones 2003). Similarly, cardiac and skeletal myocytes were seen to adhere to Ang-1 and 
Ang-2 via integrins (av, ae, pi, pa), and their survival promoted by the interaction (Dallabrida 
2005). 
Ang-2 is upregulated in most tumours, and the balance between the angiopoietins shifts 
towards Ang-2 (Tait 2004). This observation has lead to the proposal of Ang-2 as a major 
player in the angiogenic switch in tumourigenic situations (Tait 2004), and that the 
production of Ang-2 is implicated in tumour progression, and that the over-expression of 
Ang-2 by cancer cells leads to enhanced tumour angiogenesis and growth of murine colon and 
gastric tumours in mice (Hu 2003). Ang-2 was seen to be related to tumour angiogenesis in 
gastric carcinomas in the absence of Tie-2 expression, and MMP-1, MMP-9 and uPA were 











tumours in vivo (Etoh 2001). In human gliomas, Ang-2 was seen to induce the expression 
and activation of MMP2 (Hu 2003), and upreglliation of Ang-2, MMP2, and MT1-MMP were 
associated with glioma invasion both in vitro and in vivo (Guo 2005), with the glioma cells 
responding directly to Ang-2 stimulus in the absence of Tie-2 expression. These results were 
confirmed by clinical investigations, where Ang-2, MMP2, MTI-MMP and laminin5Y2 
correlated with invasiveness of human gliomas (Guo 2005). 
It is of importance to note that this responsiveness of glioma cells to Ang-2 occurs in the 
absence of detectable Tie-2 expression, through the integrin av~l and the FAK signaling 
pathway (Hu 2006). It was suggested that the highly conserved COOH-terminal fibrinogen-
like domain of the angiopoietins implies a functional association with the integrin receptor 
family, allowing Ang-2 to act as a potential substrate for the integrin receptor family in 
endothelial cells, fibroblasts and myocytes, as it not only enhances cell adhesion in both 
endothelial cells and Tie-2-deficient fibroblasts, but also triggers integrin-mediated 
intracellular signal transduction pathways in these cells. 
Studies such as those mentioned above have begun to elucidate the many roles of Ang-2 
aside from vessel destabilization and Tie-2 signaling. The ability of Ang-2 to bind directly to 
integrins on the cell surface suggests a wide range of alternative applications for this growth 
factor. 
1.5 Synopsis of Experimental Design 
In this study it was proposed that Ang-2 and PDGF-BB interact together with Ang-2 to 
upreglliate monocyte fibrinolysis. Both Ang-2 and PDGF-BB, by virtue of their release 
mechanisms (Weibel-Palade bodies and de granulating platelets) would be present during the 
very early stages of wound healing, As this early wound healing is accompanied or preceded 
by an inflammatory infiltrate, consisting in large part of monocytes, it seemed possible that 
the growth factors would have some effect on the cells. Following extravasation from the 
blood vessels, monocytes encounter a fibrin clot formed during hemostasis. It therefore 
seemed possible that Ang-2 and PDGF-BB, in their action on monocytes, might affect the 
regulation of fibrinolytic elements in the cells. 
Figure 3 is a basic flow diagram of the experimental design. All experiments utilized 
monocytes isolated from whole peripheral blood. Initial investigations into monocyte fibrin 











blood monocytes were seeded onto a fibrin clot suspended in medium. Cells were allowed to 
penetrate the clot, after which they were quantified, providing a correlative indication of the 
degree of fibrin invasion. This fibrin invasion assay was conducted under both serum and 
serum-free conditions, in the presence of both Ang-2 and PDGF·BB. Furthermore, it was 
repeated in the presence of broad-action inhibitors of fibrinolytic pathways. 
Fibrinolysis was directly quantified using fibrin(ogen) immunoblotting, after which the 
expression elements of both the plasmin(ogen) and the MMP fibrinolytic systems was 
investigated on both the RNA and protein levels. 
In order to determine the monocyte receptors through which Ang-2 and PDGF-BB were 
signaling, the expression of Tie-2 was investigated on both the RNA and protein level using 
flow cytometry. In the absence of signal, the expression of a number of integrins was 
examined on the monocytes under experimental conditions, and immunoprecipitation 
analyses of potential receptor complex was conducted. PDGFR·~ expression was analysed on 
both an RNA and protein level, by RT-PCR, enzyme-linked immunosorbent assay (ELISA) 
and immunohistochemical analyses. Using various inhibitors, the possible signal 
transduction pathways for these receptors were also examined. 
The effects of Ang-2 and PDGF-BB on fibrinolysis were also examined on other cen types 
known to be involved in wound healing, as well as on monocytes obtained from other species. 
Furthermore, the effect of Ang-2 and PDGF-BB on the proteolysis of other substrates was 
also investigated. 
Finany, attempts were made to translate these in vitro findings into a viable in vivo model. 
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Materials and Methods 
2.1 Development of an In Vitro Fibrin Invasion Assay 
2.1.1 Isolation of Human Peripheral Blood Monocyte, 
This protocol was modified from the procedure outlined by Biddison in the Current Protocols 
in Cell Biology (Biddison 1998). 
The blood donors used (as elaborated in 2.1.4) were healthy, non-smoking male adults under 
the age of 30, who had all abstained from any product containing aspirin for two weeks prior 
to the donation. The purpose of the research was fully explained to all potential donors, and 
donors were compensated for any inconvenience experienced. 
In all donations, a qualified medical practitioner was employed to draw blood from the , 
donors. 45 ml of blood was taken aseptically from the forearm of the donor, using a sterile 
SOml syringe pre-prepared with 5 ml O.lM trisodium citrate (BDH, Wadeville RSA, 
BBI02424L) (Balasubramanian 2002). The trisodium citrate prevents Ca2+-dependent 
activation of TF in whole blood, which leads to clotting. Once the blood had been drawn, all 
the following procedures were performed using sterile techniques in a Bio-Hazard Laminar 
Flow Hood. The blood was split between two 50ml tubes, and 25 ml room temperature 
phosphate buffered saline (PBS - see below) was added to each. 
10 ml ofHistopaque-1077 (Sigma, Steinheim, H8889) was pipetted into a 50 ml tube, and 20 
ml of the bloodlPBS mixture carefully layered on top using a 5 ml pipette. The layered blood 
was then spun at 2500 rpm for 20 minutes at 20°C with the centrifuge brake off. This spin 
separated the contents of the tubes into visible layers, containing (from bottom to top) red 
blood cells, Histopaque-1077, mononuclear cells and plasma respectively. In all tubes, the 
top layer of plasma was aspirated off, and the mononuclear cell layer above the Histopaque 
collected using a 1ml Gilson pipette. The mononuclear cell layers from three separate 
Histopaque gradients were combined in a single fresh 50 ml tube, and PBS added up to the 
50 ml mark. The tubes were then spun at 2200 rpm for 10 minutes at 20°C with the 











The resultant supernatant was discarded, and the pellet re-suspended in 50 ml of PBS. The 
tube was then spun at 1000 rpm for 15 minutes at 20"C. Once again the supernatant was 
discarded, and the pellet re-suspended in 50 ml of PBS. The tube was then spun at 1000 rpm 
for a further 15 minutes at 20"C. These washing steps removed the majority of platelets, 
which can cause cell clumping. 
The resultant supernatant was discarded, and the pellet re-suspended in 20 ml of serum-
containing RPMI-1640 (see below). This cell suspension was added to a 150 cm2 Corning cell 
culture flask (Corning Inc, NY) , which had been pre-coated with 5 I1g/ml human plasma 
fibronectin (Roche, Mannheim, 1051407) for an hour at 37 "C. The flask was then left 
undisturbed in the incubator (37"C, 5 % C02) for 3 hours to allow for cell adhesion. 
After incubation, the flask was rigorously washed twice with room temperature RPMI-1640 
to remove non-adherent cells. 20 ml of room temperature PBSE (PBS with 5 mM EDTA 
(Sigma, Steinheim, ED355» was then added to the adherent cells in the flask, and cell 
detachment monitored under a phase contrast microscope. Once the cells had detached, 20 
ml of 4"C serum-containing RPMI-1640 was added to the flask, and the entire suspension 
transferred to a 50 ml tube. 
The tube was spun at 1500 rpm for 10 minutes at 4°C. The resultant supernatant was 
discarded, and the cell pellet re-suspended in 1ml RPMI-1640. 20 III of this cell suspension 
was diluted 1 in 25 with PBS, and then 1 in 2 with 0.4% Trypan blue (Fluka AG, 
Switzerland, 158951-85). The resultant suspension was loaded onto a hemacytometer, and 












Serum-containing RPMI·1640 RPMI·1640 growth medium 
growth medium 2gll NaHCOs 
20 % human pooled serum 
1 % penicillin Istreptomycin 
pH 7.4, 
Supplier I Product no. 
Sigma, Steinheim, R·6504 
Sigma, Steinheim, S5761 
Group AB, 6 pooled unite, Western 
Province Blood Transfusion Service, 
CapeTown 
Highveld Biological ltd., Kelvin RSA, 
214 
~.22Ilm filtered using low protein binding Milipore, Bedfore, SCGVTOIRE 
bottle· top filter 
PBS 8 mM NaaHPO.o12H20 




Merk, Darmstadt, AC006579.500 
ACE, Reuven, P2040NN00500 
Saarchem,Krugersdorp,604202 
Sigma, Steinheim, S· 7653 
2.1.2 Analysis of Monocyte Isolation Purity Using Flow Cytometry 
The expression of the CD14 (BD, Franklin Lakes, 345 385) antibody on monocytes, was 
analysed as previously described (Herzenberg 2002) using direct immunofluorescent 
techniques. The monocytes were separated from peripheral blood using standard histopaque 
centrifugation (as detailed in 2.1.1) and resuspended in PBS with 0.5% bovine serum 
albumin (BSA, Sigma, Steinheim, A-4503). 
In order to prevent nonspecific binding of the antibody, equal volumes of the cells and AB 
serum were incubated, at room temperature for ten minutes, prior to the. addition of the 
antibody. Thereafter, 10 Ji1 phycoerythrin (pe)-conjugated CD14 (Becton Dickinson, 345-385) 
antibody was added. Pe-conjugated anti-IgG 1 (Becton Dickinson) was used as a negative 
isotypic control. The cells were incubated at room temperature for thirty minutes. After the 
cells were washed thoroughly three times with excess PBS, analysis took place on a FACS 
Calibur flow cytometer (Becton Dickinson). A minimum of 2000 cells was counted with 












All flow cytometric analyses were conducted with the assistance of Mrs Glenda Davison 
(Department of Haematology, UCT, Cape Town, South Africa) using flow cytometry 
machines belonging to the Department of Haematology. 
2.1.3 Analysis of Monocyte Isolations UsinK MorphololrY 
Monocytes were isolated as described in 2.1.1. After isolation, they were suspended in 
serum-containing RPMI-1640 growth medium, and seeded into 96 well plates (Corning, NY) 
at a concentration of 50000 cells per 100~. The cells were incubated at 37"C with 5% C02. 
Each day for 7 days, the wells were photographed using a 5x lens on a phase contrast 
microscope. Morphological changes in the cell population were monitored by an independent 
hematologist, Mrs Mona Bracher (CVRU, UCT, Cape Town). 
2.1.4 Standardization of Blood Donation Criteria. 
Initial experiments were conducted with male and female blood donors of varying ages, with 
blood taken at different times of day in order to test the experimental protocol. All reported 
experiments use healthy, non-smoking male donors of between 20 and 30 years of age, who 
completed a medical questionnaire on their lifestyles, allergies, vitamin supplements, and 
general health (and medication). All blood was drawn at 11am and processed within 5 
minutes of drawing. 
2.1.5 Cryopreserva.tion of Cells 
In order to cryopreserve cells, monocytes were isolated as described in 2.l.1, and cultured for 
24 hours in 75 cm2 tissue culture flasks in serum-containing RPMI-1640 at 37°C with 5 % 
C02. The cells were then washed twice with PBS, and lifted using cell dissociation solution 
(Sigma, Steinheim, C1419). 
The lifted cells were centrifuged at 1500 for 10 minutes and resuspended in 1 ml M199 cell 
culture medium (Gibco, 31100-027) with 10% fetal calf serum (Delta Bioproducts, RSA, 14-
501 AI). A 50 ~ aliquot was removed and added to an equal volume of Trypan Blue and 
viable cells counted with a haemocytometer. The cell concentration was then adjusted to 2 x 
106 cells per ml using M199 with 10% fetal calf serum (FCS. Delta Bioproducts, RSA, 14-











115% DMSO (Sigma, Steinheim, D-S779) was added to the cell suspension. This cell 
suspension was aliquoted into cryotubes (NUNC, Roskilde, 37541S) in a polystyrene 
container and placed at -SO°C overnight. The tubes were then transferred to a liquid 
nitrogen container (-196DC) where they were stored until use. 
2.1.6 Preparation of Fibrinogen 
Plasminogen-depleted human plasma fibrinogen (Fluka Biochemika 46313), 700 mg 120ml 
PBS was dialysed twice against 2 litres of PBS for 1.5 hours, and once against 1 litre Hepes 
buffered saline (HBS - see below). The dialysed fibrinogen solution was centrifuged at 
1000xg for 10 mins and flltered successively through O.S Jim, 0.45 Jim, and 0.22 Jim low 
protein binding Millipore fllters (Millipore SLGV025LS). Concentration was calculated by 
absorbance at A2so using an extinction coefficient of 1.55. 
Material P~eparation SupplierlProduct no. 
HBS buffer 10 roM HEPES Sigma, Stei.nheim, H·SS75 
140 roM NaCl 8igma, Steinheim, 8·7653 
5 mM CaCla ACE, Reuven, 7383 
Filtered with a 0.22 f!.m low protein binding 
filter Milipore, Bedford, SCGVT01RE 
2.1.7 Characterisation of Fibrin Gels Using Scanning Electron Microscopy 
Fibrin gels were cast in a 96 well Teflon well plate made for the purpose by Mr Bruno 
Orlandi. 2.5J.1l of bovine thrombin stock (2U/I0 J.1l. Sigma, Steinheim. T7513) was added to 
397.5 J.1l of HBS, and 28 Jil of this mixture was pipetted into each well with 7 Jil of purified 
human plasma fibrinogen stock (18.9 mg/ml, Fluka, Switzerland, 46313). Mter the fibrin 
had set, the gels were carefully removed from the wells, and fixed using 2% gluteraldehyde 
in PBS for 10 minutes, after which it was rinsed twice in PBS. The gels were then 
dehydrated by successive 10-minute incubations in deionized water, 50% ethanol, 70% 
ethanol, 80% ethanol, 90% ethanol and 100% ethanol. The dehydrated fibrin gel was then 
critical point dried (CPD) with liquid C02 using a Polaron CPD 7501 (Quorum Technologies, 
Newhaven, UK). Following CPD the samples were sputter coated with gold palladium using 
a Polaron SC7640 (Quorum Technologies, Newhaven, UK). 
These samples were viewed at 25 kV using a JSM 5200 scanning electron microscope (Jeol, 











software. All electron microscopy was conducted with the kind help of Ms Nazlia Samodien 
(CVRU, UCT, Cape Town). 
2.1.8 Analysis of Fibrin Gel Degradation 
While the fibrinogen prepared in 2.1.6 was plasminogen-depeleted, it was not possible to 
guarantee its complete absence. It was therefore decided that the experimental conditions 
should be assayed for background fibrin degradation. 
One of the major products of fibrin degradation are D-dimers (Bini 1996; Bini 1999). A D-
dimer ELISA produced by Technoclone (Technoclone, Vienna, 2599006) was utilized to 
provide a basic overview of the levels of fibrin degradation in both serum-containing and 
serum-free RPMI-1640. Fibrin gels were cast in a 96 well plate. 2.5 ~ of bovine thrombin 
stock (2U/1O ~l, Sigma, Steinheim, T7513) was added to 397.5 ~ of HBS, and 28 ",1 of this 
mixture was pipetted into each well with 7 ~l of purified human plasma fibrinogen stock 
(18.9 mg/mL, Flub, Switzerland, 46313). The solution was then thoroughly mixed, and left 
to polymerise for an hour at room temperature. 
To half the wells, serum-free RPMI·1640 (see below) was added, while to the other half 
serum-containing RPMI-1640. Monocytes isolated as described in 2.1.1 were seeded on top of 
the fibrin in half of the wells for each serum-type. The wells were incubated for 24 hours at 
37°C with 5 % C02 before the medium was drawn off. 
The ELISA was conducted according to the manufacturer's specification. Briefly, ELISA 
wells were thoroughly washed with washing buffer before the sample was added. Once 
added, the samples were incubated for 37°C for an hour. Following this, the samples were 
then aspirated off, and the wells washed again with three separate washes. The conjugation 
solution was then added and the wells incubated again for another hour at 37°C. The wells 
were then washed as before, and incubated with substrate solution for 10 minutes. The 
colour development was stopped using ·1M sulfuric acid, and measured using a microplate 














RPMl-1640 medium With 2g1l 
NaHCO. added. 
Filtered with 0.22 pm low protein binding filter 
0.1 % bovine serum albumim (BSA) 
1 % ITS liquid medium supplement 
pH 7.4 
Supplier IPrOduct no. 
Sigma, SteiDheim, R-6504 
Sigma, Steinheim 8-5761 
Milipore, Bedford, SCGVTOIRE 
Sigma, Steinheim, A·450B 
Sigma, Steinheim, 1·3146 
2.1.9 Tranlwell Fibrin InyalIDn Allay 
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of fibrin ipygWn UHY:IIMrimenttl 
dIIIim. Diagram adapted from 
Coming Transwell package insert. 
This assay was based on a model used in previous monocyte migration studies (Ciano 1986). 
It makes use of Transwells with a larger pore size (8 Ilm), with a fibrin layer added to the 
upper side of the microporous membrane. 
Upregulated invasion and fibrinolysis would shorten the time interval before which the cells 
would come into contact with the exposed microporous membrane. The increased pore size of 
these membranes ensures that movement of cells through the membrane would be relatively 
uninhibited. Increased invasion into the fibrin clot can therefore be directly quantified by. 
and reflected in, an increased number of cells in the lower compartment. 
The fibrin gel on the upper side of the microporous membrane was prepared in the following 
way. Bovine thrombin stock (2U/10 J.Il, Sigma, Steinheim, T7513) was diluted 1/160 in HBS 
buffer. 28 III of this mixture was pipetted onto the microporous membrane. Purified human 
plasma fibrinogen stock (18.9 mg/ml, Flun, Switzerland. 46313) was then carefully mixed 
into the thrombin mixture to form a resultant fibrinogen concentration of 3mg/ml. The 











The fibrin-coated membranes were seeded with monocytes isolated as described in 2.1.1. The 
cells were then incubated in serum-containing RPMI-1640 at 37"C with 5% C02 and the 
migration of the cells was estimated by monitoring the appearance of cells in the bottom well. 
After a 19-hour incubation, the cells in the lower compartments were fixed and analysed in 
the following manner. 
After the removal of the Transwell insert, cells in the lower compartment were fixed 
overnight at 4°C with 4% formaldehyde. The wells were then analysed using a phase 
contrast microscope with a 2.5x objective (Leica DM mBE, Solms, Germany). Once an image 
of the cells in the bottom well was captured using the Q-Win software associated with the 
microscope, the number of cells in the image was determined using the "count" function of 
the software. Both the number of cells, and the total area of the cells were noted for each 
well. The "edit" function of the software allowed the researcher to manually exclude cellular 
debris prior to the count. For each study, the contrast was set before the analysis, and not 
altered throughout the analysis. 
2.1.10 DAPI Analysis ofInvading Cells 
Cells present in the bottom compartment after incubation of the fibrin invasion assay (2.1.9) 
were subjected to a DAPI nuclear stain. Cells were washed twice with PBS, and DAPI 
(Promega, Madison, P5521) was added at a concentration of 1/10000 in PBS. The cells were 
incubated for an hour at room temperature, after which the stain was aspirated off, and the 
cells washed thoroughly three times with PBS. The DAPI stain was investigated using a 
fluorescent microscope (Olympus) using an absorbtion maximum of 358 nm and an emission 
maximum of 461 nm. 
2.2 Analysis of Monocyte Fibrin Invasion in Response to AnI-2 and 
PDGF-BB 
2.2.1 Serum-Containing Fibrin Invasion Assays 
The fibrin invasion assay described above (2.1.9) was modified by the addition of carrier-free 
Ang-2 (R&D Systems, Minneapolis, 623-AN-025/CF) to the serum-containing RPMI-1640 in 
the lower compartment. For the dilution curve, Ang-2 was added to triplicate wells at 











IW\l!_16.0 ,,,o .. ce,,", w"t ",~ 
'i/,IHXh,,,,,,] 
n lce'."c'] ~' I,h 0 .-' " ,<on lo~' P''''-' ''' hln"io" li lt" 
C', j)i " ,,';,,0 """ m , lbu"j,,, iIlSA) 
j)i J 1'S b.u,u, .... 'uw"' ,,, ,,,,kmc,,' 
pH H 
Suppli" J P",dud uo, 
Sl gm" Stehh""",, ~ 'IWI 
S,"", ", ~t"inn,I.,-, H_,\ )61 
,1ih,,"",,, &<1'",-,1 t',{'(lVTn ]](E 
~I"m ", ~t~i " h.i .,-" ,~_ ,,'''< 
~I gm" ~t" " h. 1 """ 1_" ,,; 
Thi" a&;ay wao based on " mo<lel u,"" ,1 m pr<',~ou, monoe)-' l" mig-ration , ludie , (Ciano 1%6), 
I, mah' '"e 0: Tran,well . with" borg..,. pon' ,i7." (H fLm), wi lh H Iilmn layer added to t he 
llppel' "ide u!'the IlnCrDporDUo membrane, 
Upre ~ulated inv",ion an d fib-,';noly,i , would ,horr,"Ll lh" tim . inle,,'al be1i,re wbicb th e cel!. 
would com,' into eonl""t wi,h the eXI~"ed microporD'" memhrane, The incN',,,,,d por~ , i7." or 
lhe", memb"aLle, en8W~. ,hat movement 0: cell , through t.h~ m~mh-" "n" would he relativ~ly 
lUunhibited, Increa sed Ulva ,i ,)n m \o tn(' fih rin clot can th ,'n,f", e he di"",;dy ql1anlijj~d by, 
a n~ rdlec"ed in, an incn'" ",~l nu mkr of "(' II, in th . lowe" c'()m~"dme nt, 
T h" fihrin g,,1 OLl ih,' upp"" ,de 0' th e mieroj)(JHJU' membrane wao pr~p"re,1 in t. h,' foll".""n g 
way &JVlne thrombin ,lock ClUll() I' L Sl ~lJla, Steinheim, T7.'ilR) wa._ dihlt~d I!lW ill IInS 
burfer. 28 ~I o:tbi, mixtu re wail plpHted ont<) I I", microporm" "",mbraLle_ PUl'i'ied buman 
rJl a,llw fibrinogen ,toc~ (18.~ mg.lml Flub , Swit.,,,riaLld, 4(i:llH) w,," ,hen carefully mix"d 
ln io lh~ 'hromhm mixt"l~ to :Ofm " r .. "I" ,nl fihrin"g~n cone"Ll Il'H li 'ln 0' :lL11Rlml. The 











the membrane in both the treated wells and the control wells can provide an indication as to 
the chemotactic properties of the growth factor. 
Transwell permeable support chambers with 5 Jim pores were purchased from Corning 
(Coming, NY, 3421). The upper compartment of each Transwell was seeded with monocytes 
(isolated as detailed in 2.1.1), at a concentration of 50 000 cells in 100 pI serum-containing 
RMPI-1640. 
500 ~ of serum-containing RPMI-1640 was placed in the lower compartment, to which Ang-2 
(R & D, Minneapolis, 623-AN-025/CF) or PDGF-BB (peproTech Inc, Rocky Hill, 100-14) was 
added at concentrations of 500 ng/ml or 20 ng/ml respectively. 
The cells were then incubated at 37°C with 5% C02 for 5 hours, as determined by the 
literature (Emofsson 1996). Mter incubation, the Transwell inserts were transferred to 
sterile 24 well plate into wells containing containing 4% formaldehyde (Merk, Darmstadt, 
AC004003.2.5), and incubated overnight at 4°C. The inserts were then incubated for 5 
minutes in Mayers haematoxylin (see below) washed for 5 minutes under running water, and 
then rinsed twice in 100 % ethanol (Merk, Darmstadt, AB000983.2.5). Before allowing the 
membrane to dry, the cells and excess fibrin on the upper side of the membrane were wiped 
ofi'using a cotton-wool bud soaked in PBS. 
Mter allowing the excess ethanol to evaporate from the membrane, each membrane was 
excised from the supporting upper compartment using a scalpel. The membranes were then 
mounted on micro slides (Marienfeld, Lauda-Koningshofen, 75x25mm), using aqueous 
mounting medium containing 15 mM NaNa (Dako, Glostrup, S3025). 
Each m~mbrane was analysed by the researcher as well as an independent observer on a 
light microscope (Olympus) in the following manner: 5 representative fields were chosen 
from the whole membrane at a magnification of 20x. The number of cells in each field were 















50g Potassium Alum 
0.2g Sodium Iodate 
Dissolve in lL distilled water using gentle 
heat 
Ig Citric Acid 
50g Chloral hydrate 
Add and dissolve well. Boil 5 mins Cool 
Supplier/product no. 
Merck, Darmstadt, 15938 
Saarchem, Krugersdorp, RSA, 
5823480 
Saarchem. Krugersdorp, RBA, 
1605020 
Saarchem, Krugersdorp, RSA, 
1591500 
filter with 0.22 J1ll1 low protein binding Milipore, Bedford, SCGVTOlRE 
filter 
2.2.3 Cell Proliferation ELISA 
In order to ensure that any alteration in cell numbers seen in the cell invasion assays was 
not an artifact of increased cell proliferation, the effects of Ang-2 on monocyte proliferation in 
a serum-containing environment were measured using a Bromo-deoxy-Uridine (BrdU) 
colorimetric cell proliferation ELISA (Roche, Mannheim, 1 647229). 
Monocytes isolated as described in 2.1.1 were seeded into serum-containing RPMI-1640 in a 
96 well plate (Corning Inc, NY) at a concentration of 50000 cells per well. The cells were 
allowed to settle for 2 hours before Ang-2 was added to the experiment wells at a 
concentration of 500 nglml. 
Human saphenous vein endothelial cells (HSVEC) stimulated with bFGF were chosen as a 
positive control (personal communication, Dr Neil Davies, CVRU, UCT, South Africa). 
Human saphenous vein was obtained from discard by the Cardio-Thoracic Surgery Unit at 
Groote Schuur Hospital, Cape Town, South Mrica. HSVEC were isolated from the fresh 
tissue by Mrs Ronnett Seldon (CVRU, UCT, Cape Town). 
Cells stocks were stored in 7.5% dimethyl sulphazide (DMSO -Sigma, Steinheim, D-8779) 
and 10% heat inactivated human pooled serum (Delta Bioproducts, RSA) in M199 media 











For use, cells were thawed at 37"C and seeded directly into 150 cm2 culture flasks (Corning 
Inc, NY) containing 30 ml of the endothelial growth medium (see below) containing 10% fetal 
calf serum (FCS), and incubated at 37"C with 5 % carbon dioxide for 24 hours. Following the 
incubation period, the medium was replaced with fresh growth medium with 10% FCS, and 
the flasks returned to the incubator. Cells were used at passage 3 for experimental 
purposes. HSVEC were seeded into endothelial growth medium (see below), and (additional) 
bFGF (1 ~g/ml) added to the wells. All wells were incubated at 37 "C with 5 % C02 for 24 
hours. 
After the incubation period, the BrdU proliferation marker was added to the wells at a final 
concentration of 10~. The wells were then incubated overnight, and assayed according to 
the manufacturer's specifications in the morning. Briefly, following the incubation, the 
labeling medium was removed by aspiration and 200 ~ of FixDenat was added to the cells. 
After a 30-minute incubation, this was removed by aspiration, and the anti-BrdU-POD 
antibody added at a working concentration of 1/100. After 90 minutes of incubation, the cells 
were washed thoroughly with three separate washes of washing solution. 
After the final wash, substrate solution was added to the wells, and the cells incubated at 
room temperature for 10 minutes to allow for colour development. Colour development was 
stopped with 1M sulfuric acid. Absorbance was measured using a microplate reader (Biorad, 
California, Benchmark) at a wavelength of 450 nm, with a reference wavelength of 690 nm. 
Control wells for the assaying procedure were set up as described below: 
Well contents Blank 
Culture medium 100 iU 
















Endothelial growth MCDB medium 181 with 1.18g1l NaHCOs added 
medium Filtered with 0.22 I'm low protein binding mter 
1 % penicillin I streptomycin 
2 mM L-glutamate 
10 ng/ml epidermal growth factor 
5 ng/ml basic·fibroblast growth factor 
1 glml Hydrocortisone 
pH to 7.4 
2.2.4 LIVEIDEAD! Viability/Cytotoxicity kit 
Su.pplier I Produ.ct no. 
Sigma, Steinheim, M-8537 
Sigma, Steinheim, S·5761 
Milipore, Bedford, SCGVTOIRE 
L-Glutamine Flow Labs, RSA, 15-
801-15 
PeproTech Inc, Rocky Hill, 100-15 
PeproTech Inc, Rocky Hill, lOO·18B 
Sigma, Steinheim, H08gs 
The LIVElDEAD® Viability/Cytoxicity Kit (Molecular Probes, Eugene, L-3224) was obtained 
in order to check the viability of cells after various treatments with inhibitors. The kit 
contains two different solutions - calcein AM and ethidium homodimer (EthD-1). Live cells 
are distinguished by the presence of ubiquitous intracellular esterase activity, which can be 
determined by the enxymatic conversion of the virtually non-fluorescent cell permeant, 
calcein AM to the intensely fluorescent c:e1cein. This fluorescent signal is retained by living 
cells, producing intense uniform green fluorescence in live cells. EthD-1 enters cells with 
damaged membranes and undergoes a 40-fold enhancement of fluorescence upon binding to 
nucleic acids, thereby producing a bright red fluorescence in dead cells. 
The assay was conducted according to the manufacturer's specifications. Briefly, monocytes 
were seeded into a 96 well plate and cultured in serum-containing RPMI-1640 (2.1.1) in the 
presence of various inhibitors such as aprotinin (Bayer, Germany, 01057001, 50 ng/ml); 
GM6001 (Chemicon I ternational, Temecula, CC-1000. 6 JA.glml); amelioride (Sigma, 
Steinheim, A74410-IG, 50 14M); cycloheximide (Sigma, Steinheim, C-1988); wortmannin 
(Sigma, Steinheim, W-1628, 0.1 14M); SB239063 (Sigma, Steinheim, S0569, 100 nM) and 
apigenin (Sigma, Steinheim, A3145, 10 14M). Following a 24-hour incubation at 37"C with 6% 
C02, cultured cells were rinsed thoroughly in sterile PBS. The calcein AM (1 14M) and EthD-
1 (2 J.LM) were added and the cells incubated at 37°C for 30 minutes. 
Following this incubation, fluoresence in experimental and control cell samples were 
measured using the appropriate excitation and emission filters (calcein: 494/517 nm, EthD-l: 











Controls were prepared as follows: 
Description of control Assignation 
Fluorescence at 634 run in the experimental cell sample labeled with calcein F(646) ..... 
AM and EthD-l 
Fluorescence at 530 nm in the experimental cell samples labeled with calcein F(530) .. ", 
AM and EthD-l 
Fluorescence at 645 nm in a sample where all the cells are dead, labeled with F(645) .... 
EthD-lonly 
Fluorescence at 645 nm in a sample where all the cells are dead, labeled with F(645)min 
calcein AM only 
Fluorescence at 530 nm in a sample where all (or nearly all) cells are alive, F(530)mll> 
labeled with EthD-l only 
Fluorescence at 530 nm in a sample where all (or nearly all) cells are alive, F(530)", .. 
labeled with calcein AM only 
Fluorescence at 530 nm of a cell· free sample with dye added F(530)o 
Fluorescence at 645 nm of a cell·free sample with dye added F(646)o 
The percentage live and dead cells can be calculated from the fluorescence readings 
determined by the following equations: 
% live cells :::: F(530)gm - F(530)min X 100% % dead cells :::: F(645)gll1 - F(645)mj!l x 100% 
F(530)max - F(530)min F(645)max F(645) 
2.2.5 Analysis of Growth Factors in Serum 
Aliquots of serum-containing RPMI-1640 were analysed using two different commercially 
available ELISA kits. VEGF and PDGF-BB levels were determined using ELISA kits from 
R&D (R&D, Minneapolis, DY293B and DY220). 
Both ELISAs were conducted according to manufacturers' specifications. Briefly, ELISA 
plates were incubated with working solutions of capture antibody in wells overnight at room 
temperature according to manufacturer's specifications. Following this incubation, the wells 
were washed 4 times, and block buffer added for an hour, also at room temperature. This 
was then aspirated off, and the wells washed as before. 
The samples were then added to the prepared plate, and incubated at room temperature for 2 











added to the wells. After a 2-hour incubation, the wells were washed and aliquots of avidin 
peroxidase added. The wells were incubated for 30 minutes at room temperature, after 
which they were washed thoroughly. Substrate solution was then added to each well, and 
the wells incubated at room temperature to allow for colour development. 
The plates were read using a microplate reader (Biorad, California, Benchmark) at 405 nm 
wavelength, with correction set at 650 nm. 
2.2.6 Serum-Free Fibrin Invasion Assay 
Monocytes were isolated as described in 2.1.1. After lifting the cells from the flask with 
PBSE, cells were resuspended in RPMI-1640. Transwells were coated with fibrin as 
described in 2.1.9, however coated wells were placed in compartments containing serum-free 
RPMI. These Transwells were seeded with monocytes at a concentration of 50000 cells/well. 
The cells were allowed to settle for 2 hours, after which the Transwells were treated as 
follows: 
PDGF·BB (peproTech Inc., Rocky Hill, 100-14B) was used at 15 ng/ml (Ernofsson 1996), 
while Ang-2 was used at 500 ng/ml. The Transwells were incubated for 19 hours, after which 
the cells in the lower compartments were fixed with 4% formaldehyde, and analysed as 
described in 2.1.9. 
The serum-free invasion assay was also repeated with the addition of goat polyclonal 
antibody to human uPA receptor (Abcam, Cambridge, ab3129. 4 ",g/ml) and mouse 
monoclonal to human integrin fJ2 (Chemicon, Temecula, CA, MAB1927. 3 ",g1ml) to the fibrin 











2.3 Production and Analysis of Monocyte Conditioned Medium and Cell 
Lysate 
2.3.1 Production otMonocvte Conditioned Medium and Cell Lysate 
2.3.1.1 Production ot Conditioned Medium 
Monocytes were isolated as described in 2.1.1. Cells were seeded into 96 well plates (Nunc, 
Roskilde) at a concentration of 50000 cells/well in serum free RPMI medium (2.1.8) ... The 
cells were allowed to settle for an hour, after which Ang-2 and PDGF·BB were added to the 
experimental wells at a concentration of 500 ng/ml and 20 ng/ml respectively. The wells were 
then incubated at 37°C with 5% C02. In certain experiments, the inhibitor's aprotinin (50 
nglml), GM6001 (6 J.tg/ml) and anti-uPAR (4 J.tg/ml) were also added to the culture medium. 
After 15 hours of incubation, the conditioned medium from triplicate wells was drawn off, 
and stored at _20DC until use. 
2.3.1.2 Extended Time Analysis of Conditioned Medium 
Monocytes were isolated as described in 2.1.1. They were seeded into 96 well plates 
containing 100 J.tl of serum-containing RPMI-1640 at a concentration of 50000 cells per well. 
The cells were allowed to settle for 2 hours. 
Mer two hours, the medium was aspirated off 3 experiment wells, and 3 control wells. In 
these wells, the complete medium was replaced with serum-free RPMI-1640. Ang-2 and 
PDGF-BB were added to the experiment wells at 500 ng/ml and 20 ng/ml respectively, and 
the wells incubated at 37'C with 5 % C02. Conditioned medium was drawn off after 24 hours 
and stored at -20·C. This incubation in serum free conditions was repeated with triplicate 
wells on successive days from day 1 to day 4. 
2.3.1.3 FDP-Containing Conditioned Medium 
96 well plates were coated with a fibrin gel layer in the following way. 2.5 fJ.I of bovine 
thrombin stock (2U/10 J.tl) was added to 397.5 fJ.I of HBS buffer (2.1.6). 28 fJ.l of this mixture 











carefully mixed into the thrombin mixture. The mixture was left to polymerise for an hour at 
room temperature. 
Wells were seeded with monocytes isolated as described above (2.3.1.1), and Ang-2 and 
PDGF·BB added to the wells as described before. The wells were then incubated at 37°C with 
5% C02. At 15 hours, the conditioned medium from triplicate wells was drawn off, and 
stored at -20°C until use. 
2.3.1.4 Cell Lysate, 
12 well plates (Nunc, Roskilde) were seeded with monocyes (isolated 2.1.1) at a concentration 
of 550 000 cells per well. Ang-2 and PDGF-BB were added to the serum-free RPMI-1640 at 
500 ng/ml and 20 ng/ml respectively. At 15 hours conditioned medium was aspirated off 
triplicate wells, and the wells washed twice with PBS. 50 Itl RIP A lysis buffer (see below, 
(Maquoi 1998» was then added to each well, the contents of each well scraped with a rubber 
policeman and the wells incubated for 1 hour at ",°C. The fluid was then drawn off, and the 
process repeated with another 50 Itl of RIPA lysis buffer. The lysates from both incubations 
were pooled and stored at -80aC. 
Material Preparation 
RIPA lysis buffer 50 mM Tris·HCl (pH 7.4) 
(Pichiule 2004) 150 mM NaCl 
1 % Nonidet P40 
1% Triton X·1OO 
1 % Na·deoxycholate 
O.l%SDS 
5mM Iodoacetamide 
2 mM Phenylmethylsulfonyl fluoride 
SupplierlProduct no. 
Sigma, Steinheim, T·6066 
Sigma, Steinheim, S-7653 
Sigma, Steinheim, 1-3021 
Sigma, Steinheim, T·8532 
Sigma, Steinheim, D·675O 
Sigma, Steinheim, L-3771 
Sigma, Steinheim, 1-1149 











2.3.2 General Immupoblotting Techpique 
2.3.2.1 Reducing SnS-Polyacrylamide Gel Electrophoresis (SnS-PAGE) 
Blocking for Samples used Table 5. Detailing !!QJ.U'Ce of samples for various immunoblots 
Ang-2 As detailed in 2.2.2 
p-actin As detailed in 2.3.1.4 
FDP As detailed in 2.3.1.3 
Integrin 132 As detailed in 2.3.1.4 
MM:P3 As detailed in 2.3.1.1 
MM:P7 As detailed in 2.3.1.1 
MTI-MM:P As detailed in 2.3.1.4 
PDGFR-fl As detailed in 2.3.1.4 
uPAR As detailed in 2.3.1.4 
Samples were diluted with the sample buffer (see below) in a 4:1 ratio, and heated at 90·C 
for 4 minutes to further assist denaturation. 
10% polyacrylamide gels containing 0.01% SDSwere prepared using the Biorad Miniprotean 
II vertical electrophoresis system (Biorad, California, 165-2940). The composition of the 
stacking and separating gels are detailed below. 
Reagent Separating (10%) gel Stacking (4%) gel 
Iris Buffers 2.5 mi (1.5M, pH 8.8) 1.65 ml (C. 15M, pH 6.8) 
Water 4.1 mi 3.35 ml 
10 %wlvSDS lOOJ.Ll 
Acrylamide I 3.3ml 1 ml 
bis Acrylamide (30 %) 
Ammonium Perswphate 44111 
(50 mglml) 
TEMED 9J.Ll 
Table I. Detailing the COmPOsition of the 1Q% oolyacrya.mide gel 
In all gels, 5 ",1 of pre-stained SDS-PAGE standards (Biorad, California, 161-0374), based on 
the Laemmli method, was loaded to allow for the quantification of molecular weights. The 





















29% (w I v) acrylamide (ultrapure) 
1% (w I v) N,N'-methylene-bis-Acrylamide 
0.22 Jl.m flltered 
200 mM Tris base 
3% (w/v) SDS 
0.1% (w Iv) Bromophenol blue 
40 % (v I v) glycerol 
pH6.S 
2.5% (v I v) 2-mercaptoethanol added 
immediately before use 
0.3% (w I v) Tris base 




Trizma base, Sigma, Steinheim, T-6066 
Sigma, Steinheim, A-3553 
Sigma, Steinheim, M·7279 
Milipore, Bedford, SCGVT01RE 
Sigma, Steinheim, T·6066 
Sigma, Steinheim, L3771-100G 
Sigma, Steinheim, B·8026 
Sigma, Steinheim, G·2025 
Sigma, Steinheim, M-7154 
Sigma, Steinheim, T·6066 
BDH, Wadeville RSA, BB101196N 
Sigma, Steinheim, L3771-100G 
Semi-dry transfer of proteins from gel to nitrocellulose membrane were executed using the 
Trans-blot SD Semi-Dry Transfer system (Bio-Rad, California). Prior to transfer, the 
blotting paper and nitrocellulose membrane were soaked for 10 minutes in transfer buffer 
(see below), The transfer-stack was assembled in the following way: 3 x blotting paper 
(Sigma, Steinheim); Hybond ECL nitrocellulose membrane (Amersham Pharmacia Biotech, 
Little Chalfont, RPN303D) cut to fit the gel; th~ polyacrylamide gel containing the separated 
proteins (withetacking gel and wells removed); 3 x blotting paper. The stack was placed on 
the machine stage with the membrane towards the positive electrode. 
The proteins in the polyacrylamide gel were electrophoretically transferred to the 
nitrocellulose membrane at 15V for 45 minutes. Following the transfer, membranes were 
dried overnight at room temperature. 
Dried membranes were blocked with 50 ml TBS-T (see below) containing 5% non-fat milk 
powder (parmalat, RSA) for 1 hour at room temperature with agitation. Following the 











Blotting for Primary Antibody Dtlution Supplierl PrlOduct nlO. 
Ang-2 Goat anti-human Ang-2 1/2000 RDI, Flanders NJ . ,. 
(polyclonal) RDI-ANGI0218NabG 
Il-actin Rabbit anti-human Il-actm 1/1000 Abeam, Cambridge 
(polyclonal) ab8227 
FDP Rabbit anti-human fibrm(ogen) 1/10000 Dalto, Glostrup 
(monoclonal) Aoo80 
Integrin pz Mouse anti-human integrin pz 1/1000 Abeam, Cambridge 
(monoclonal) Abeam, Cambridge, ab657 
MMP3 Mouse anti-human MMP3 112000 Sigma, Steinheim 
(monoclonal) M6552 
MMP7 Rabbit anti-human MMP7 1/2000 Chemicon International, Temecula 
(monoclonal) AB8117 
MT-MMP1 Rabbit anti-human MT-MMPl 1/1000 Chemicon International, Temecula 
(polyclonal) AB815 
uPAR Goat anti-human uPAR 1/500 Abeam, Cambridge 
(polyclonal) ab3129 
Table 7. Detailing the Primary antibodies Used during immunoblotting 
The primary antibody was diluted in TBS-T containing 5% non-fat milk powder. The final 
volume antibody solution was calculated for 100 ~l per cm2 of membrane. All blots were 
incubated with the primary antibody for an hour at room temperature with agitation. 
Following the incubation, the membrane was washed twice for 10 minutes each in TBS-T. 
Blotting flOr Secondary Antibody Dtlution Supplierl Product no. 
Ang-2,uPAR Peroxidase conjugated anti-goat IgG (rabbit) 113000 Abeam, Cambridge 
ab6741 
Il-actin, Peroxidase conjugated anti-rabbit IgG (donkey) 1/3000 Abeam, Cambridge 
fibrin(ogen), ab6802 
MMP14, 
MMP3, Peroxidase conjugated anti-mouse IgG (goat) 1/3000 Abeam, Cambridge 
Integrin pz ab6789 
Table 8. Detailing the secondary antibodies Used in i.Jnmunoblotting 
The dilution volumes of the secondary antibodies were calculated as for the primary ones 











antibody for an hour at room temperature with agitation. Following the incubation, the 





25 mM Tria base 
193 mM glycine 
20 % methanol 
20mM Tria base 
137 mM sodium chloride 
0.1 % (v/v) Tween·20 
pH 7.6 
2.3.2.3 Detection and Analysis 
Supplier/Product no. 
Sigma, Steinheim, T·6066 
BDH, Wadeville, RSA, BBI01l96N 
IUovo,JohsuIneaburg,!tSA 
Sigma, Steinheim, T ·6066 
Sigma, Steinheim, S· 7653 
Sigma, Steinheim, P·7949 
In order to visualize the membrane, equal aliquots of ECL detection solutions 1 and 2 
. (Amersham Pharmacia, Little Chalfont, RPN 2106) were mixed and pipetted over the 
membrane. The final volume of the detection solutions was calculated to be 0.125 ml per 
square centimeter of membrane (manufacturer's specifications). The membrane was 
incubated for 1 minute with the detection solutions before they were poured off. 
The membrane was then wrapped in cling-film and placed onto X-ray Hyperfilm (Amersham, 
Little Chalfont). After a detection time of 1 - 10 minutes, the film was developed using 
Structurix developer and fIXer (Agfa, Monsel, G 128 and G333c). The film was then rinsed 
thoroughly and air-dried. 
The developed x-ray films were scanned using a Flat-Bed scanner (Umax Astra 1220S) using 
a transparent media adapter, interfaced to a Macintosh computer. For scanning Adobe 
Photoshop was used (Adobe Systems Inc, Moutainview, California) in gray-scale mode with 
scanner spatial resolution at 100 dpi. The image was saved as a TIFF file for machintosh. 
The images were analyzed using of the NIH (National Institute of Health) 1.62 densometric 
analysis software. Lanes containing the bands of interest were marked for analysis and the 
optical density (number of pixels) of each band was recorded, and a curve plotted. The height 
of the curve is the mean of the OD of a given row of pixels in the marked lanes. Using the 
line drawing tool, base lines were drawn beneath each peak so that the areas beneath the 











tool, and the measured areas analysed using the uncalibrated OD option. The values were 
automatically annotated to the graph. 
2.3.3 Zymography 
Zymography is an electrophoretic technique used to identify proteolytic activity in enzymes 
separated in standard Laemmli SDS polyacrylamide gels co-polymerised with a protein 
substrate (gelatin) under non-reducing conditions. 
After the removal of SDS from the gel, the denatured MMPs are able to refold themselves 
and digest the substrate (gelatin). Once the gel is stained with Coomassie Blue, the digested 
area is visible as a clear band, the size of which is proportional to enzyme concentration and 
activity in the sample. 
2.3.3.1 Non-Reducing Polyacrylamide Electrophoresis with Gelatin or Caesin 
Polyacrylamide gels with a 10% separating gel, and a 4% stacking gel were prepared as in 
2.3.2.1, however 10mg of gelatin (Sigma, Steinheim G-8150), or 3mg of casein (Sigma, 
Steinheim, 6905) was added to the separating gel, and the mixture was incubated at 56"C for 
15 minutes prior to pouring. All gels were prepared using the Biorad Miniprotean II vertical 
electrophoresis system (Biorad, California, 165 - 2940). 
Samples (collected as described in 2.3.1.1 and 2.3.1.2) were diluted with the zymography 
buffer in a 4:1 ration. 6 ,,1 of each sample dilution, as well as 6 ,,1 of a cell-free control was 
loaded onto the polyacrylamide gels. In all gels, 5 ,,1 of pre-stained SDS-PAGE standards 
based on the Laemmli method, was loaded to allow for the quantification of molecular 
weights. In addition, 6 ,,1 of pre-prepared MMP-2IMMP-9 (kindly donated by Mrs Mona 
Bracher, CVRU, Cape Town, South Africa) was loaded onto gelatin-containing gels allow for 












Material Preparation SupplierlProduct no. 
Zymography buffer 200 mM Tria base Sigma, Steinheim, T -6066 
3% (w Iv) SDS Sigma, Steinheim, L3771-100G 
0.1 % (w I v) Bromophenol blue Sigma, Steinheim, B-8026 
40% (v I v) glycerol Sigma, Steinheim, G·2025 
pH 6.8 
Tank buffer 0.3% (w I v) Trie base Sigma, Steinheim, T-6066 
1.4% (w I v) glycine BDH, Wadeville, RSA, BBI01196N 
0.1 %SDS Sigma, Steinheim, L3771-100G 
2.S.S.2 Washing. Incubation and Detection 
Gels were then washed twice in 2.5 % Triton-X 100 (Sigma, Steinheim, T-8532) at 37·C for 15 
minutes with agitation to remove traces of SDS. The gel was then transferred to a container 
with substrate buffer (see below), and was incubated for 18 hours at 37·C with agitation. 
After this, the gel was stained for 15 minutes in a detection solution (see below), and de-
stained in de-staining solution (see below). The fmal gels were scanned on an Umax Astra 
1220S Flat-Bed scanner at 100 dpi without compression and saved as TIFF files. The image 
inverted in Adobe Photoshop 7.0 so that the OD of the bands could be reported as positive 
values, and analysed using the NIH densometric analysis program (NIH image 1.60). 
Statistical analyses were performed as detailed in 2.3.2.3. All gels were dried using drying 
solution and stored for further reference. 
Material Preparation SupplierIProduct no. 
Substrate buffer 50 mM Tris base Sigma, Steinheim, T·6066 
5 mM calcium choride ACE, Reuven, C0439NN00500 
pH8 
Detection solution 0.1 % Coomassie Brilliant Blue R250 Sigma, Steinheim, B-7920 
42 % methanol Dovo,ReA 
16 % glacial acetic acid BDH, Wadeville RSA. BBlOOO17P 
Destaining solution 15% methanol Dovo,ReA 
7.6 % glacial acetic acid BDH, Wadeville, RSA BBIOOO17P 
Drying solution 30% methanol Dovo,ReA 












Samples were separated on a 10% polyacrylamide gel, as described above (2.3.2.1). Following 
separation, the gels were analysed by silver staining, using the BioRad Silver Stain Plus™ 
kit (Biorad, Hercules CA, 161-0449). Briefly, gels were fixed for 20 minutes in fixative 
enhancer solution (see below) with gentle agitation at room temperature. The eifative 
enhancer solution was then decanted, and the gel rinsed in 400 ml of deionized distilled 
water for 10 minutes with gentle agitation. This rinse step was repeated three times. The 
gel was then stained for 20 minutes with staining solution (see below). When the desired 
staining was reached, the gel was placed in 5% acetic acid to stop the reaction. After 15 
minutes in acetic acid (BDH, Wadeville RSA, BB100017P), the gels were rinsed in high 
purity water for 5 minutes. The gels were then scanned using scanned on an Umax Astra 
1220S Flat-Bed scanner at 100 dpi without compression and saved as TIFF files. The images 





50% Reagent grade methanol 
10% Reagent grade acetic acid 
10% Fixative enhancer concentrate 
30% Deionized distilled water 
10% Silver complex solution 
10% Reduction moderator solution 
10% image development reagent 
70% Deionized distilled water 
SupplierlProduct no. 
llovo,RSA 
BDH, Wadeville RSA, BB100017P 
Biorad, Hercules CA, 161-0461 
Biorad, Hercules CA, 161-0462 
Biorad, Hercules CA, 161-0463 
Biorad, Hercules CA, 161-0464 
Immediately before use add 100% Biorad, Hercules CA, 161-0448 
development accelerator solution 
2.3.5 PDGFlH ELISA 
PDGFR-fJ expression in monocyte cell lysates was assayed using a PDGFR-fJ ELISA kit 
(R&D Systems, Minneapolis). Monocytes were isolated from whole blood and cultured for 15 
hours in serum-free RPMI-1640 containing Ang-2 (500 ng/ml) and/or PDGF-BB (15 ng/ml). 
The cells were then lysed (as in 2.3.1.4) and the concentration of protein in the celllysates 
tested as above. The ELISA was then performed on equal quantities of celllysates according 












2.4 Analysis of Gene Expression in Human Monocvtes 
2.4.1 RNA Isolation and Reverse Transcription 
RNA samples prepared from monocytes incubated for 6 hours at 37"C in serum-free RPMI-
1640. The RNA isolated using RNEasy Micro-RNA isolation kit (Qiagen). The final RNA 
suspension (- 12 ~) was divided into four equal aliquots and immediately stored at 
80"C. Prior to use, the concentration of each RNA sample was assessed using RiboGreen 
(Molecular Probes, Leiden, R-11490) according to manufacturer's recommendations. 
40 ng of each RNA sample was subjected to reverse transcription, using the Promega 
ImProm-II reverse transcription system (Promega, Madison, A3800) and a Hybaid PCR 
express PCR machine programmed according to protocol specifications. Briefly, the 
experimental RNA was incubated for 5 minutes at 70"C with 0.5 Ilg Oligo(dT) primer 
(Pro mega, Madison, C110A). Following this, it was chilled in ice-water for 5 minutes, and 
centrifuged to collect condensation. 
The RNA-primer aliquot was then added to the reverse transcription reaction mix containing 
components of the ImProm-II reverse transcription system in a microfuge tube on ice. The 
reaction mix contained ImProm-II 5x reaction buffer, MgCh (2M), dNTP mix, Recombinant 
RNasin (Promega, Madison, N211A) Ribonuclease inhibitor, and ImProm-II reverse 
transcriptase. 
The mixture was then annealed for 5 minutes at 25"C, and extended for one hour at 42°C. 
Following this the reverse transcriptase was inactivated by heating the mixture to 70°C for 
15 minutes. AU heating steps were carried out using an automated PCR machine (pCR 
express, Hybaid). 
2.4.2 Semi-Quantitative Polymerase Chain Reaction 
Primers for the genes of interest were ordered from the Central Analytical Facility (CAF) at 
the University of Stellenbosh, Stellenbosch, South Africa. The primers were designed by the 
researcher using the Primer-S web-based primer design software 6vww.genQme.wi.mit.edu/cBi-
bin/wimer/primer3: Dec 2004 - July 2006). The sequences used for each primer pair are detailed in 











Gene of LeftPrimer Right Primer 
Interest 
,(-actin 5'TGGCATCGTCACCAACTGS' 5'AGGCGTAGAGGGACAGCAS' 
HPRT 5'CCCTGGCGTCGTGATTAGS' 5'GCCTCCCATCTCCTTCATC S' 
MMP2 5'ATGACAGCTGCACCACTGAGS' 5'ATTTGTTGCCCAGGAAAGTGS' 
MMPS 5'GCAGTTTGCTCAGCCTATCCS' 5'GAGTGTCGGAGTCCAGCTTCS' 
MMP7 5'GAGTGCCAGATGTTGCAGAAS' 5'AAATGCAGGGGGATCTCTTTS' 
MMP9 5'TGGACAGCGACAAGAAGTGGS' 5'GCCATTCACGTCGTCCTTATS' 
MMP12 5'ACACATTTCGCCTCTCTGCTS' 5'CCTTCAGCCAGAAGAACCTGS' 
MTI-MMP 5'TAAACCCAAAAACCCCACCTS' 5'GCCTCATCAAACACCCAATS' 
PDGFR-P 5'GCACTTTTATCCACCCAGGA3' 5'GTACTTGGCTCAGCCTCCAGS' 
Tie-2 5'TCGAGGAGAGGCAATCAGGS' 5'CTGAGCATGAGGCAGGTGT S' 
uPA 5'TGTGAGATCACTGGCTTTGGS' 5'TTTTCCATTGGGGGCCAGS' 
uPAR 5'TCACCACCAAAATGCTGTGTS' 5'AGGCCATTCTCTTCCTTGGTS' 
Table 9. Primers used durin, semi-quantitative PCR 
PCR cocktails were set up according to manufacturers specifications as detailed in the table 
below. 2 ~tof each RT-PCR reaction was used for each PCR reaction. 
Reagent Snpplier Working conc. 
Left and right primer CAF, University of ImM 
Stellenbosch, RSA 
MgCl2 free buffer (M1901) Promega,Madison Ix 
MgCh (A351l) Promega, Madison 2mM 
dNTP mix (1969064) Roche, Mannheim 2mM 
Taq polymerase Promega. Madison l.25U 
Table 10, Comoosition of PCR cocktail 
The PCR cocktails were placed in an automated PCR machine (PCR express, Hybaid), and 
the reaction carried out under the following conditions for 35 cycles: 
Denaturation 94 ·C for 30 seconds 
Annealing 
Extension 
60 ·C for 1 minute 











All PCR products were analysed on a 1% agarose (Whitehead scientific, Johannesburg, 1800) 
gel containing 0.1% ethidium bromide. The gels were visualized using the BioRad Geldoc 
1000 system. 
2.5 Analysis of Potential Signaling Molecules 
2.5.1 Immunocytochemistry (ICC) 
2.5.1.1 ICC Analysis of Selected Cell Membrane Proteins 
Monocytes (isolated as in 2.1.1) were suspended in serum-free RPMI-1640 and seeded onto 
8-well Lab-Tek Permanox chamber slides at 70000 cells per well. Perma ox plastic is a 
solvent resistant polymer suitable for tissue culture and fluorescent applications 
(manufacturer's information). Ang-2 (500 ng/ml) and PDGF-BB (15 ng/ml) were added to 
specific wells, and the cells incubated for 18 hours at 37"C. 
The primary antibodies from the Integrin Classics Investigator Kit (Chemicon International, 
Temecula, ECM435) were diluted 1/1000 according to manufacturer's specifications in PBS 
containing 1% BSA, and the solution incubated with the cells for 1 hour at room 
temperature. "Secondary-only" control slides were incubated with PBS containing 1% BSA. 
The primary solutions were then aspirated off, and the cells washed three times with PBS. 
The secondary antibody, also in PBS with 1% BSA, was added to the cells at concentrations 
of 1/50 (Cy3-tagged donkey anti-mouse IgG, Jackson, Suffolk, 715-166-150), and allowed to 
incubate for a further hour at room temperature in the dark. The cells were then washed 
three times with PBS, also in the dark. 
Coverslips were then mounted onto slides with a drop of VektaShield Mounting Medium 
with DAPI (Vector laboratories, Burlingame, H-1299), and the coverslip sealed with nail 
polish to prevent drying and movement under the microscope. Prior to analysis, the slides 











2.5.1.2 Microscopy ADalysis 
2.5.1.2.1 Fluorescent Microscopy 
A Zeiss axiovert 200 fluorescent microscope and Zeiss Axiocam (Department of Anatomy and 
Cell Biology, UCT, RSA) were utilized to visualize the slides produced in 2.5.1.2. Cells were 
visulalized using a mercury vapour fluorescence lamp with DAPI and Cy3 f'llters. The DAPI 
fliter has an excitation boundary of 358 nm and an emission boundary of 461 nm. The Cy3 
f'llter has an excitation boundary of 550 nm and an emission boundary of 570 nm. All images 
were taken with a 40x objective. Images were captured and analysed using the Zeiss 
Axiocam imaging software. Images were saved as TIFF files. 
2.5.1.2.2 Confocal Microscopy 
Confocal microscopy was utilized to determine the exact position of the fluorescent tag in 
relation to the cell. A Leica DM IRBE confocal microscope and associated imaging software 
were used to optically section cells stained with Cy3 (prepared as described in 2.5.1.2). 
Using a 6ax water immersion lens, optical stacks consisting of 1.5 ~m steps were taken 
through the sample using the software provided with a scan speed of 400 Hz. The pinhole 
was set at 1 Airy Unit, while the photomultiplier tube 2 (PMT2) were set at 3.53 (offset), 
822.6V (voltage). AOTF (568) was 80%. The SP mirror 2 (emission window) was set at 589 
nm (left), and 673 nm (right). 
2.5.2 Immunoprecipitation 
2.0.2.1 Sample Preparation 
Monocytes isolated from whole blood (2.1) were seeded into 12 well plates (Corning, NY) and 
incubated with serum-containing RPMI-1640 for 5 hours at 37"C with 5% C02. The medium 
was then drawn off and replaced with serum-containing RPMI-1640 with 500 ng/ml Ang-2. 
The cells were incubated for a further 8 hours. 
The cells were then washed thoroughly with PBS to remove unbound Ang-2. 200 ~l of lysis 
buffer (see below) was then added, the cells scraped with a rubber policeman, and incubated 











tube, and the wens re-scraped with another 200 !Jl of lysis buffer. This was also added to the 
lysate-containing eppendorf. 
The protein concentration of the celllysates was then quantified using the BCATM Protein 
Assay Kit (Pierce, Rockford, 23227). Briefly. according to manufacturer's specifications, 25 fJ.l 
of each sample or standard (Albumin 2mglml, provided by manufacturer) were pipetted into 
a microplate well. 200 fJ.l of the working reagent (see below) was added to each well, and the 
plate mixed thoroughly. The plate was then covered and incubated for 30 minutes at 37°C, 
after which it was cooled to room temperature. The absorbance was measured at 540 nm. 
Material Preparation SupplierlProduct no. 
Lysis Buffer 1% Nonidet P40 . BDH, RSA, 56009 
Ix Protease inhibitor cocktail Sigma, Steinheim. P8340 
Working reagent 50 parts BCA reagent A Pierce, Rockford, 23227 
1 part BCA reagent B Pierce, Rockford 
2.5.2.2 Immunoprecipitation 
Cell lysates generated in 2.5.2.1 were added to an eppendorf tube along with 500 !Jl of 
purified water, and 3 fJ.g of purified monoclonal mouse antibody against human integrin fJz 
(Abeam, Cambridge, ab657) was added to the samples. In control samples mouse IgG was 
added instead of the antibody (Abeam, Cambridge, ab9404). The contents of the eppendorf 
were then gently mixed, and incubated for an hour on ice to allow immune complexes to 
form. 
In order to precipitate the immune complexes, 20 !Jl of Protein-G sepharose (see below) was 
added to the eppendorf. The mixture was then incubated at 4°C for an hour with gentle 
agitation. The antibody-antigen-Protein G complexes were collected by centrifucation (13000 
RPM for 15 minutes at 4°C), and resuspended in 2x sample application buffer (see 2.4.2.1). 
These samples were then resolved on a 10% polyacrylamide gel and probed for Ang-2 or 
uPAR (see 2.3). 
Material 
Protein G-Sepha.rose 
Preparation SupplierlProduct no. 
20 J.!l of Protein G-Sepharose was Sigma, Steinheim, P8296 
washed three times with 500 J.!llysis 












2.5.3 PDGFB& ELISA 
PDGFR-~ expression in monocytes cell lysates was examined using a PDGFR-~ ELISA kit 
obtained from R&D Systems (R&D Systems, Minneapolis, DYC385-2). Cells isolated as 
described in 2.1.1 were suspended in serum-free RPMI-1640 and seeded into 12 well plates at 
a concentration of 0.5 x 106 cells per well. The cells were then incubated for 15 hours at 37GC 
with 5% C02 with Ang-2 (500 ng/ml) and/or PDGF-BB. 
Following the incubation procedure, the cells were washed three times in PBS, and lysed as 
described in 2.5.2.1. After an hour incubation at 4GC, the lysates were collected and spun for 
10 minutes at 13000 RPM. The supernatants were then transferred to another eppendorf 
tube, and stored at -80GC until analysis. 
The ELISA was conducted according to manufacturer's specifications. Briefly, an ELISA 
plate was coated with the capture antibody provided. After overnight incubation at room 
temperature, the capture antibody was washed off (3 x PBS) and the plate blocked with 1% 
BSA for 1 hour at room temperature. The plate was then washed 'as before, and the samples 
and standard added. After a 2-hour incubation at room temperature, the plate was washed 
as before, and the detection antibody added for 2 hours. The plate was then washed as 
before, and strepavidin added at the recommended concentration. After a 20-minute 
incubation at room temperature in the dark, substrate solution was added to the wells. 
Following another 20-minute incubation, the colour development was stopped with 1M 
sulphuric acid. The colour intensity was measured on a microplate reader (Benchmark 
Microplate reader, BioRad, California) at 450 nm, with an extinction wavelength of 540 nm. 
2.6 Extension of Findings to Other Models 
2.6.1 Matrigel Invasion Assay 
Growth Factor-Reduced (GFR) Matrigel Matrix (BD Biosciences, Bedford, BD356230) is 
purified and characterized to a greater extent than original Matrigel Matrix, and has 
reduced levels of growth factors (except TGF-P). Of the growth factors that remain, all are in 











GFR Matrigel is soluble at temperatures lower than 4°C, and gels rapidly at 22°C to 35°C. 
This necessitated that the product was kept on ice before use, and pre-cooled pipettes and 
plates were used during the preparation process. 
The serum-free fibrin invasion assay (2.2.7) was repeated using GFR Matrigel instead of 
fibrin. 35 J1l of GFR Matrigel was pipetted onto the Transwell membrane and allowed to gel 
at 37°C for half an hour. These coated wells were placed in compartments containing serum-
free RPMI. Monocytes isolated as described in 2.1.1 were resuspended in RPMI-1640 and at 
a concentration of 50000 cells/well into the coated Transwells. PDGF (20 ng/ml) and Ang-2 
(500 ng/ml) were then added to the bottom compartment. The Transwells were incubated for 
4 days, with the cell invasion assessed every day as determined by the number of cells 
appearing in the bottom compartment. After 4 days the lower compartments were fixed with 
2.5% gluteraldehyde, and analysed as described in 2.1.9. 
2.6.2 Analysis of the Effect of Ang-2 and PDGF-BB on Other Cell Types 
HSVEC were obtained and maintained as described in 2.2.3. Human fibroblasts were 
obtained from a human abdominoplasty sample and maintained as described. Human aortic 
SMC primary cultures were prepared from the intimal-meidallayer of an aorta from a heart 
transplant donor as previously described (Ross 1980). The cells were characterized by a-SMA 
actin immunocytochemistry. Primary cultures of human dermal fibroblasts were prepared 
from a 7.5cm x 7.5cm abdominoplasty sample obtained from the operating theatre. All cells 
were isolated by Mrs Mona Bracher (CVRU, UCT, Cape Town, South Africa) and used under 
passage 4. 
The fibrin invasion assay described in 2.2.1 was repeated with the three different cell types. 
Fibrin-coated Transwells were seeded with each of the three cell types at 80% confluence in 
MCDB-131 medium containing 20% HPS. To the endothelial cell medium, 10 ng/ml 
epidermal growth factor (peprotech, Rocky Hill, NJ, 100-15) and 5 ng/ml basic-fibroblast 
growth factor (Peprotech, Rocky Hill, NJ, 100-42) were also added. Ang-2 (500 nglml) was 
then added to the bottom compartment of the experimental wens. 
The Transwells were incubated at 37°C with 5% C02. The fibrinolytic potential of the cells 
was monitored by regularly assessing the number of cells appearing in the bottom 
compartment as described in 2.1.9. Cells in the bottom compartment of Transwells in 














MCDB medium 131 
1.l8gJl NaHCOa 
Filtered with 0.22 !lm low protein binding f"Ilter 
2 mM L-glutamate 
pH to 7.4 
2.6.3 In vitro Analyses with Animal Monocytes 
2.6.3.1 Analysis Using Rat Peripheral Blood Monocytes 
Supplier I Product no. 
Sigma, Steinheim, M-8537 
Sigma, Steinheim, 8-5761 
Milipore, Bedford, 8CGVTOlRE 
Blood was taken from male 3-month old Wistar rats (which were scheduled to be culled) 
through exsanguination by cardiac puncture. These operations were kindly performed by Mr 
Noel Margraaf of the Animal Unit (UCT, Cape Town, RSA). The blood from three rats was 
pooled, and 10% trisodium citrate added. The monocytes were isolated from the blood as 
described in 2.1.1. 
2.6.3.2 Analysis Using Baboon Peripheral Blood Monocytes 
Baboon blood was generously provided by the Cardio-Thoracic surgery department, UCT, 
South Africa. These baboons had been obtained by the department for an ethically approved 
study of cardio-implants. The baboons were caught in the wild, quarantined for 4 weeks, and 
then housed at the Medical Research Council Animal Centre at Delft, Cape Town, South 
Africa. While at the Animal Centre, the baboons were dosed with Vitamin B, Ivomec and 
tuberculin tested. The baboons were otherwise medication-free at the time of blood drawing. 
All baboons were fully anaestatised in preparation for the aforementioned cardio-implant 
procedure. Prior to the commencement of this procedure, 50 ml of venous blood was drawn 
from the forearm of the baboon into a sterile syringe containing 5 ml of tri-sodium citrate, 
and monocytes were separated from the whole blood using a Histopaque gradient, as detailed 












2.7 In Vivo Analyses 
2.7.1 Preparation of' Beparin Discs 
Porous polyurethane (PU) discs coated with deaminated heparin were kindly supplied by Dr 
Deon Bezuidenhout and Mrs Anel Oosthuizen (CVRU, UCT, South Africa). Briefly, the PU 
discs were subjected to surface modification by grafting acrylic acidJacrylamide copolymers to 
the surface. This precursor step was then followed by surface modification with ethylene 
diamine, which added surface amines to the disc. To these modified discs, the deaminated 
heparin was then added. The reaction was tested using Toluidine Blue which, when added to 
the disc, causes it to become dark purple. An unsuccessful reaction would remain clear. 
Material Preparation SupplierlProduct no. 
Acrylic Acid MW72.06 Aldrich,147230 
Acrylamide MW71.8 Aldrich,148660 
Ethylene mamme dihyrochloride MW 133.02 Fluka, 03580 
Deaminated Heparin Celsus Laboratories, 57262325 
2.7.2 Analysis of Ang-2 Binding to Heparin 
Ang-2 was diluted in sterile PBS to a concentration of 1 ~g in 50~. This solution was placed 
in a sterile well of a 96 well plate. The heparin disc was dropped into the solution, and the 
plate incubated at 4"C overnight. 
The following day, the saturated disc was taken out of the well and placed on a sterile 
surface. 10 ~ of the fluid inside the disc was drawn off using a pipette. This was stored at -
20"C for further analysis. The disc was then washed three times in 1 ml PBS (2.2.1) for 20 
minutes at 37"C to remove any unbound Ang-2. The disc was then incubated in 1 ml of PBS 
at 37"C. The PBS was replaced at 12, 24 and 48 hours, and these aliquots stored at -20"C. 
Following the incubations, another 10 ~ was taken from the disc and this aliquot, as well as 
the disc, were also stored at -20°C. 
The aliquots of PBS were then freeze-dried for 2 days on Virtus benchtop freeze-drier after 
which they were rehydrated in 10 ~ of PBS. The samples were separated by SDS-PAGE, 











described in 2.3.4) (Biorad, California, 161-046). Each blot was run with a standard of 
recombinant Ang-2 at a known concentration. 
2.7.3 Coating: Heparin Discs With Fibrin 
Heparin discs were prepared with Ang-2 (1 ~g) and PDGF·BB (1 ~g). The growth factors 
were added to 50 ~l of PBS and incubated with the discs overnight at 4°C. Holes were drilled 
in a 4 mm Teflon sheet with a diameter of 7.5 mm. This sheet was sterilized with 100% 
ethanol, and placed on a sterile petri dish. Fibrinogen (10 mg/ml) and thrombin were added 
to the holes in the Teflon sheet, and a disc containing the growth factors was gently inserted 
3 mm into the gel, allowing a fibrin coating of 1 mm on all surfaces of the gel. 
2.7.4 Analysis of Fibrin Coating: Using: Scanning: Electron Microscopy 
The fibrin coated discs were treated and analysed as described in 2.1.7. 
2.7.5 In Vivo Analysis of Tissue Ing:rowth into Fibrin-Coated Heparin Discs 
Heparin-coated discs (2.7.1), filled with Ang-2 and/or PDGF-BB in PBS (2.7.2) and 
encapsulated in fibrin (2.7.3), were implanted subcutaneously in 3 month-old male Wistar 
rats (VCT Animal Unit, UCT, South Africa) by Dr Stephan Dobner. This procedure was 
approved by the animal ethics committee of UCT, as determined by the Treaty of Helsinki. 
Prior to the operations the rats were anaesthetized using ketamine and rampin by Mr Noel 
Markgraaf (Animal Unit, UCT, South Africa). Six rats were used in these experiments. In 
each rat 2 incisions were made on each side of the spinal cord. Into each rat a PBS-, a 
PDGF-BB-, an Ang-2-, and an Ang-2IPDGF-BB-containing disc were implanted. The order of 
the discs was rotated between the rats. The incisions were sutured closed and the animals 
returned to their cages. Mter 4 days the rats were euthanised by carbon dioxide by Mr Noel 
Markgraaf, and the discs explanted. The discs were fixed overnight in 3% 
paraformaldehyde, and then stored at 4°C in 70% ethanol. 
2.7.6 Immunohistochemical Analysis of Implanted Heparin Discs 
Discs were embedded into wax using the HistocentreZ (Shandon, Thermo-Fisher Scientific). 
The sample in the wax block was then cut into 6 ~m sections and incubated for 1 hour at 











were then covered with 1% BSA for 30 minutes, and rinsed 3x in PBS. The ED1 antibody 
(mouse anti-rat ED-I, AbD-Serotec, Raleigh, MCA341R) was diluted 1:1000 in 1% BSA and 
added to the slide. Mter 2 hours incubation, the slide was then washed 3x in PBS, and the 
secondary antibody (1:50, Cy3-tagged donkey anti-mouse IgG, Jackson, Suffolk, 715-166-150) 
added. The slide was then incubated for another 2 hours in the dark. The section was then 
coverslipped using VektaShield Mounting Medium with DAPI (Vector laboratories, 
Burlingame, H-1299). 
2.7.7 Development of an Ang-2-Carrying Adeno-Associated Virus 
2.7.7.1 Production and Use of Competent DH5a Cells 
2.7.7.1.1 Preparation of Competent Cells 
24 hours prior to the procedure, LB plates (see below) were streaked with DH5a obtained 
from the glycerol stocks maintained at -80"C by Mrs. Ronnett Seldon (CVRU, UCT, South 
Africa) .. 5 colonies were picked from the LB plates and inoculated into 100 ml of SOB 
medium (see below). The cells were grown for 2 hours at 37°C with continual shaking at 280 
RPM. The flask was then transferred to an incubator maintaining a temperature of 18°C. 
The cells were grown with continual shaking (280 RPM) for approximately 25 hours until the 
OD600 reached 0.6. 
The cells were placed on ice for 10 minutes, and then spun down at 2000 x g for 10 minutes. 
The pelleted cells were re-suspended in 30 ml of ice-cold TB buffer (see below), and DMSO 
(Merck, Darmstadt, 802912) added to a final concentration of 7%. The suspension was 
incubated on ice for a further 10 minutes, after which the cells were aliquoted into 200 ilL 
aliquots and snap-frozen in liquid nitrogen. The aliquots of competent cells were stored at -


















0.5% yeast extract 
0.5% NaCI 
0.1 % NaOH (1M) 
1.5% agar/agarose 
Autoclave. Cool to 56". 
Add ampicillin to 100 Ilg/ml 
2%tryptone 
0.5% yeast extract 
0.05% NaCl 
Autoclave 
1% KCI (O.25M) 
0.5% MgSO. (2M) 









8igma, 8teinheim, 8-7653 
Sigma, Steinheim, 8-5881 
Whitehead, R8A, 1800 
Pronadisa, 1612.00 
Pronadisa, 1702.00 
Sigma, Steinheim, 8-7653 
Saarchem, RS,A. 504202 
8aarchem, RS,A. 4123920 
Sigma, 8teinheim, 8-5881 
Sigma, Steinheim, P-1851 
ACE, Reuven, 39NN00500 
Saarchem, RSA, 504202 
ACE, Reuven, 880287623 
0.22 11m filtered using low protein Milipore, Bedford, SCGVT01RE 
- binding bottle-top mter 
Transformation of Competent Cells 
Aliquots of competent cells were removed from the· 80°C and slowly defrosted on ice. 10 1'1 
of recombinant DNA plasmids (see below 2.8.6.3) was added to each 200 1'1 aliquot, after 
which the cells were incubated on ice for 30 minutes. Following this incubation, the cells 
were heat-shocked for 40 seconds at 42°C. The tubes were then returned to ice, and 800 1'1 of 
pre-warmed SOC (see below) was added to each aliquot. The suspension of cells and medium 
was then incubated at 37°C for a further 40 minutes, after which the cells were plated LB 
agar containing 100 I'g/ml ampicillin. The plates were incubated overnight at 37°C. 
Material Preparation SupplierlProduct no. 











2.7.7.1.3 Miniprep Analysis of Competent Cell Transformation 
For each miniprep analysis, 5 ml of sterile LB medium was inoculated with a single bacterial 
colony from the plates (generated in 2.7.7.1.2), and grown to saturation overnight at 37°C 
whilst shaking at 280 RPM. 1 ml of each saturated bacterial suspension was stored at -80°C 
in 2 ml eppendorftubes with 1 m199% glycerol (Sigma, G-2025). 
2 ml of the saturated bacterial suspension was aliquoted into a 2 ml eppendorf tube. The 
cells were pelleted by spinning the tube at 13 000 RPM for 5 minutes at 4°C. The 
supernatant was discarded, and the pellet re-suspended in 100 1'1 of GTE (see below). This 
suspension was incubated at room temperature for 5 minutes. 
Next, 200 1'1 of NaOH (200 mM)/SDS (1M) (Sigma, L-3771) was added, and the suspension 
placed on ice for 5 minutes. 150 1'1 of potassium acetate solution (see below) was then added, 
and the contents of the tube vortexed at maximum speed to mix, and placed on ice for 5 
minutes. Tubes were then spun for 3 minutes at 13 000 RPM to pellet the cell debris and 
chromosomal DNA. The supernatant was transferred to  fresh tube, and mixed with 800 I'L 
of 95% ethanol. This was incubated for 2 minutes at room temperature in order to 
precipitate the plasmid DNA. After centrifuging the mixture for 1 minute at 13 000 RPM, 
the supernatant was removed, and the pellet washed with 1 ml of 70% ethanol. 
After air-drying the pellet, the DNA was re-suspended in 50 1'1 of TE buffer (see below), and 
further purified using the phenol xtraction method described below. 
Material 
TrislEDTA (TE) 
Potassium acetate (5 M) 
GTE 
Preparation 
25 mM TrisCI pH 8.0 
10 mMEDTA 
autoclaved 
29.5% glacial acetic acid 
KOH pellets to pH 4.8 
TE with 50 mM glucose 
SupplierlProduct no. 
Sigma, Steinheim, T·6066 
Sigma, Steinheim. ED355 
BDH. RSA, BBIOOO17P 











2.7.7.2 Creation of Recombinant Plasmids 
2.7.7.2.1 Phenol Extraction and Ethanol Precipitation of DNA 
An equal volume of phenol/chloroform/isoamyl alcohol (25:24:1, Sigma, Steinheim, P·3803) 
was added to the DNA suspended in TE (generated in 2.8.6.1.3). This mixture was vortexed 
vigorously for 10 seconds, and microcentrifuged for 30 seconds. Due to the visible phase 
separation in the micro centrifuged sample, it was possible to remove the aqueous phase with 
a 200 ",,1 pipette. This was transferred to a new tube, and 1110 vol. of 3 M sodium acetate 
(Saarchem, RSA, S821010) pH 5.2 was added. Next, 2.5 vol of ice·cold 100% ethanol was 
added, the sample vortexed, and incubated at ·80DC for 15 minutes. 
Following the incubation, the sample was microcentrifuged for 5 minutes, and the 
supernatant discarded. Following the addition of 1 ml 70% ethanol, this centrifugation step 
was repeated. The ethanol was then removed, and the pellet allowed to air·dry, before being 
resuspended in 30",,1 TE buffer. The plasmid samples were stored at -20"C. 
2.7.7.2.2 Analysis of Plasmid DNA Using Restriction Enzyme Digestions 
All restriction enzyme digestions were conducted utilizing a generalized protocol making use 
of restriction enzymes, buffers, and bovine serum albumen (BSA) obtained from Promega 
biological research products. In each digestion reaction, 10 ",,1 if miniprep solution was added 
to a solution containing 13.7 ",,1 nanopurified water, 3 ",,1 of the appropriate digestion buffer, 
0.3 ",,1 BSA. To this mixture 2 ",,1 of restriction enzyme, and 1 ",,1 RNAse were added. The 
digestion mixtures were incubated for 2,5 . 3 hours at 37°C, after which an aliquot of the 
digestion was analyzed on an agarose gel. 
Restriction Catalogue Buffer used Lengtbof 
enzyme number digestion 
Bam HI Roo2I C 2.6 MS 
EcoRl Rooll H 2.6 MS 
Not 1 R6431 D 3Ma 
Pst 1 R611l D 2.6 hrs 
Xba 1 R6lS1 C 2.5 Ma 











2.7.7.3 Production ofAAV-GFP andAAV-AnI-2 
2.7.7.3.1 Amplification of Genes 
The GFP and Ang-2 genes were amplified by PCR (as in 2.6.2) using the primers below 
(made CAF, University of Stellenbosch, Stellenbosch, RSA). The pEGFP-Cl plasmid was 
used as a template for the GFP amplification, while eDNA (2.6.1) from endothelial cells was 
used for Ang-2 amplification. The primers were: 
GFP Ang·2 
Left: 5' GCT GAT CTG AGT CCG 3' Left: 5'GCT GCT GGT TTA TTA CTG AAG AA 3' 
Right: 5' GTG AAC CGT ATC CGC 3' Right: 6' TCA GGT GGA CTG GGA TGT TTA G 3' 
The mixture was subject to a 25 cycle PCR (pCR express, Hybaid) with each cycle having a 
MOC annealing temperature (1 minute); 72°C extension temperature (3 minutes); and a 95°C 
denaturation temperature (1 minute). 
A fraction of the PCR product was analysed using a 1 % agarose gel. The remainder of the 
reaction was purified using a PCR clean kit (Qiagen), and stored at - 20°C. 
2.7.7.3.2 Cloning of PCR product 
The pDrive cloning vector is part of the Qiagen PCR cloning kit that exploits the single A 
bases present on PCR products amplified using Taq polymerase. Ligation reactions were 
conducted according to manufacturers specifications using a 2:1 ratio of PCR product to 
pDrive plasmid. The ligation reaction was incubated at 4°C for 30 minutes, and 
subsequently used to transform DH5a competent cells (as in 2.7.7.1.2). 
The transformed cells were plated onto LB agar plates containing 100 ",glml ampicillin, and 
incubated overnight at 37°C. 
2.7.7.3.3 Miniprep Analysis of Ligation Efficiency 
4 colonies from each plate generated in 2.7.7.3.2 were chosen at random and the subjected to 
the alkaline lysis miniprep procedure (2.7.7.1.3). 5 ",L of each miniprep suspension was 











The digestions were analyzed on a 1% agarose gel, which was run at SO V for 30 minutes. 
Based on the results of the gel, an aliquot of the plasmid isolated from miniprep three was 
sent to the CAF, University of Stellenbosch for sequencing using primers to the T7 and SPS 
promoters, which flank the position of the insert in the pDrive plasmid. 
2.7.7.3.4 Cloning from pDrive into pCMV-MCS 
AA V preferentially packages inserts of a certain size range. As the GFP insert was only 500 
bp, it was necessary to use a pCMV-MCS containing a 700 bp stuffer fragment of nonsense 
DNA (fragment of pCI-neo) obtained from Mrs. Ronnett Seldon. Making use of this stuffered 
plasmid would ensure that the final size of the DNA insert of the AA V would be in the region 
of 1.2 kB. For the Ang-2 insert (1.5 kB) it was not necessary to use the stuffered pCMV-
MCS. 
Both the pCMV-MCS and the insert-containing pDrive plasmids were digested with two 
restriction enzymes for 3 hours at 37°C. For the GFP insert, Pst-l and Xba-l were used, 
while for the Ang-2 insert, Bam HI and Xba1 were used. The digestion products were then 
separated on a 1% agarose gel, and the relevant bands excised and cleaned using a Qiagen 
gel purification kit. 
Aliquots of both purified fragments were ligated together in a 5:1 (insert:vector) ratio 
overnight at 4°C using T4 ligase (promega). 10 JAL of the ligation mixture was used to 
transform a 200 JAL aliquot of DH5a competent cells (2.7.7.1.2). The cells were grown 
overnight at 37°C, after which 10 colonies were analysed by alkaline lysis miniprep 
(2.8.S.1.3) and Eco RIlPstl restriction enzyme digestion. 
2.7.7.3.5 Creation of pAA V -MeS Containing Recombinant DNA 
Aliquots of both pCMV-MCS constructed in 2.7.7.3.4. and pAAV-MCS were purified using 
phenol extraction, and digested with Not1 for 3 hours at 37°C. Due to the small size 
differences between the resultant fragments in each digestion, the products were separated 
and analyzed using a O.S% agarose gel (130 V for 5 hours). The appropriate bands were 











The purified product from the pCMV-MCS digestion was further digested with alkaline 
phosphatase (Promega, Madison, M1831) for 0.5 hours at 37°C to prevent self-ligation. The 
alkaline phosphatase was subsequently inactivated by incubating the sample at 57°C for 10 
minutes, after which the entire sample was purified using a Qiagen PCR purification kit. 
The fragments ofpAAV·MCS and pCMV·MCS were then ligated in a 1:2 ratio overnight at 
4°C using T4ligase. 10141 of the ligation mixture was then used to transform a 200 14 aliquot 
of DH5a competent cells (2.7.7.1.2). The amplified plasmid was extracted by alkaline lysis 
miniprep (2.7.7.1.3), and analysed by Pst1 restriction enzyme digestion. The digestion was 
analysed on a 0.6% agarose gel. 
2.7.7.3.6 Production of AA V Viral Stocks 
HEK 293 cells were seeded at 3 x 106 cells per 100 mm tissue culture plate in 10 ml of 
DMEM growth medium 48 hours prior to transfection. The cells were only utilized for 
transfections once they had reached 80% confluence. Following the AA V helper-free system 
designed by Stratagene, 10J.l.g of the recombinant pAAV-MCS (generated in 2.7.7.3.5) pAAV-
RC and pHelper were added to 1 ml of 0.3 M Ca h (ACE, RSA, 39NN0500) and mixed 
gently. 
The HEK 293 cells were then transfected using the calcium phosphate transfection method. 
ImL of 2 x HBS (see below) was aliquoted into a 15 ml tube, to which 1 ml of CaCh (0.3 M) 
containing 10 J.l.g of pAA V-MCS was added in a dropwise fashion. The HBSIDNAI CaCh was 
immediately added to a 100 mm plate of 80% confluent HEK 293 cells. 
The plate was then incubated for 6 hours at 37°C, after which the medium was removed and 
replaced with 10 ml of fresh DMEM growth medium. The transfected HEK 293 cells were 
then incubated at 37C with 5% carbon dioxide for 72 hours. Following the incubation, the 
cells were scraped from the plate into a 15 ml tube, so that the cells and the growth medium 
formed a suspension. This cell suspension was subjected to four rounds of freeze/thaw by 
alternating the tubes between liquid nitrogen and 37°C water bath. 
The cellular debris was collected by centrifugation at 10 000 x g for 10 minutes at room 











antigens have shown that there is substantial heterogeneity of phenotype (Gordon 2005). 
Further variation has been also been noted in monocyte activity between donors, for example 
in VEGF response to hypoxia (Schultz 1999), and inter-individual heterogeneity has been 
suggested resulting from environmental, epigenetic or genetic causes (Osnes 1994; Schultz 
1999). As all in vitro analyses utilized freshly isolated monocytes obtained from a number of 
donors, considerable effort was made to standardize the monocyte isolation procedure and 
characterize the cells obtained. 
Monocyte/macrophage migration in fibrin gels has previously been shown to be dependent on 
both fibrin and thrombin concentrations and on the nature of fibrin crosslinking (Ciano 
1986). Bearing this in mind, the fibrin clots cast under experimental conditions were 
investigated for casting reproducibility and regularity, 
3.1.2 Characterizatiop of HumAn Peripheral Blood Monocvtes 
The purity of the monocyte populations derived whole blood by Histopaque density 
centrifugation and fibronectin adherence (2.1.1) can be variable if poorly isolated. It is 
pO$sible that isolated monocyte populations can contain variable numbers of platelets, 
neutrophils and other leukocytes. This margin of foreign cells can be, to a large degree, 
contained by stringency of the washes during the centrifugation steps, and the removal of 
any neutrophil or platelets from the monocytes adhered to the fibronectin through vigorous 
rinsing prior to lifting the monocytes with PBSE. The suitability and reproducibility of the 
Histopaque isolation technique was tested using CD14 flow cytometry as well as by 
morphological analysis. 
3.1.2.1 CD14 Flow Cytometry 
CD14 is a membrane-associated glycosylphosphatiylinositol-linked protein expressed by 
monocytes and macrophages. CD14 acts as a co-receptor with TLR4 and MD2 for the 
detection of bacterial lipopolysaccharide, and is associated with monocyte activation (Goyert 
1988; LeVan 2001). It is routinely used as a marker for monocyte populations in flow 
cytometry (Hubl 1995). Therefore, selected cell isolations from whole blood taken from a 
number of donors were analysed for CD14 expression (2.1.2) - thereby assessing the purity of 
the isolated monocyte populations (monocytes were assumed to be activated due to 
incubation on fibronectin). As shown in figure 6 below, 99.97% of the gated cell population 













2.8 Statistical Analyses 
Preparation 
280 mM Nael 
1.5 mM NailiPO. 
50mMHEPES 
pH adjusted to 7.1 immediately prior 
to use 
SupplierlProduct no. 
Sigma, Steinheim. S·7653 
Sigma, Steinheim, S-9638 
Sigma. Steinheim, H·3375 
For each group of experiments, one-way ANOVA was performed when more than two groups 
were compared. A two-tailed Student t-test was used to assess differences between two 
groups. P < 0.05 was considered significant. Data was presented on bar graphs as mean 












Results and Discussion 
3.1 Development of an In Vitro Fibrin Invasion Assay 
3.1.1 Introduction 
Monocytes are one of the first cell types to be recruited to the wound area during injury 
(Dvorak 1995; Jackson 1997; Croll 2004; Moldovan 2005). Once traversing the endothelial 
barrier, monocytes penetrate the fibrin clot and differentiate into macrophages (Duffield 
2003). The mechanisms by which monocytes migrate into fibrin is an area of considerable 
research (Loscalzo 1996; Moldovan 2000; Bar-Or 2003; Levi 2004), and many of the 
molecules stimulating this migration have yet to be defined. 
In order to investigate monocyte fibrin invasion in vitro a novel assay was developed in 
which commercially available Transwell permeable supports were utilized to' suspend a 
fibrin clot in serum-containing medium. Monocytes seeded onto of the clot migrated through 
the fibrin and the semi-permeable membrane, and accumulated in the lower compartment of 
the Tranwell, thereby allowing for accurate quantification of the level of fibrin invasion. This 
fibrin invasion assay differed from other such assays in that the adaption of the Transwells 
allowed for relative ease of invasive cell quantification. While other invasion assays depend 
on manual counting of sprouts, tunnels or cells, the design of this assay allowed the number 
of invasive cells to be quantified using image analysis software, thus substantially reducing 
the potential for error. Before this assay could be utilized to investigate the effect of Ang-2 
and PDGF-BB on monocyte invasion, however, it was necessary to standardize certain 
parameters, including the monocyte isolation procedure and the casting of the fibrin clots. 
Heterogeneity of the macrophage lineage has long been recognized and is, in part, a result of 
the specialization of tissue macrophages in particular microenvironments. Circulating 
monocytes, which give rise to mature macrophages, are also known to be a heterogeneous 
population, although the physiological relevance of this is not completely understood (Gordon 
2005). Monocyte morphology has shown considerable variation in size, granularity and 
nuclear morphology (Gordon 2005). In addition, studies of the mononuclear phagocytes 
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3.1.3 Standardization of the Isolation Protocol 
Personal communications (Assoc Prof H. M. Wu, Ohio State Uni., USA; Assoc Prof P. 
Tipping, Monash Uni., Australia), as well as reports in the literature (Ernofsson 1996; 
Schultz 1999) suggest that the endogenous activity of monocytes differ both between donors, 
as well as within subsets of individual donors (Jin 2004). In order to standardize the 
donation criteria, monocyte fibrin invasion was repeatedly assessed under differing donation 
conditions. 
As mentioned above, monocyte invasion into fibrin clots was tested using the novel fibrin 
invasion assay described in 2.1.9 of the materials and methods. Briefly, a fibrin clot was cast 
on top of the microporous membrane (8 ~m pores) of a Transwell chamber. Cells were seeded 
on top of this clot, and allowed to migrate through it, through the membrane and collect in 
the bottom compartment. Experiments involving Transwell permeable supports are almost 
always quantified by counting the number of cells present on the underside of the semi-
permeable membrane (Siegbahn 1990; Ernofsson 1996), however recent studies have 
suggested that counting the cells in the bottom well is a viable alternative method of 
quantification (Ellingsen 2000). 
3.1.3.1 Analysis of Assay Quantificatiop 
In many studies (mostly of cellular chemotaxis) involving Transwell permeable supports cell 
movement was quantified by counting the number of cells present on the underside of the 
polycarbonate membrane (such as (Siegbahn 1990». After incubation the cells and the 
remaining on the upperside of the membrane are wiped off with PBS, and the remaining 
cells stained with haemotoxylin and counted manually using light microscopy (2.2.3). 
Transwells with the largest pore size (8 ~m) were selected for these experiments, in order to 
allow the monocytes (12 - 15 ~m diameter) free movement from the membrane into the lower 
compartment. Previous studies of in vitro migration of mononuclear cells in modified Boyden 
chambers (Ellingsen 2000) suggested that increasing the pore size of the membrane from 5 
~ to 8 ~m resulted in an increase in the number of non-adherent cells. Therefore, the cells 
present in the bottom compartment were also investigated as an alternative form of 
quantification. These cells were quantified by automatically counting the cells in the bottom 











Figure 8 below is a representation of the different quantification methods. The diagram 
represents the figures obtained from counting both the underside of the membrane 
(represented as average number of cells per field) and the bottom compartment (total 
number of cells) from 2 different donors (experiments done in triplicate). As in the donors 
represented in the graph, the results from most donors exhibited around a 16x increase in 
cell numbers between the membrane and the bottom compartment quantification techniques. 
The similar fold increase in cell numbers between the quantification techniques in most 
donors suggested that both methodologies were adequate for the quantification of these 














Fiore 8. Comparison between 
Quantification methods for fihrin 
invasion MMY· A schematic 
representation of the comparison 
between quantifICation methods in two 
different donors (in triplicate). 
Columns 1 and 3 represent the average 
number of celle per field on the 
underside of the semi-permeable 
membrane. Columns 2 and 4 represent 
the total number of celle in the bottom 
compartments. In donor 1, the number 
of celle in the bottom compartment is 
17x greater than in a field of the 
membrane (columns 1 and 2), while in 
When the two methods of quantification were compared, counting the cells on the membrane 
appeared as a less viable alternative for two reasons. Firstly, the amount of force needed to 
clear the remains of the fibrin clot from the upper side of the membrane in order to mount 
the membrane on a slide meant that it was possible for cells on the underside of the 
membrane to be dislodged during the clearing process. Secondly, no suitable image analysis 
software was available to enable the cells on the membrane to be counted automatically, as 
the small, spherical nature of the cells in comparison to the numerous pores present in the 
membrane made cell identification difficult. This necessitated the researcher selecting fields 
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cryopreserved human monocytes, or a monocyte cell line in order to minimize time 
expenditure. 
Many different cell tpes have been immortalized into cell lines, allowing researchers the 
option of using the hardier cell line alternative as an approximation for the primary cells in 
experiments. A survey of existing literature revealed that the use of the available monocyte-
like cell lines in monocyte studies was rare. It was speculated that this was due to the fact 
that most, if not all, existing monocyte-like cell lines are not actual immortalized monocytes, 
but rather cells from other origins which displayed monocyte-like characteristics. CCL46 (a 
kind gift from Prof Lutz Thilo, UCT), a monocyte-like mouse cell line investigated for 
possible use in these experiments was of lymphoma origin. Preliminary comparative 
experiments of fibrin clot invasion between this cell line and monocytes isolated from whole 
blood (2.1.1) proved unsatisfactory, as the cell line failed to invade the fibrin clot (Figure 
lOA). This suggested that the behavioural patterns for the two cell types were very different, 
and that using the CCL46 cell line was not appropriate. 
Investigations with cryopreserved human monocytes (cryopreservation described in 2.1.5) 
correlated with references in the literature of reduced cell activity (Osnes 1994), and 
displayed much lowered viability in culture. Therefore, based on these observations, in all 
further experiments monocytes were isolated from fresh whole peripheral venous blood 






















3.1.3.3 Isolation Criteria 
-typo 
Fiore] I, Monocyte·like cell lines and 
fibrin invgioll. A. While freshly isolated 
mOllocytes (columll 1) showed 
considerable fibrin invasioll under serum-
containing experimental conditions, 
CCL46, the monocyte·like cell line, 
showed no observable fibrin invasion over 
the same time (column 2). n == 2. 
The protocol for the isolation of monocytes from whole venous blood involves separation of 
these cells from other cell types using a combination of density centrifugation and 
preferential adherence of monocytes to fibronectin. Although fibronectin is known to be an 
activating factor for monocytes (Xie 1998), its use in the isolation processes was unavoidable. 
As all cells used in experimental and control treatments were isolated in the same way, it 
was believed that the impact of this activation on experimental results would be minimized. 
Alternative isolation processes, such as the Miltenyi Biotech (Gladbach, Germany) Cell 
Separation kits, were investigated as possible substitutes, however no viable alternative was 
found due to the prohibitive costs of these and other commercially available kits. 
It was found that the number of monocytes isolated from the same volume of whole blood 
could differ by several million cells from one donation to the next. 5 million cells were 
therefore taken as the average yield for an isolation of monocytes from 50 ml of whole blood 
(personal communication, Mrs Mona Bracher, UCT, South Africa), and isolations with yields 











3.1.3.4 Demonaphic Criteria 
It has been suggested that the endogenous activity of monocyte differs both between donors, 
as well as within subsets of individual donors (Ernofsson 1996; Schultz 1999; Jin 2004). This 
information suggested that it 'Would, be beneficial to select all donors from a si~ilar 
demographic. Therefore.., all donors used for experiments were males (all white except 1 
Indian and 1 black) of between 22 and 29 years of age. For all donors, blood was taken at 
least three times in order to allow for internal comparison of cell functioning between 
experiments (as determined by fibrin invasion assays 2.1.9). Although all the donors used in 
the experiments presented in this thesis were male, many of the experiments were also 
repeated using female donors, to determine whether the results were sex-specific. Figure 11 
indicates that average fibrin invasion was not a sex-specific characteristic, and that 
monocytes isolated from female donors invaded fibrin in a similar manner to those isolated 
from males. 
- ---
Fion 11. Comparison between 
monocytes isolated from male or female 
.do.wIm.. The graph represents the average 
number of' cells present in the bottom 
compartment after the cells were 
subjected to the fibrin invasion assay. 
The amount of fibrin invasion between 
monocytes isolated from females (column 
1) and males (column 2) displayed similar 
invasive profiles. 
p = 0.62. n = 2. Experiments in 
triplicate. 
Monocyte activity has previously been reported to be influenced by a number of exogenous 
factors, including stress and sleep deprivation (Savard 2003), health (Schultz 1999) and diet. 
These parameters were explained to each donor, and donors were routinely asked to report 











on the study, any blood donation during which the procedure caused reported discomfort was 
not used in experiments. 
Aspirin is known to have analgesic and anti-inflammatory properties, and is also an inhibitor 
of platelet aggregation. It inhibits fatty acid cyclo.oxygenase by acetylation of the active site 
of the enzyme, and the pharmacological effects of aspirin are due to the inhibition of the 
formation of cyclo-oxygenase producers including prostaglandins, thromboxanes and 
prostacyclin, thus affecting monocyte activity (Gordon). Potential donors who had taken 
aspirin (in the form of tablet, cough syrup, supplement or otherwise) were taken off any 
study for at least three weeks in order to allow the aspirin to clear from their system. 
Lastly, a personal communication (Assoc Prof P. Tipping, Monash University, Australia), as 
well as references in the literature suggested that certain elements of the blood with 
cyclically varying concentrations, such as glucocorticoid and prostaglandin levels (Shapiro 
1993; Lee 1995; Morand 1999), as well as PAI-1 (Dobrovolsky 2002), could affect the 
functioning of monocytes. Studies suggest that glucocorticoids influence the expression of 
many different regulatory molecules, including the PDGFs and their receptors, uPA, 
stromelysin-2 and MMP12 (Beer 2000; Esmon 2001). Indeed, it was noted that donations 
from the same donor at different times of day could cause moderately different results in 
identical experiments. All blood was therefore taken within ten minutes of 11:00 am. 
3.1.4 Preparation and Analysis of Fibrinogen and Fibrin Gels 
3.1.4.1 Analysis or Background Fibripolysis 
In vivo, fibrinogen, a major component of plasma, polymerises in the presence of platelet 
degranulation, leading to formation of a fibrin clot, which is believed to serve as an 
extracellular matrix enabling migration of cells such as endothelial cells and monocytes. In 
vitro, a fibrin clot can be formed by adding thrombin to fibrinogen (in the presence of 
calcium), both of which are commercially available. The fibrinogen was purified and 
prepared as described in section 2.1.6 and the thrombin according to manufacturer's 
specifications. 
Unfortunately, as a plasma protein, fibrinogen isolations (even those done commercially) are 
often contaminated with other plasma proteins, the most important of which is the 











plasminogen-depleted fibrinogen was purchased for the purpose of these experiments, it was 
necessary to test all batches of fibrinogen used for possible plasminogen activity by Mrs 
Mona Bracher (CVRU. UCT, Cape Town, South Mrica). 
In addition, the addition of human pooled serum to culture medium increases the amount of 
plasminogen present in the experimental milieu (Jockenhoevel, Zund et a1. 2001),making 
the standardization of baseline fibrinolysis in both cell-free and cell-containing experimental 
conditions vital. 
Plasmin is known to degrade fibrin(ogen) into a number of different fibrin degradation 
products (FDPs) (Bini 1999). One of th~e major plasmin-dependent fibrinolysis by-products 
is a D-dimer fragment composed of two 90kDa monomers (Bini 1996; Bini 1999). Due to its 
prevalence in plasmin-dependent fibrinolysis, the relative quantity of D-dimer FDPs in a 
supernatant is commonly taken as a measure of plasmin activity. Commercially available D-
dimer ELISAs have been designed for both clinical and laboratory use. 
As described in section 2.1.8, a D-dimer ELISA was performed on selected samples in order 
to determine the contributions that the fibrinogen, serum and cells made to the baseline 
fibrinolysis. Fibrin clots were incubated in 96 well plates in either serum-containing (SCM) 
or serum-free medium (SFM). Freshly isolated human peripheral blood monocytes were 
seeded onto some of the clots. After overnight incubation at 37°C the conditioned medium 
was drawn off and the ELISA conducted on the samples. Figure 12 below presents a 
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are susceptible to changes within the blood, such as fluctuating glucocorticoid levels (Morand 
1999). Furthermore, monocytes isolated from different donors showed variability with 
regards to fibrin invasion potency (as seen in 3.1.3.1). 
The fibrin(ogen) used to cast the fibrin clots was tested for background fibrinolytic activity in 
the presence and absence of human pooled serum. The fibrin gel orientations were also 
scrutinized using electron microscopy. in order to ensure reproducibility. Using the 
parameters defined in this section, it was determined that a high degree of reproducibility 
could be obtained using the novel fibrin invasion assay. This reproducibility allowed for the 
assay to be used in further investigations involving Ang-2 and PDGF-BB. 
3.2 Analysis of Monocyte Fibrin Invasion in Response to AnI-2 and 
PDGF-BB 
3.2.1 Introduction 
Ang-2 and PDGF-BB are cytokines known to be present during the early stages of tissue 
injury and wound healing. Ang-2 is released from the Weibel-Palade bodies of activated 
endothelial cells (Fiedler 2004), while PDGF-BB originates from, amongst other things, 
degranulating platelets (Hosgood 1993). The early release of both these cytokines into the 
wound environment suggests that they would be present concurrently with the fibrin clot 
and the inflammatory response. 
In this series of experiments monocyte fibrinolytic response to Ang-2 and PDGF-BB was 
assessed in vitro using the ovel fibrin clot invasion assay discussed in section 3.1. Monocyte 
invasion into these clots in vitro was first investigated under serum-containing conditions 
similar to those occurring during clotting and haemostasis. These experiments were then 
repeated in serum-free conditions in order to further analyse the nature of the effect. 
When investigating an interaction in vitro, it is vital for physiological conditions to be 
maintained as far as possible. References in the literature of concentrations of Ang-2 used in 
vitro were noted to vary considerably according: such as 100 ng/ml (bovine microvascular 
endothelial cells (Mandriota 1998», 500 ng/ml (human dermal microvascular endothelial 
cells (Hawighorst 2002», 1 J1g!ml (human umbilical vein endothelial cells (Witzenbichler 
1998», 2 J1g/ml (murine microvascular endothelial cells (Mochizuki 2002». Therefore, prior 











curve. Active concentrations of PDGF-BB for monocyte functioning, however, have already 
been well established, and the concentration used in the following experiments was 
determined from the literature (Siegbahn 1990; Ernofsson 1996). 
Monocyte migration into fibrin clots remains a subject of debate, and different studies have 
alternately shown their dependence on both plasmin (Loscalzo 1996; Levi 2004; Murdoch 
2004) as well as MMPs (Moldovan 2000; Bar-Or 2003) during fibrinolysis. It was therefore 
imperative that the mechanism(s) of fibrinolysis be identified under these experimental 
conditions. Indeed, the plasminogenJplasmin- and MMP-systems have also previously been 
shown to be interdependent (van Hinsbergh 2006) and concurrently operational (Collen 
2003), making it possible that any fibrinolytic activity seen was a combination of the two 
systems (Hiraoka 1998; May 2005). Initial experiments into the nature of the invasion 
observed in these experiments was therefore conducted. 
3.2.2 Analysis of Monocyte Fibrin Invasion in Response to Ang-2 in a Serum-
Containing Milieu 
As very little research has previously been conducted on the interactions between Ang-2 and 
monocytes, the effect of Ang-2 was fU'st investigated in a serum-containing environment, 
which resembled aspects of the wound-healing environment. The human pooled serum used 
in these experiments was prepared from commercially acquired human plasma, which had 
been clotted for 24 hours, so as to allow for maximum platelet degranulation and release of 
stored factors, such as PDGF-BB (Hosgood 1993; Hoyle 1999). Using this serum in the 
experiments allowed for the effect of Ang-2 to be assessed in an in vitro environment 
resembling aspects of the wound milieu, without the need to alter too many other 
parameters. As Ang-2 is known to be released by from the Weibel Palade bodies upon 
stimulus by triggers such as hypoxia (Mandriota 1998; Yuan 2000; Fiedler 2004), very little 
of this growth factor was present in human pooled serum. Recombinant Ang-2 was therefore 
added to the experimental wells. 
3.2.2.1 Ang-2 Increases Monocyte Fibrin Invasion in a Serum-Containing Milieu 
In order to determine the optimal Ang-2 concentration from the suggested concentration 
range mentioned above, a dose response analysis was conducted using Ang-2 concentrations 
from 100 nglml (Mandriota 1998; Witzenbichler 1998) to 1 fJ.glml (Witzenbichler 1998). As 











significant increase in the number of monocytes present in the bottom chamber of the 
invasion assay. Based on the dosage curve analysis, 500 nglml was selected as the Ang-2 
















FiOre 14. Relatiye increase in 
monocyte fibrino!,ysis due to the 
addition of Ang·a to the invasion assay. 
A A dose response curve for Angta 
showing the ~rease in the number of 
cells in the bottom compartment when 
cells are exposed to increasing amounts 
of Ang-a. *p < 0.05 (compared to 
concentrations :s 250 ng/ml). 
Experiment in triplicate (1 donor). B . 
Summary of the increase in the number 
of cells in the bottom compartment 
when Ang·a (500 ng/ml) is added to the 
bottom compartment. *p < 0.00l. 9 











Once a suitable in vitro Ang-2 concentration had been determined, the invasion assay 
described in 2.1.9 was repeated on 5 donors in 9 independent experiments in triplicate. In 
these experiments it was observed that the presence of Ang-2 in the bottom chamber resulted 
in a 60% increase in the number of monocytes migrating through the fibrin clot, relative to 
media containing serum alone (Figure 14B, p < 0.001). In all experiments, clear evidence of 
fibrinolysis could be visually discerned in both the experimental and control wells, with the 
zones of lysis (such as described in 3.1.4.1) present in the fibrin in the Ang-2-containing wells 
being larger, therefore suggesting heightened fibrinolysis activity. 
These experiments suggest that Ang-2 operates in a serum environment to promote 
monocyte invasion into fibrin. It was observed that after incubation, zones of lysis similar to 
those observed in 3.1.4.1 could be seen in the fibrin clot, suggesting that the fibrin invasion 
was occurring through some fibrinolytic mechanism, upregulated by the presence of Ang-2. 
3.2.2.2 Analysis of the Chemotactic Potential of Ang-2 
A number of different growth factors have lately been shown to exert a chemotactic effect on 
monocytes, such as MCP-l, TGF-~ (Gyetko 1994; Sage 2002). No previous investigations 
have been conducted on the possible effect of Ang-2 on monocyte chemotaxis, although Ang-2 
was not seen to exert a chemotactic effect on endothelial cells (Witzenbichler 1998). The 
manner of quantification of the fibrin invasion assay described above (3.2.2.1) made it 
imperative to ascertain whether Ang-2 had a chemotactic effect on monocytes. If monocytes 
were stimulated by an Ang-2 chemotactic gradient, counting the cells in the bottom 
compartment would not be an accurate representation of Ang-2 dependent monocyte fibrin r' 
invasion. 
The Ang-2 fibrin invasion assay described above (3.2.2.1) was therefore repeated, however 
Ang-2 was placed in the top compartment instead of the bottom one, thereby reversing any 
Ang-2 concentration gradient. It was reasoned that the repetition of the results reported 
above in figure 14B would suggest that the Ang-2-stimulated fibrin invasion observed was 
independent of an Ang-2 concentration gradient. When Ang-2 was added to the upper 
compartment of the Transwell inserts, 4 experiments in triplicate with 3 donors showed that 
the cells in the bottom compartment increased by an average of 49% (Figure 15, p < 0.01). 











compartment differed non-significantly from that elicited by Ang-2 in the bottom 
compartment. 
--
Fllgn! 15. Mlr2 does not jnfluence 
monocyte chemotavs under 
experimental conditipns. Schematic 
summary of the average increase in 
cells in the bottom compartment when 
Ang-2 (500 nglml) was added to the top 
compartment. "'p < 0.01. 4 
experiments in triplicate (3 donors). 
In order to confirm the results observed in figure 15, another chemotaxis assay was 
conducted using an experimental model (see 2.2.3) previous used in a number of monocyte 
chemotaxis studies (Siegbahn 1990; Ellingsen 2000). Also using Transwell inserts, the 
monocytes were suspended on the semi-permeable membrane in a chemotactic gradient 
along which they are free to move without any impediment. The semi-permeable membrane 
facilitates the movement of cells in response to the concentration gradient, allowing for the 
potency of the gradient to be quantified by counting the number of cells present on the 
underside of the membrane after incubation. 
In these experiments, monocytes were seeded onto the semi-permeable polycarbonate 
membrane (5 ~m pores), and incubated for 4 hours under serum-free conditions in an Ang-2 
(500 ng/ml) concentration gradient. Due to the smaller pore size, the chemotaxis 
experiments were quantified by counting the cells on the underside of the membrane 
(Ellingsen 2000). As described in 2.2.3, 5 representative fields from each of the triplicate 
experimental and control membranes were chosen at random under lOx magnification, 











FiliN" 16. Ang-2 is not chemotactic 
for monocyte". Ang-2 does not 
significantly alter monocyte migration 
through the Transwell membrane. 
p > 0.6. 2 experiments in triplicate 
(2 donors). 
Figure 16 displays the results of the chemotaxis investigation. Based on the results obtained 
from the two independent chemotaxis experiments, it was conjectured that under the 
experimental conditions, Ang-2 exerted no chemotactic force on human peripheral blood 
monocytes in the presence or absence of serum. It was hypothesized that the movement of 
cells observed was due to random cell migration (chemokinesis), as the migration numbers 
were equivalent in the experimental and control membranes. Furthermore, these 
observations confirmed that the method of quantification of the fibrin invasion assay was 
appropriate, and that cells appearing in the bottom compartment after incubation were not 
attracted by a chemotactic gradient. 
3.2.2.3 Analysis Qfthe Proliferative Potential of Ang-2 
As the monocyte fibrin invasion in response to Ang-2 was quantified by counting the number 
of cells present in the bottom compartment after incubation with the growth factor, it was 
also necessary to confIrm that the positive increase observed in 3.2.2.1 was due to increased 
invasion, and not due to Ang-2-stimulated cell proliferation. Therefore, despite previous 
observations that circulating peripheral blood monocytes are not highly proliferative 
(Duffield 2003), as well as Ang-2 not being proliferative for endothelial cells (Witzenbichler 













Fion 17. API[·2 does not exert a 
proliferative effect on human 
monocytes. OD450 nm measures the 
quantity of BrdU in the cellular 
preparation. Cells were incubated for 
18 hours. As can be seen from the 
graph, the amount of BrdU 
incorporated by cells treated with Ang. 
2 (column 2) did not differ signifICantly 
from untreated cells (column 1), while 
both did not differ significantly from 
the blank (column 3) or the background 
control (column 4). Endothelial cells 
treated with bFGF (1 mlf/mI) were used 
The BrdU colorimetric assay allows cell proliferation to be measured using an immunoassay, 
which quantifies the incorporation of BrdU into the DNA of proliferating cells. As seen in 
figure 17 (p :> 0.05 between columns 1 to 4), after 18 hours of incubation neither the 
untreated monocytes nor those treated with Ang-2 under serum-containing conditions 
exhibited proliferation significantly above the blank or background control. These data 
suggests that Ang-2 does not affect monocyte proliferation. The positive control (Figure 17, 
column 5) of endothelial cells with bFGF showed that the assay was functional. 
This result confirms that the monocytes used in these experiments were not dividing, either 
with or without Ang-2. These results, together with those reported in 3.2.2.2 suggested that 
any increase in number of cells in the bottom compartment could be taken as a true 
reflection of monocyte fibrin invasion. 
3.2.2.4 Ang-2-Induced Monocyte Migration Through Fibrin is Dependent on Both 
MMPs and Serine Proteues 
Monocyte invasion into fibrin has previously been reported to occur through a number of 
different mechanisms, including plasmin-dependent (Blasi 1997; Levi 2004; Murdoch 2004), 











Lanir 1988) mechanisms. Broad-spectrum commercially available inhibitors were therefore 
utilized in order to facilitate an initial assessment of the mechanisms of the monocyte 
invasion observed in 3.2.2.1. In these experiments the Transwell invasion assay utilized in 
section 3.2.2.1 was modified to include the inhibitors in both the medium as well as the fibrin 
clot. 
The following inhibitors were chosen for their use in identifying the mechanism of monocyte 
invasion under these experimental conditions: aprotinin, GM6001, and cycloheximide. 
Aprotinin is a serine protease inhibitor, and affects the functioning of both tPA and uP A as 
well as plasmin, while GM6001 is a peptide-based zinc-chelating hydroxyamate that acts as 
a broad-spectrum MMP inhibitor (Lund 1999). Cycloheximide is a protein-synthesis 
inhibitor, which binds to the 80S subunit of eukaryotic ribosomes and prevents the initiation 
of translation (Prager 2004). All inhibitors were used at concentrations recommended by the 
manufacturers. 
Prior to the experiment, the possible cytotoxicity of the various inhibitors was assessed using 
the LIVEIDEAD® Viability/Cytotoxicity kit (Molecular Probes, Eugene, L-3224). Monocytes 
isolated as described in 2.1.1 were seeded into a 96 well plate, and exposed to the inhibitors 
for a 24-hour period. Following this incubation, the viability of the cells was tested as 
detailed in 2.2.5. At the concentrations used in these experiments, cell viability in the 
presence of each inhibitor was above 85 % (Figure 18). 
--
FilNre 18. Monocyte yiabUM does not 
significantly decrease in the pre!!ence of 
!!elected inhibitors. Monocyte viability 
under experimental conditions (99%, 
column 1) does not significantly differ 
from viability under treatment with 6 
mglml GM6001 (86%, column 2), 50 nglml 
aprotinin (88%, column 3) and 15 mglml 











The addition of cycloheximide to the fibrin invasion assays knocked out all monocyte fibrin 
invasion in the presence of Ang-2 (Figure 19, column 4, p<0.05). These data indicated that 
Ang-2-stimulated monocyte invasion into fibrin is dependent on protein synthesis. 
'* . 
WIlIIA"'2 1llIIIt/Ol9-2 .... _1 1llIIIt""·2 .... ~ 1llIIIt""·2 .... ~ --
Fiore 19. GM60Ql. Anmtinin and 
CycloheJi'mjde decrease Ang-2-inciuced 
monocyte fibrinolysis· 
Column 2, 3 and 4 reflect the decrease 
in Aug·2·treated cells in the bottom 
compartment in the presence of 
GM6001 (4-fold, column 2) apmtinin 
(24·fold, column 3), and cycloheximide 
(230 fold, column 4) relative to cells 
with Ang-2 (column 1). Results are 
displayed as a percentage of untreated 
wells. 
*p < 0.05. 5 experiments in triplicate (4 
Interestingly, both proteolytic inhibitors significantly reduced the monocyte cell invasion in 
response to Ang-2. GM6001 repressed Ang-2-dependent cell invasion by 4 fold and aprotinin 
by 24-fold (Figure 19, column 3 and 4 respectively, p<0.05) demonstrating the involvement of 
both types of proteases. As demonstrated in the graph above, both the inhibition of the MMP 
and the plasmin(ogen) systems lowered fibrin invasion below that of the untreated cells. As 
results suggested, not only that monocytes utilize both fibrinolytic systems for the fibrin 
invasion seen in the control wells, but also that the heightened fibrin invasion seen ill 
response to Ang-2 was due to the upregulation of existing fibrinolytic mechanisms. 
Plasmin activation of various MMPs is well established (van Hinsbergh 2006), while MMP 
activation of the plasmin(ogen) system is beginning to be understood (Ugwu 1998; Collen 
2003). Some research has shown a functional overlap between MMPs and the 
plasminogen/plasmin systems, and a requirement for both plasminogen deficiency and MMP 
inhibition for complete inhibition of the healing process in wounds (Lund 1999). Based on 











Ang-2 and serum-derived factors, the upregulation of elements of both the 
plasminogen/plasmin and the MMP fibrinolytic systems involved degree of interaction 
between the two systems. Futher investigations would be necessary in order to clarify this 
possibility. 
3.2.3 Analysis of the Effect of An,-2 on Monocyte Fibrin Invasion Under Serum-
Free Conditions 
The previous experiments established that Ang-2 affects monocyte fibrinolysis under 
conditions similar to those during haemostasis. Interestingly, when the invasion assays 
were repeated under serum-free conditions, Ang-2 did not have an effect on monocyte 
fibrinolysis. This observation suggested that Ang-2 was indeed acting in a context-
dependent manner. The ability of Ang-2 to interact with other factors, such as VEGF has 
previously been reported, and it was likely that Ang-2 was interacting with an element of the 
human pooled serum (Mandriota 1998). PDGF-BB, as a product of platelet degranulation, 
seemed a likely candidate for investigation, as the human pooled serum utilized in these 
experiments was prepared from plasma which allowed to clot for 24 hours, so allowing for 
maximum platelet degranulation and release of such stored factors (Hosgood 1993; Hoyle 
1999). 
3.2.3.1 Analysis of Components of Hum@n Pooled Serum 
The human pooled serum used in these experiments was prepared from commercially 
acquired human plasma. Previous work done by Dr Mike Beck (Medtronic Inc, Minneapolis, 
USA, personal communication) analysed the concentrations of various growth factors in 
human serum. In this work, keratinocyte growth factor (KGF), bFGF, VEGF (74.1 pg/ml) 
and HBEGF (heparin-binding EGF-like growth factor) an were found to be at concentrations 
of less than 100 pglml. PDGF-BB, however, was seen to be at a concentration of over 3401 
pg/ml. 
As these data were obtained from single serum samples, the EIJSA analyses were repeated 
on the human pooled serum used in an experiments reported in this thesis. PDGF-BB and 
VEGF were chosen as representative high- and low-concentration growth factors. When the 
EIJSAs were repeated (2.2.6), the concentration of PDGF-BB in RPMI-1640 with 20% 
human pooled serum was found to be 851.11 pglml, while the concentration of VEGF was 











utilized in these experiments, PDGF-BB was present at a concentration of 4255 pg/ml, while 
VEGF was present at 50 pg/ml. While the concentration of growth factors in the serum-
containing medium samples tested differed slightly from those of the serum samples tested 
by Mike Beck, it is likely that this was due to variations between donors. 
3.2.3.2 Ani-I-Mediated Fibrin Invasion Requires PDGF-BB Under Serum-free 
Conditions 
Under serum-free conditions PDGF-BB was used at a concentration which had been 
previously used for in vitro work with monocytes (15 nglml, (Siegbahn 1990; Ernofsson 
1996», in contrast with the concentration of PDGF-BB in the serum-containing medium (851 
pglml) as determined by ELISA analysis (3.2.3.1). In the serum-free milieu, neither Ang-2 
nor PDGF-BB individually increased monocyte fibrinolysis (Figure 20, columns 2 and 3). 
Notably, the combination of both PDGF-BB and Ang-2 together restored the invasive action 
and resulted in a a-fold increase in invasion above the untreated wells (Figure 20, column 4, 













lin'" 20. AnI-2 and ppGl·BB act 
cooperatively to induce monos:vte 
fibrinolysis under serum-free conditions. 
PDGF-BB (15 ng/ml) and Ang-2 (500 
nglml) did not significantly alter 
monocyte fibrinolysis (column 2 and 3 
respectively), however Ang-2 and PDGF-
BB added together resulted in a 3-fold 
increase in the number of cells in the 
bottom well (column 4), 
Although Ang-2 and PDGF-BB administered together in the serum-free milieu induced a 
more pronounced increase in monocyte fibrin invasion than in a serum-containing milieu (for 
the same time period). it was noticed that the average number of cells accumulating in the 
bottom compartment was lower under serum-free conditions. Based on the results of the D-












monocYle EbI'lrlOl)"i , wa, SN'n to 10<, highe!' LLnJ"r .. ,rum-containing condilinn"_ Th"",, oiaw 
.ugg",h that mnnocyt< invasion mto lihrin i" inf1:lenc~d by the "'mhinalion of gl'owth 
laclnr' pre""nt mlh,· "erLLm_ 
The, e cxpH'im~nIS sllUngly 'LLgge,t Ihnt An~-2 and PDGF-llll aet (;)(l\!"ratively to influ"nc~ 
mnnocyl~ l'ib!'in inva,ion _ A, ""~n from the "",1':lm-j'I''''' lllye"tig"tirnw ncith"r growth bctol' 
mJ,y,dunlly ,, [Tects mOllocyte in"a,ion, hnweY'·I' tngHlw!' th"y cau,e a 200% In,r~a,~ In 
tihrin invasinn a tx"'e wnllUl cdb Th" (;)mp"ri,nn hetw~~n ;",-,,,inn in Ihe pre"cnce of 
"erum and in ,,,rLLm-fr,,e "mdilinn, "I"" "llr:~e,l" thnt thc hclol" pre"",n t in the ,erum mav 
al"" playa role in affectin~ monoc,.t~ inva,i"n, 
3.2.3.3 Anaivsj5 of t h ~ rhemflt;u·tk Pot~nti "I flf PDC F _BB 
J'JX;}-'-l:lB ha" iX'~n "ati.Caclnri ly u""d in a numhel' nl inv""on "nd chemolaxi" a"say" and 
ha, ]",en ,hOWll co) eXH't a chemotactic elf""t On monocyte" undcr ,,,·rta in in ,;itn! conJilion" 
contn,d;cteoi the chcmot"c:t ic: dC,,(-\ oj' PDG F -llll (G!'ay,'" 198!l). .&.cause of thcse cnnflictllll( 
l'~ , ul t" the chcmotacl;" pot-cntia I oC PDG F _ BB wa" tesled unde!' the exl"'l'l melltal cond it-ion"_ 
llerau,,· nfJne oj' lhc p,..,vious reports haoi d~tccted any prnliferatiw "fI,d nj' !'W,F-llll nll 
mnn,x,yt"" no prfJlij',· j",c;nn a",ay wa. conciLLcce;l 
Th,· '''''p''''imenial mnJ,·1 ("'". 1_~,:I) cho,en 10!' ehe,e eXI"'l'iments was the sn me "" the onc 
d(',,,rih,·d ah",'e i:{_~_~_~) emJ h"s suw,,,j'ully )",,'n "sed in pre;-ious mOllocyte ch~motaxi" 
,Iudi,·s (Sicgh"hn 1~91J, Elliru.;,,·n ~()OOI_ 
In the"" eXp<:'rimenr." mOnnc}~,e' WCrE' "ccdcd onto Ihe p'lIY'"rhnna(,· mernhI'all~. and 
incuh"\,,J fnr 4 hours in ",,' urn-ln·,· nwJium wieh a !'Dr-F-DD (15 ll~imL (Si~~hahn 19ftD)} 
"nnc~n tJ'ation ~!'aJlenl 
unoierside "j' the m~mbran~ (Elling"~n 2(00), A" deocri1o<,oi in 2,2_3, " r~prc, enh'li,," liclJ, 
from c"ch of the triplicat~ cxperimenr.,,] anJ (;)ntro] m~mh,."ne, w"re cho>E'n nc ranJ"m 

















,hc" ",t,~"e ,e"P'm",' I'mm , h,' mo,,,,, ,"." 
",. 0.00. ,,= lex"",;m ,nt, ,n ";"1"" ,, 
.. \s eon he '''''". unll.,r th" "xp"'-; n~'ntal con(hc;un<. PDGF-BB (Figur~ 21. p > O, O ~) doe,; not 
nth",- ;m-" ,t;ga t;"n" I,uch as (S;,, ~L"hn l~)~)) , it j, )l<Js,ible that thi" "itrere nce could be 
"ccu unleu fuI' L." uiffel'en! expel'; men tal design such a, differen t media u .. d, 
3.2.4 !il,ill)Jl)~n 
The l1se or a n{Jvel fiL,oin i'h'ashm ""say system lllu;cated theil· a t concentrations of above 2GO 
ng-/ml Ang-2 increa.ed nwnocyte inva,; ivene,;" inw fibrin dot,; III ,,' rum_con taining 
"nvirnnmento_ Furth"r pXl"'rim"n to WP'-" connllct(,n u<ing an An~.2 concentl,,,tion of 5IJO 
nglmL h,,,,,d un the uata frum the uih1l1"n CUi'V(> Cnd"r the expel'imental c-onu;l·ion", Ang--2 
>va" noc >'en to ,rimula!e either chemota~i, or proliferatiDn in monocytes, "" th e choice of 











Th" inmrpo'-M.lOn ur the bl'Oad-spedn,m inh ibitors, aprutinin and Gr..HiOIlI inl" lh(' lin ri n 
im-",ion provided e"idence Ihat 'h,' h",g-Illened librin inva, ion ob'"£vPd ,n Ih" pr",""'c~ 01 
Ang--2 we" depend".,l on hoth -"n., e Pl'o,",,""es '" well a s .\1.\11'"_ Tn add it;".,. t.r('"t.))) c.,t, of 
ell(' fibrm im-a,ion a""ye wnl, cycloheximIde .101'1",<1 all " .. li im-a,io.,. mOlc"ti"g- Ilw! tlw 
incl'ea"ed ubrinuly,i , in th,' p",'""nc(' of .. \ n)1-2 In\'oh'ed "n upr~~ul"tiull uf pwt.-e in _yn n'"SI", 
rpon remo,'al of se rum from the expenment"i .,ei,-up it wa.< nni,pd lh"t Ang-2 f"ciilc"lp.< 
monoc;-, e fibri" In\',,,iun In con,iunclion with PTJGF.RB. a.,d that. indn'iduall;-' th" g,-"wt-h 
racLUr, had no sIgnificant efrect on monucyt" fibrinoiy,i .•. ,ugg"<ling thai lhe Iwo ad '" c-o-
facw", 1'01' increa,in~ mon()·cyte fibrinoly,i,_ 
p""'i,,,,,ly h('('n ",'pocted lo inil'ract with ,,,h,,c growth fac;,,," in a "oopen,live ma nll l' r 
(Mmoo np","rl' 1997; T!()ia;;h Hl>!R Paom ~1~)2; Rll., ,,,, 2(~)~) [hi. i_ the fIt'8l Tl'pOrl of (hem 
actin g ln~e\het 
3.3 AnahHiH of Allg'_~_ am! PDGF BB Stimul,,~cd MOllocyte ,FibrinolyHi~ 
3_3,1 iut,'odue tion 
1'h~ r,,"uit, from th .. in hibltor .ludy (:12.2,4) "ugge,,,,d 'hat the Ang-_2IPDGF_RR_m"dialed 
fibrin il1va,ion w,,, a te"ulL ur l!pre~ulaled l'ibrinolytic mechani_m", In thi' .,,,",i()n ",,,'eral 
"h'm""t.., of hot.h t.he pla.min(oRen) and 'he M'\I I' fibrillulytic eyetems w"'" analy~"o 
1'h~ capacity to ",'~lde variuu. mm\><lulld, i. em im\><lr\am propelOy 01 cell, in th" mOno(,)''''-
mam)phage lin"age, in addilion lo the ph"RuC;-'\ic alld emli~en p)'e"entin~ lunction' (P"ilcr 
200:)), '\Iun""yle~ a)'e know n to "",')'et-e a n\lmber of p,,,tl'n"'" in r""l",nse (0 "iRnalinR 
mole<ule" inclllriing a numh"r of diff"c .. nt MMP" MMP1 . .\1.\11'2. MM1':1, MMP£! . .\-1.\11'10, 
MT1_'\f\fP M'T4-M'\I1', MMPEl, MMP25 (Bar-Or 200:;). '\lonoc~"Ue,' are aloo kno".-n to 
expre" elemenls of the plasmi"()~~nlplasmm ,yst-em, ;nduoing \lPA and uPAR (Blasi 19~)i. 
I.e,·i 200·1), ""d human penph"rai hl,oo.-J mon()cyt,, " haw p"''''iou;;i;' heen re\><lrled W produce 
up to 10' uPAR mol~cule" per cell (Bill"i 1 ~B7), ,\, a mu1,ifundirm,,1 ' .... cep\or uPAR i" 
known to promote periceill!Jar proteoiy.i" and ma<,rix al ta chm"nt. a" ,,,,,11 a., aff"c~,in ~ 
pro!eina"" ~xp",""ion rillring ma""'phag<' diff,,",ntiatl()n (M"nshik()" 300~), uPA i" produced 
a' n 1m'>',," tale t.han uPAR , but il loa, been ob""",,ed lha\ mice lacking- ul',\ ~xpr~ssion are 
not "ble lo recrlLil &uffici~n; numb<en of macrophn~ee dunng ini1amma,i()n. , ugg",,'ing that 
!,his ell"ym~ i, important in th" c"liular immu n" "}"'t.<'m (P")i,,r 2()II:l)_ 
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3.3.2.1 Initial Anah-s is of Fibrin Do ,;: rarlatwu 
FDP 'COll"lilling eondilioneJ m"Jlulll ._ "mp l ~, w"re gen ('r'lC,·d ",_ d"cu,,~d In 1.:1.1.:1. An,,~ 
l .'i hour '. 1n" con di T,LoMJ ru,dilliL w," '''' ''''' n off "nd r<"ol~"d on" I W', [ib~Lll gL"l, anJ FDP" 
wero chnRn a~ Tepr~oom.ativ" hano~ (as ~hown In ~\I::l"'e 22B) fro m the fllmn o" g"adatlon 
pO ttO'11. "nd " n al~"ed fo, 3 eliffer('nt Onl'Ol'~ m 4 md~l)('ndc ll1 e~l)("i m"m.~ In r,,"pl ie,,'.('. llSl ng 
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" ,-, -; ~, 
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• ' :! I L I >. ,. ,.~. ", , .. " "-, 
, 
!\m" ~ "Hi rD{;[·on i "L"'"~' ·h,' b . l ,,[ 
fib'i ",h" i, ,\ .~11 th,,,,, I",mi, (I"," , .. 1 
:', '". :<1, L klla ""p,.',,,r .. clyi .,.;'j" ,'L"i ", 
"'",''''''''';'' .n. IO', i, ,1>0",," , ~ ""ifi"'E 
inc,',""" in o.,.MitO' m t.h" P'"""" ,,:. ,\n._:' 
"',"m~ t[,<" m , .n, wi," eith., I'D{;r _lln m 
An;; ~ "~"'" ' p"" ,,-,_ n _ .j "xp" i,,",",., 
iH L","I",, '_" iO "',,' ,," K ~,p' .",n'-"ivc 
I''"''"'" (,I "'''' oc;~, r",m o.,""",,ion 
imm,,,,,-,,"'t ._" ,-,w , ,",ii,,,,'e t ne bmi, 
Tll all dono r,_, H maI'ked lllcl'eas~;n HDl' hanJ. was ""en in th e imm\lnohlol . of Ih" , ampl", 
CI'"aleJ Will! An g-2 anJ I 'DG l' -BB, w hi I ~ th~ .a tnple;; t,,,·ateo with e ilh", ,\ ng.2 0 ' 1' 1 lG]7 -BB 
,_h o",""J no "~ nificall' incI'ease (Fi~Ul'e 22A, ~l'OUp 4, po( 0,05), Ciampi", Ir"a t.!'d wilh ~ ilh"r 
~I'ow 'h factol' alon~ J;el not ,how an), . ignifi cant a lt"r'lT.io n in lh" d"nsily of ll!~ FDf' 
cordination of An;:-2 anel l 'DGt'-B R " ljlj1orh ng t.h" d""a ob",in"J f~orL lh" fiLI'i ll invasion 
and; "hib it.or ~",eli"" (:'-2) 
Interesting ly, Ih" th rt~, L"nd,_ analysed lllcreased ul d"n8it,,. ahove the con:rol "a'r_p l e~ "t 
Jifit,r"nt. kwl. - :lW"o, iJ% alld 60% res~ecl ivelv 1'01' hanel;; 1 _ 3, "l'hi;; " ' ;:g",I,,d Ih"t ,\ng_2 
and PDGF-BB in~rease fihrinol),;;is bv up,'egu jat.in;: cerlai n "I" m"nl. of Llw fiLrinol)'lic 











:J.:U.~ I'ur,th"r AllUi.}:!li.~ of Fibrin Vf!:U\da\ion PlI.u"[ps 
A, th" FTJP b"n~' cii<l not apl",a r to incr~aS<? at the ,am~ inl~m i c_,' ill re"pono;<; 10 An~­
VI'IlGF-DD tr~almenl (:l"'_~_l). il wa, I-""'jble Ihat an analy,i. of th" fibrin ""gradacion 
pattHn oboerv",,( b" imm"noblottin~ might be able to she" ,ome li~ht Oll >ome of t he 
fibrinolY,ln" illyol,'e J ill ch~ ob"'n'ed l'ibrin d~p'aciation 
























T~hk 12. '1\.01" ,'OW"" eliu;'o, Ofji'H'~' tic'iT~ 
mosh;,·, ,,( ''''"_(i",,O ''il "i /L 'mW'O ..-iP, __ !i.I,::iwI""", 
.~ll "Iu('$ '" in .n, (\lini 1'''""_ I),,;,, ", i~"..a. ",,' 
hi ~h l, ~ht," 
1'"bl" I~ abo,'e ""mmnri'e , ",,''lIlt, obla ine" tv Bini et a l (Rini IHIl9) in Iheil' analy,i" oftl", 
ci"gr"Jation or cw,"-linke~ hl>rin by vario ,," fibl'inol"sino, Although th., ~e~rn<lation 
pati"rn" app~nl' ,ilwlar, t·her" "rI' uniyu~ balld, ill eac h <l~gn"hlion ~rofil~ (hi~hlii'hteci), 
wllidJ m ig ht ,erve to i<l~ntify tb" fihrinoly ,in, inyojye<i in the ci('gra",,,ion pl'l',:e"" 
In ord~r to inve,ti~nt.e the ')1'''' of J',brm "~~rndMioll tmn~s pr<KilH:<'[1 b~ I!){Jnoc-"tes in 
r<"J){Jn8~ tD tr~atment- with Ang-~ an" PDGF-DB, tlw immllnoblol, of Ih,· wnJiliGneci mecii" 
llS~~ in 3.8.2_1 W"rI' r<"lnal""",d, and all th~ band. ,i",ci "n" qualllijj~d ",inl: n moh:uiar 
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Pu " il,ic' .!:,_,}'o'~'. Ik,,,-,,,,b ic' 
I." d """"' i,,, ,I b, (~'"; H.<'jJ\) 
~ml',l M~U'7 M1'1 PI"",i" 
MI.-U' , , 
, 
/ i"" / (0 11 
, i c,~" , 
, .'49) 
/ i'<o:' /r __ 'W, , .'~) , r,1&:, , , , / Of;) 
"]C', .' I 12', , d~) 
'Iu~" 1' , ;\H,,1> ,i. of f;brif\. dog. "do' "'" -" __ ,' " rn Il'om 
m"",x",,,, (",Iumn ' Iml",,,,,, , ,hc' w' c" tx "Crt" 
/""",1)'" ." "Iou I,,"" I",m., ,mi"",l-" ~";zh ,'.,n",,! 
Cc,I",,,,,.,)· ,,,~lic.,,., ",-",,1),_ ' "'Y'''' , ,,,,,,''';0", Ie" b " ,," 
'".d" 
Th~ hano. " a t fi2 anti 41' kDa lUe "nlq"e t" the }1Tl-M.\'11' dr-gnHj,,,,ion pTI)::Ll" "'rnngh 
su~gestill~ n·s invDI""m~nt \n ,10" tlc ~,'a a,,'ior, ",' J\bl'i" iI' the condltionr-o. mr-o.lum <ampl,," 
Similarly. the h"I'a' at "'·1 8nd .) ~ kTl" "uggest Ih " lr"'oh',,m"d of I,la-,mil', As ni l th" )",no" 
pr,,"cnt Ihal C'Olud hal' " been cau sed by \j)TPH :!no. )[)-]P7 ae~radali'Jll ", ow alilD p re-"n! 111 
l' lthN I. h,., )ITI.II1M), "" ,10" ~ia ,"nin o.egmdatlO" pa tt"rn_' no ("n,·],,"in,," co,,)d })e d educ ed 
ll(llll the ;m nmnoh lot _ for th"", Iwo ""Z,Vlll"" 
II' ord,-'l' to "xt~na lhe"" o)"","','atiDn". the ailsay wa, '''1' '-''''.,,0. wllh Lh" mco"IXJraliol' of 
pia"mir,ogell. apl')!inin and GMC()OI_ ), "''''' h()~ca u,a! the"" addit.ion" would .,imiLu-]y 
I"" ,',ae irJorma lion as to w hi"h Ii hrin o.c~,.",1a lio n bar,d, w"re a l'"'UIt of whi"h "" 'ynw.'_ 
"""I, 
e" I ~J 
~nd 
,\1' ;'Nt,,'] G." 
"' •. ,,,d 
J~aJ>k u, 'I,." ," "Id" 'C>' 01 ""'illi ....... ". 'pro In'" 
JJ<><iG.Mj'"" oit"" ""'n,.,,·" "h<l,h"'.i< hoI;.-
''OP,,--,.,nt, -h . ",,,d, ""''''0' HI ',b'iHI" ~C-"J 
m,,~umh:, _, 0' co"',","''" m"Ii"m t,!.-on h", 
me,_"":.-",, z~""n 0H :'M,n (u,h,,~,· 1) w"h ,h, 
n,JiC",,, "I pl"m~"'1" " (",I'.,m" "i "p, ... "',,in 0\P, Ml 
"tim!. ,,"nm" ,<;, '"" (,{',1",")1 '" I Zid wlum,,") ./ 
















2 3 I 2 
'0'])"' '''',,,, "n'"o"" ,,,.11, II ~.mo" ole:, (ro", 
cd" "",""",,,<1 wib pl"mi,-.-,~. n ,t."o Ii. La~, 2 
Column. 3 and 1 (Tabl~ H ) l'BP"""" J1t the libnn (,~~radati() n patte,'", of monocyte" ,""(,e;:! 0)1 
fibrLn when ire,,'ed with el,her apruiinin ur GM6001 The cobmn.< indical€ that 3]lrutinin is 
'1'11i, ;, )lronnbly dll " j" th,· s ll b."'lll"n t ma(,tivnti~n of pb.min.acllv" led "nIP. (van 
Hin , berg-h 2000), lJ1"""B,tin~Il'. tlw Dn ly ban(, r~ma;J1iJ1~ in tlw nprotini n_tr{ ",-,," ,nmpl", 
wa, al ~2 kD" (FiltlL'" ~31 - ,Jlle which i. hnol"n w be g~n"ra\e<:! by MT J-r..lMI' fi brinolysis 
{Tnole 14) G"\1600 1, (>n t.lw ot 'wr han d. ,,,l ,,ctiv,,l y in hih'kd a(t.ivity of cere,,; n ~J"J p ,_ and 
the prOOll C! inform ation ,lw P". G.'l60{) J i , wportp" to mhibit. MM l'l 2, :1, fi, "nd fl )<'mm th" 
"'311 lt., p l'B;;" n"' o abo"". now""Pr. i t "PI' '''' hkdy t.h "t. G.\1600 J .,1"", in nil",." "'11' j ·"f\IP 
Th~ addiliun o[ pla, ,,unogen to th~ fihrin ~~l (Figure 2::, c'olumn~) c'lUsd a g~nerallllcr"a,e 
in pH,,"uly_; , [clrth er confirming that pia_min wa' m'"~ral '" monucyt~ fibrinoly"i" 
111 tere'till~ly, t hio up re!:" li ation ",." 110" unifol'm. nnd th e ban(;, nt ;;8 . . ''i. onci 1-1 kJ.la "'N~ 
considBrabiy (;nrhl' t ltall thB other ba llG . (t'igme 2:)1, This l '~" u lt, m cOlltra"" to n ulliform 
upn·gu lahon of }<'fl\'<, d~( ·" flll'll",l' ",,~g(' ;;t. th at. th" }<'TJPs prool "'''ci wn"n monO<T\p, arp 
mcubated "llh Ang -~ and PDG F -nn on fibrin are a ,.."ult u[ buth th e pia_min(oge n) and the 
/"IMP ;;y<t,('m ;;_ 
While the res'~lt<; of this exp~r.mem ar~ Jll nu w ay mncl·~_,V€. they do '<"p»ort th€ fillGingo 
oi""",,"" \n ;3,~ , 2.1 , that both oN'in € prote a se,. such ns pb;millo~ell. nnci mnlrix 
m~tallopl'Ol€a"€s , eopocially '\11'1-.\nll', are in,'oh·oo m Ang-2 1'1lGF-BB-;ndc,"~d 
fibl'inoly;;i"_ II was tholl g-h l that th€ oitl"rBnc~G bel"'~~l1 th€ ,..,sult, of th€,,, ~xperime n"o 










and th,' invailion ail"ay, could b<: explained b) difference, In se ni<l(i"I(Y of lhe aSi<ay,_ alld 
a lilo th~ po>eibilit ." of :ho cells focusin g lheir fihrilwlyli<- "e,i" lly in lh" iln'".,wn ""' ''Y''. an~ 
lher~lore iln'ading lIl(' f ih rin mor" quid l)'_ 
·3.3.3 Elenwnts or the Plasmin{ounl Syst"m art Inv!!1Y!1lLiJL1h" Upn'guiatiol1 of 
Fibduohsh in Mooocytes TI'efite d with :\ng_2 'lnd rD(;_~ll ll 
As di.'l< 'us,,·d ill :h" "'dion I.~_ U th" pbsmin{og"nl fibrinolyt.ic cascad" consist" of s"v~r al 
""in" P.,.<lt,,,,,.,es. indud ing plasmi nogo n and t·ho plailminoR~n activator" d'A and u l'A 
(Lijnen 2002; van Hin,berj(h 2006), ul'A acti\'atc s plasmino~en on Ihe cell ,ui'face. where it 
is anc hored b v :he receplor uPAR De8 pi(" re,,~n( r"p',rt., of ,,")1 sunaee-a, ,,xi,,(,,,) lPA 
aclivil)' IGrohmyer I\J\J:-J , Elli , \\J\)7I . It is !wn"r"ny """plod t.ha t lIs m"jo.,. f\ln d ion is a ., ,, 
"cel'clod p la,minoRen activawl', Ail tho l'eilu lts in 3,2.2.1. and 3.3,2 iltl'onj(ly il URj(en 'he 
invoh'em~n t of p lasmin in t he obsel'ved mOlloc.v(~ Ehrinolysi,. (he e>.p ressioll of uPA. cPA 
and uPAR w~re ;",'esllga,ed ill (h i, ,"",cl ion, 
An analysis 01 tl'A and u l'A expl'oSi<;on ill monocytes by RT-l'CR (ooction 2.6) revoaled that 
l!IHler our exp erlm,'n",l mndi,ions u P,\ w'" exp,..,,,,ed . but llol upre~uI,,'ed. ill mono('yles 
l~e"r.ed wit.h PDGF-DD alld Ang-2 "ompan·d to untre"tcd ""II., (Fig'llre 24A) C"l1\'~"'e ly 
lP,-\ e:<pr""",n was nol dd""leci in any of (he mon<M'Y'" "ampl"s (lanes I - 4. fi~ure 24B), hu t 
"""., ~d",:(d in (h" llSVE[. ",ml']" (I'o.<i,i"., mn lrol. bn" (i) _ Whell uPAIl e"p r~,," ion wa, 
analy3<'d u"in~ IlT-PCR IFIRure 24[.)_ the re·,,~l'to' w", ".,.,lllo h~ expressed In unlrea,ed 
monocyte" (I an~ I), ao wdl a il t h""" t l'~ated with 1'1lGE-BH (la ne 2) 01' ,\n g_~ (lane 3.1, 
Intc1'O"tingly. the ~xp1'O,sion of ul',\R appear"~ r." b<: margim,l ly incr"a",d in mo nc"ytes 
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O~l".L'-'-"--'-'P~\ ly ,-" -PA ,,,-d,, " ;[" " ;,,,,",,1 
ccrJ,-"" • . A, Tel' ""nd "' ,,,,.'0" "P.' KI<. 
b" ttom "",d ;, ',_""'_l' pel( ",", ,~l L"' ,~"" 
"'''"'''",''" ( .. "" 1). ,b,·", _r'_'oleu ~"h ,bi 2 ' L,ne 
"j, " ",,,.J wd l'DG l'-lm (In'''' oj ""d bo".h _" " 2 
"0' ~I)Gf' 1m rlon , 1) h,d "mil" ",v, l, of "FA 
''l'''''"'" flob ii',·"'la,,, ~'",,' oj "ad ;j~V~C 
n."" ,;) .1"" ex",hi,," "'''''''''' ·,,1 "1',\, In'''' 7 i . 
a ~","' "I,,,, H. ~O" p",,,1 "p"no" ,PA pell 
]-,,"om ",_.di" ITT!. lo",_" 1 _ _ , '''_' ' mum",.'." 
'"",~,"'U i ll "'"le'" ~';,h ,I.llg·~ (2; , 1.,..,1.." "'-+ 
PDGF_nn ',0" "-'"led wd. Aug :: "0" nlGf IHl 
(.,}, I."" .. [.,"'bl" .... ,,-, CO" Ix ' >0O" lie_'" Ii,,,,,, 
H. dO' lT~vrr (in'" 0) ,,,hibi"" t l',\ "P"" " " 
",,(I., exp" im " ,' , ] "·",di,("",, l~,", 7 " " "' E -" 
bi n", ll,,,',,", ""d i. " ,~ "" reI( ''-'''''C'] C. To" 
",n.] '"r"""O" "PAll peR flu'lc'", """d " ,_ 
(li. L,~nLOd ~'ilt. Aog 1 '~), ,"oot" w"]' PnGnlll 
t:;}, ,,,,,,," w;lhA"._2 ""J l'UG f IHl {~ l .L.r , ;; i, 
n w ,[c,' blaok iY"'o", p'''','I;" 1 "'-,'-, P f'R "',""O~ 
no",J O~ ,h<; !'en 1'"Sul", it ,,"'a, decided chac j'llrthn .cud"," of Ih~ l'ln,min(og'"'' "y._lr-m 
wOLli,1 '''' (oullli~.,J io u!,A and lLPAR , 
(I,erl eolli ~ Ol)j: Le " 2004: Murdo"h 2004) 
CDl1llUr--rCla11r produ"" d uP'" ,,"i',,)()di", coulJ De WU1~"J, Tlwr~j'or~. only uP_\f{ "Xl''''""''''' 
"oul d '''f' Inv,,,tiga i eel un a prutem le,' ~L in orii ey 10 co),fj-rm I'C H. )"(,,"it. _ u i'A n WI" a"" I "8eJ 
U""' ~ cell lv . at e. ubt,Qj t) Pel from mO:-1Ocy-.,"._ I n('u '''0 ,,'d wit.h Ang- 2 a nd/u1 POG 1'-B1l. Ly"" \~" 
W"",' ",,,.,h-,,J o~ j()'!O SOS-PAGE ~~ls, allJ uPAR conC~:-1tr" l io:-1 dr-V,,'mined U8"'g 























f i' "," ~.(i . . '\',g 2 aH" rUG!' l!J:i "ni''''' 
u l '.\~ c' ,,,,,,,,,-,,, '" !<om"" m" ,x"l, ,'ell 
~ roll, t''"to" ",ith ""I: 2 "nd 
P f) C), 1m ,h'"",,", 0 87 ',; ""''c.,,,' 
ila,,,,",,,,k,nn <) m "r.\I: ,'XP"''''''" in 
"'ml"'n~'H Lu ",,,,, .• ,,., I'j)Gr·nn_ 
,b",,', "'p"",",,,i,,. '"" To~ _ "PAR 
(obH'"\. "',,,'" = ~'''L~' 1<, U)") 
(Fig-me 2.0, ",lumn.-hne41. '1'reatClent with l'llG 'P_ BB 0" :\11 ~_2 " lone did nuC "lgnificantlr 
am<:t ,'xpn·,.iOll (Fig-me ~fl. " ,lUI'L!lllan" 2 " lld 3:,. 'T hi" sugge8\-8 thnt ,.h" '-\l1g_2ip ])GT'_nn· 
oiepeno elll ClOllOC!''-<' illv" , ioll oh<nved Hl :1 .2 im'ul ve d ul' AR 
im nll!nohl olr,ing-. 1\0 <i ~l1 a; ;V"" oecedeo in " llY ul th " ex r}e ri Clen"'" Dr wll,.rol <a mp],',. 
,trongly ",~g",tinl' ch,lT. th" ll 'P:\ R dd'<:C<' ri i ll lh " lIT-pe R (J ,J.J,li reICLained immobilize<i 
011 the' c" ll ", rf,,,,e uncil i nl"rll "h~"d and deg,-ad"d , 
3.3.3.3 l!!bibiLion of uP AI{ ~:. I! .n-'"tion 
III ol'de l' lu lill k lhe ub"erwd llpregulation or ul'AH to th,' monoc)'!." fil,,~n inv",;oll . eh e 










added w both 'he [,bnn and the medIum or. 0 4 Ilgiml (manllhcl\lrer·recomm~nded 
('oncenlro lionl. 
* 
." 1 I 
1',,.,,,-.:' 26. be",;"",, IIr .)'.\I! 
fe'rdi";, inhb", .,,.,·2.'1'l){Wrr· 
m,ilj"CL.-J L","""" LO A"""""" 
C"i,~,k,i< 1h .ddi!LO" oi ,"". 
u!,,\H ",,,I,-,,h- ",d "-,, .ff". 
(Column' ~ ,"a 4J, 
1,,-,nL_"""; wiC" , 11 oll'" ,,,,,,",,",,,,1 
o _ 1 ex",,,,,,,,,",, ,n ",,,Ii.,,, (., 
"',"""J 
A" shown;n figure 26 (p"' 0.051. blocking uPAR achvw,- in ,he fibrin in'-a,ion a""ay removed 
the lllCl'ea,e in mon,>cyte fil)rmol,V,i" ,een during lrealmem ",ith Ang-2 and PDGF-BR 
Inler~slingl,V. ho",~ver. the mlg"" ion of the concrol mon()cyl~' lreat~d wllh anti-uPAR W~l" 
no' "ignificanliy ,.Jeered in compari,on to 'he m,her cunlrol cell". mdic'''lllg' Ihal uP.'ill w:u 
It i" imerestinR, ho,,:ever, thal inhihition of uP.lli did not cau,e fibrin in'-a,;on le '-els co drop 
klow "'ntrol I~wlil . Rece t. ",,"€or<;h on invasion haw sllgg-esl~d t.hal nolh '1,jT1 MMP and 
uP AIl are <:o'''''l'w«ed on Ihe in '-adopodia of ilwading ('ell < (Fllrmaniak-Ka"mi~",zak ~1)()7) 
Fllrthermore. r~'€OrL'h on monocyt.e" oct"-ol~d with j-;· I.nr. ~xhinit~d enbanced .urhc~ 
eXl're .. ion of uPAR and MT1·M"'IP. a" well a" in<',-.,a <ed ,ecre,ion ofMMP~) and ctl'A, while 
exhibiting enhanced in"a,ion inca Ma lrig-el (May 2005). The,e ob"en'ationil contribute co ,he 
understanding- ,hat ilhrinolysis m monocytes lil potentially a complex intera('tion III whi('h 
member" of hot.h t.h~ I'lo , minugenipla,min and t.he MMP fibrinol,V!ic ",V,tem, inl~ra,", Il I" 











3,3.3..1 inhibition of u1' A t"u nclion 
and function, as a known ,, 1',\ (':,nct;on inhibito,' (Wa'lg- 199';: Jankun 200l, fly,," 2002). A, 
""cOlnm~nd"a hy t.he 1il"""'.llTe. ,,,,,ilorid,, w,,' \J,~d "I a "~T"','ntr,,\ioll of 'iO ~M to iuhibit 
uP.>. h~ct"'~ in oit'"" Th" LTVElTJF. . ;n" Vlabihty/Cy'"toxic]ty Kit (2.~.") alJ(l "'l'll~l·ln'~ 
fibrin invasion ao,ay, (2.2 7) w~,.., ",'!wated, wnh ',h" lIl""rpma!i()1l of amiim'"k ill Doth lh" 
llDl'ln Rd aud ,h~ culture n',ednn 
, '''' 
• • 1 
lilli!.I'1h~" It. , cloi",n 0;' .mi"'i J. b 
U:" C,,,,, i",'a.i,u '''OJ' """v'o b. 
h. ;~, ,,",cl ~'",i""j}'l" dr,,,, , . ,~"d ')" 
'" ~ 0,00" ,,,,in,, . Ii oll .. , tn'.tmed. 
,1 "'",\'i""'"H ;" coir ;;". " r2 """''',) . 
'b."atmH.t of til(' fibl'ln invasion a",ay with arr.ilond" proJuced a "",.y "imilar ""fpe l to "I"'t 
seen w;:h ar.t.i "PAH l1'iglll'~ 1" P <: O,OO,,}, in bot.h ,'xI""irr.enb. ~h)C kiLg either llPA ~r 
',ll'"\H bncti~r. l'~"LlleJ in the re~lOva1 of Ill" "pr<'glli>,leu "'U", )(;yt~ iLvasion «"'n deLeing 
!?<'atrr.('nl ""th Ang·2 and .l'DGf··flfl In n~i'.he,. sc~"a:ciu, hDW",",'~, aid the inhilHliu" of 
bnClion 8iglliilcantly low"~ th e i n"" ,ill r. Ldol" l·hat of t·ll<' control we 1k This "Ll~g-~,t~d that 











~.J.1 1'UB,guhlJip!J..of l\I'fI_)'I~ll' R"llres"io" in ,\lonon'Les Trea!&d wiLli Allg-~ 
and PDCF_BB 
A" discu;se-J in che inl]"(>dw:lion (1,~.l,~.I) MT1 _\11>'fp i< known t.n he" fihl'lonlyt,lC M!>.II' 
thot ploy"" l;cy rnk in the l'eerni! ",en! of monoe;te, dllring llillamlw,t.Hlll (\{",i"<-Rom,,n 
~OOr,), The a naly,i, of !'DI' pa,[erll, dis<' lme-J 1ll ,ed,,,, n :1,:1. 1 <ugg,,;ieO it," i nvol"eme nt ,n 
fibTinolytic eff",t ohs~n'ed throllgh 'he ",lIT. llb ",on of mon(X:~·te" hy Ang_ ~ "ml i'D C: F _Illl 
An R naly,i, of R', A i'ob k,l from monocyte" tr"ned with Ang-2. J'DG }'-Ell. or both indica ted 
thot )l,lT 1-M)I,ll' exp,e""ion In monocytes is regulated on a tr .. mcrlption .. l le ,'el by lhe 




--- --- 212 "p 
O"J""~o" 0H,'1 W\1P R~'A Top """"I; , ,,'TTl 
,,-!'I!P RT· ITR. ,," "om p"nd ;, ,'_",,;n ET·PrIL 
PlJGI' BB l]an, 2) ""c1 Ang 2 (I' ..... ' 3) " 'l giv do no' 
" " ,,'(0<.' }IT] .\-IMl' BI<A "'pr'''''''' "00", th"t or 
C.,.. coow l !"n, j " howo\" r ;~'th" tI,o, ,'"",. "0 
0', ... :"",,,](, ;nc ,,,, .o i" RI<,\ o, p,o" ioo Ii'n, -Ii, 
.-\, can he ,een from lh" rep,'",eniath-e gel (Figure 2H, l"ne 4i. Ang-2 ,,,,d PDGF-DD reSlll,ed 
in an llpre~llb'ion []fRl\-A ""pie" in ih" cell. :\Ieir.her Ang.2 nor pDGF-DD "lone "[["':led ihe 
expre".ion nf ,\1'1'1-':-'11\11' (Figure 28, IRne" ~ RnM 3). mau,,*, of the low quality []; the p,n 
A, a m"mbrane·b[]llnd "\f!..-IP. :\IT1-:\'I:\IP np,,,,,i[]n wa, anai;-',ed 1ll Ihe eeli lysate, of 
mon[]c;-',", ,,,,aced wi,h Ang-2 andior I'DGF-DB The reslll" of 4 different donnr. analysed 
in criplical" are detailed in che l'igu,." 2!1 below, 
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:t:l""~"J Analy~i~ of II.;"A llxpuss jQU 
Reve"e il" <Jl'ml't. lo~ a nal}'"i. of Jvllvfl'3 ane! MM1'7 ~xpl"e"ioll ill mOllocyl e" 'l'ea'erl with 
\n;:--2 ane! I'VGl'-.I:ll:l e!iJ " ot l.., ,·eal SigllilicI<Jll e>,pl'e""iOll oj' eichel' M"fP ;"1 Imy 0' Ih" 
dlf'I",, ~ t ,ampl,,"_ 'T'hi, ", lgg",wd "hm, monoc)'te, ,mJer 'he conJitione; ' tue!ieJ Jid not 
,ecrete eilher 0[' tbese "lMl' " 
In orrle" 10 co,L'll"m ' he !,ene exp re;;,ion re, ll lt., abo" I' (:j .:i.~_I\ Ml>H? alld 1>Thll'7 p"o 'e"l 
"xl'",,"inn WI" ,,100 ,!uJi <Od_ Whil~ ,,,,likel)', it i;; pO,oible ['or R,\ .. \ a naly",,, ,wi In "ol'l'ela,~ 
with wolei" ex pr,,"<io~ 0'''' in lran"laiiolll, l a nrl JXl >t-translati onal mecha~i"m< Ihl'OlIgl, 
inc r"a"" in mHNA l,alf-live", ane! imracellular ;;Im'age pnol" '\' Ix"h ,,-IMP:'I anrl "nll' 7 a re 
oe<reteJ ,,-II>H's, t h" oondi ,i nll"') merlllLm j'l'om tl'eatect monoc}'te" W'" ,,"al), "<Od U"ill~ 
l mmulloblot ,i,,~ for MMI'3 10' 'k D,,) an rl M"U', 12H kDa} _ 
Ilolh t h" M,,-IP3 a Ile! "L\U'7 i mm"~ohlo" rI"-"ol"o ,imilal' banJ" j'-1;;t abo"" ,)II kDa_ '!'hi< 
sip"l wa< " I"" j)"e'~llt ill immllllobiots dev"',,d wit.h th" ""<:Olldal')' antibodiee; o~ l y, prl",i ng 
'hat. it wa < a 'al<e I'o",li,'e I'hi" ,i;:-nal had alon I"" n nh",,'v ed rlUl'lll~ llnr~jated re;;earch 
JOll" by other member< of'h" hl"raio,,)' aIle! i, wa, probable that ,hi . band wa" due io nOll-
, p"cifie bi ndi n!' 01' r.lw a n,ih nd](," tn IlSA I'l'~::ell t in ihe ,emm-li'ee m"rli"m (j)(,r"oll" l 
commllllicatio", "ho ,,-Iona Drach,'" eVTHJ, UC-T)_ 
.'\eith~r the M_\'11'3 llnr ih" MM'P7 immuliOhlob ha d any other hanJ" and il wa, d"c id",) , h al 
,,-nIP :, and " niP, wel'e ~ithel' a b,enl from Ih" sampl,, ", nr "X!>J'I',""d ill ve"y low q'-1amitiee; , 
/.),nlOgral'hy i, "" "lt~"naliH method :01' th~ Jet"" ,io~ 0: M~i1'<_ wh i"h wa , u o;eJ lo 
j'(,anal)'"e lhe ""mple, fl'o m 3,_,.0 2, It i, an elocl'ophor"',i c v",hn iquI' 10" Ih e ioellti:"icacio" of 
pl"ltooiylic aeli ,'ity in "n7.YJ11"" "" 1'''''''''',) in i,nl),,,,,,,),l:<lniJe ~e), "o-)XlJymerisoo wit.h a 
prot.ei ~ ""h<t,,,t.,, II ~d "l' llOn -l'ed lL[""~ "onJitiol," A"al)"si, i;; ba ,eJ on the abi lily of MI>lP, co 
",'old al'ee e!enaiul'ill~ SDS " removed , ane! to di!,e" the co_pnly n"'rl 7."rl "ub""'al,,_ Slaillin!, 
' he gel wi lh Cooma"ie Bill" allow. t. he dig" ,t."d arl"" 10 h" vi"ible "" a d eal' hand a~ai"ot a 











tlw :\IMP, 10 ", gem the il ll"" t,'a te, lb" M"e ()'ff~r"nc" bdw~en t W(' form, "Ilow, fDr 
ylHlnt LiLc"t ion of Mt1\;e:pro-j'"rm" "rtbe NIM p , '" t h ~ ,, 0 mple, 
A, bolh g"lat.in ,,,,d CO""'" or,' il uhnr ate' of :\IMl':J "r.d "I"IP', 7.ymo~r"pblC anoly"i" (,f 
expre"'lOn in "on"itLon"d m,·d ium W" e ronOllCkd " "inR i:><.,th a" wb"lral"., r-,"'Lth"r g"b"i~ 
nm' c"""n "ymD~rophy dN('cte d any significa nl exptes"on of ,,,(h,,r NI"IP. Th",,, r,,;; u1lil, 
wgw her with tlwse fwm 3.·3.-1 ,1 and ;1,:J.4.~ 'lrnr.gJ) imh"a l"d 11", h:k of invo iv,'m"~ t ~f 
M:\IP:l ar.d MMI'7 in lbe mOI" ' :)'le fibrlnoiy, i, ob.,,'r,",," in th",,· ~,p"rim""k 
.1..1.6 SUmnW"l 
Th" AIl g·2/PDGt'·BB-. timlllate d fibrin in,'asior. "~""rib.ed in :12 wa . oonfirtMd to b<> Ae " 
result "I inc re ased fibrino lYiliil thro"~lt ,mmll"ohlmtln): A"oiy", of JlTJP Jlurt.h,'rmor,·. "n 
"r."i)·, i, of eh" "perific band" in the fihrin(o):"n) immunoblotil In<ii c,, l,,d th,,1 both the 
pio emmfogpn) "n,i th ,· NlNIP fibrir.olyei(' ,,)·,Iems wet", inwlved. as hod previoll il iy k~" 
(,bil" fHd in ·3 .2.2.5 
exp'",esio" we r" llpregnia l",i on Ihe Rl\A ,md pl'Olein lev,·ls FurthermOl'e. lunctio" 
inhibiewr. of uPA and ul'AH confirm~c: 'he criricr,l involvem~nt of Ih",,, fibrir.olY'H' ele mellls 
Ln Ih,· AnR-~iPD(-;}'-BB respon,"" ln t~restin~ly. llPA s""retion is 0 cha ract."r',ti" f"atur" of 
"cei va I"" m"no,,)·tes (Pej Ie!' 200;1), " u~R~slinR rhal the up,..,~ulo !.ion of th" uP Aiu PAR 'y"em 
i . in line with hei~h\er.e" nwr."cyl~ ac!ivll y, 
m"lb(,u()iogy 
nwn"c}"[~s involwo: specific ~lem~me of both fibrinol}"[ ic "y,te ms, ami n()1 an ov"ra ii in(""'",,, 
in pf()te"lytic mechani.m". 
3.4 
".4,1 
:\INIP!I (as discus"",, in L2.1.2.~) bas been Sll~Rested a, a c"mponent of the an~io~~nic 
'witch. thron gh it. invo lv~ment i" VM;P-A ,..,l~""" from tlw e xtl'oceihllar ''''''I~,Oll' (Be rg·,·r. 











addilior., bach )"'TMP2 " no M~U'9 have aT", P"""ollsiy I:>een ,hown to aITo"t kuko,cyt~ 
traffic;;; ng uuring lllr101l11l1ation (l\IcQuihhan ~OOO: \'ietzlel' 21)(X1 Corry 2004; (;r~~nl "" 
20()f,)_ T hus incre"""d expn'''''ln n[ g"l"l,nooo" in mOllllcye" < could >ug~e>1 0 moT{' "WO",Ve 
pTllfile [or the leukoc,~e, in\'olwoi m wound he"lir.~. Full,ermo"" MMP2 "no MMl'8 hove 
previously been ue"<:ribed '" marke" fnr monocyte a~tivation snd di lJ~renti"e; on (Xi e [!I!IH; 
)"len,hikov ~00 4 1_ 1'llGr~for~, susl oineo upr"~ulali(Jn (Jf thelr n pl'e><" ln wuulu >ugge,t tho', 
1\n~- 2 ond I'll(;}'-BB we're acti\'atin~ agent, for lI~Jnn':yte,_ 
MMPf) wa" fil'.' de,cl'iheu hecau,e of it. ahili!y to cIGo"~ F.C)"l mol ~Cl,I ~< " ,el, 0< ""lhgen, 
ond gdotins ,n '.', /r.; Suh""'lu~nlly thG li"t of i!" suh"trot~s hos exponded to include a 
number or ocher m" !>';x " nd non -m" trix compound s (Ldon~hl 2()!l11_ In krGsti ngly, a recenl 
r.ephro\>alhy siuuy ,howeu ~IMP9 able to directly de!:rade fibrin I:>oth in "i/ro ond ill- V1'.'O 
(Lelon~ht 200T), de"vin~ the "o nl(' fihr'n ond fihrinogen chain< a, ~IT1-~IMP (Hirauka 
[9 91\), In cr.uolhelial cdk ~-IMP2 he," bee n .. en ,0 accivatc pro_uPA ll<mnd io uPAR , ihus 
initia,lllg fibnnnlytic aclivi ty '" a VEGF-lIwdulaied ,e4uence of Gwnts (Proge" 20041 
Consi,tenl with the"", oh"l'rvotion<, a l'ecenl <ludy ir. MMP2!~-IM1'8 doubk nl,l l mi"" ,howed 
high level> ul' fiblin(o!:l'n) OCCU111ll1M,inn, ""gge'lir.~ eh,,' the ab .. nCl' or both gehlin""'" 
llIl p'u", fihl'inolytic activlCY (1.,0 mh{'rt, 200B) 
n!rthel'mo"". ~-IMP2 i. cnnr.eded I(J fihrinoly,is, in ihat ie> octi,,"tinn i< u~]X"ndent on 
"nocher fibrinoh·,ic MM P. M1' l_MMP _ MMP2 for m, a irilIwlecular c(Jmplex with '111'1 _'I.' MP 
and 1'IMP2 on the ce ll , u,.f oe(". wlwr~ it, i" oN,i"or.eu he· proleoly,ic cleaya~e. The octiv"tion 
of ~n1P2 I, iherefure directly rG loted to thl' ~xpT{'", i"n and aeli"ley of ~IT 1 -~IMl' (K"zes 
2(1(10: Laneur 2[Hll), 
~n1P2 and ~IMP9 expression and acti,;,y were on" Iy-,("u u<ing ~elallll zYlIHJ:,:'l'aphy, Thi, 
meihooolol:}' "wol""s 'h~ Ueb'Todolion of the !:,eblin s Uhslm'" hv the !:e)"rin"se. in th~ 
samples_ Prior w quontilicotion ono ly,,' . i! ;va . npc",.",,'y w determine the ran!:e in which 
,he con""nlro, ion of "n7.ym~ WO. l'eDe<:",d un the ~elln" linear manner, The b"nu int~n<i,y 
WO. delGrmlr.ed w li~ in the linear l",~iun by ehe dilution curve using 0 pnsiti"G cnn'"ol fur 
~nIP2.C\'IMP9, which was" kind ~iit j'rom Mr" ~Ion" l:\r"cher rCVTn:, CCT1_ Gel> were ab(J 
run with a negativG CDntro l (cdl_fr~~ m~diuml to er.<U I'e eha l ehe gruw,h medium had no 











3.4,2 ADl(-2 and PUG!'-»» AITeet !'.H[P9 Expression 
l\lon""yie pl'O" llf,·,ion of "\1"\\ P9 hm teen prev iou oly wdl (hX'ument~d ("UC h m (Shapiro 1 ~9:1; 
lpvi ~OO", Murdoch 20(H)) , Inl(,,'e"'in~l)", in ,,,ldihon t~ hein~ a marker i'or mon""yle 
adi""tiLJn (Xi~ 1998; "\\enshikov 200·1), the level of "xl're«ion h,, " b.<,.,n ,hown t.o "'" 
rl~pendent on a number of difi'el'enl ["ew r., .u('h '" "urn;trute un(l the pr~i'i€noo oi' other 
factor, (Lel'ldi 2(~Jl). For "",aml'LL" C" lt. el ,,1 demon<t.nlt.erl tJw: i\1i\11.'9 expre"ion inCl-eased 
<l'll ("gi,liLOa n y fLl nowing ,](1 h~"i~n t{l c~lbl:en and plmele" (Galt 20(1). 
3A.2.1 Anal,'sis of RNA Expression 
R~vec,. ',mn«:cil'tiLJn anal,ni. ",veakd Ihat. me,noLOY''' ," 'l'ea led with An~-~ and I'DG1'-BB 
"xhibil,,u inc,,,,,,ed :'I·J:\IP9 e:.:pre", ion in comparison t~ unll-e"ted c~lh, or thLl,e tr""ted with 
eithe r Ang-~ ~r 'PTHiF_Hrl (FiguN:1IL bIl<>~) 
- . .. '"'" .. . 
, 
Pi"un .In. ;\" ' -• • n( PI)"" '·IlJL;QI",J>,,,,·.ill,,,",,,,, 
mm'o,,_;e ~'I"If9 11";\ ""'''''i<t '1'"" "a,,01 .. 0.-
'dMI'll RI_l'elt (129 "'), ",' Oo<t.om i, 0' ·,_.ct,,_ 
<"I" OJ'' RT _peR,," ,Ie. '~DC '~Dplco L..",_' 1 i . 0; 
\l",,,ca'" "I]" " of Ar_._H",~"i, ,,.11<, l 011'1)"','_ 
1l1l·,,,,,,M e, lJ,. ."i, ., of An._~ a"i, I'l)(;}'_nn_ 
,~ __ .b! ,,,16 
:'L\n~ i. secrel~d b,' monocy", in t l", 'ym~gen form and activated in 'he exlracellub,' 
~m;"mn"'nt. 'C".ing ~dalin zymogl'aphy, :'11:\11'9 e"pl""ion and activa:ion '''''" un" ly",,,] 
lLnd",' a number of different conditi~n " detailed bel~w_ V~rificu"ion of 1..1", :'I[M'P adivily 
obsel'Ved in the condition~(] nw(lium wu ' dLJn" hy in('uh"lin ~ zymogram ~e], in a "Uh"Tale 
butTer mn,,'ining Ihe ,,,,kium-LOhelaling agenl EDTA, :'I1:\lP. are dependent ~n LOalcium fOF 
,I",ic <ll'lLL'1 Ul'a! i nle ~ri\y and one of the i'ea CUreS Iha: di,tinl:ui,he" Mi\l l'" i, th" In hi hi lion of 
tl",iF ,](,tivily })y ciwb,ing agem, slLch a. EDTA (Lepldi 2(01), 2 "ym~~ram, ,wre run 
mn',ainmg identical sample" of cell-CDnditi~ned IUedium, One ~~l w,," incuh"",d in "ukium 
rontainml: sub.lnlt·e huffer, "nrl t lw or l"'F in t l",,,, mnLO,mtn,tion, o[ EDTA in ,ub.lrale 
huffeF :~5, ,'.(1 100 m1' D_ TnhibitiLJn o[ ~"b': nol)"ic aClivily })y EDTA contlrm~d the 
I'roteLllyli(' "nzyme. under analyse" were lIl\ll'" (data not sh~wn), 
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'"~n0'l \0"0 .!J1J" lWJl " It! u ~;)'l0UJ.L '(tlJO~ h lJ~ "I" UCl}X ~\liJ.6 [ "Xi s,n.bJlllJ(ll p,""A ~l,'" JO 1,)C. ?().It! 
",,,o~'1 ~ <s 'f,clT'JIX )0 UOrlOll DO.!d "'1'1 ,Ell! 1 0 'l!OllUqHJHJI'" ;)'j.{>OHOm )0 ,a~,1'j, !;p~J J lj.J. 
U1 llOl,"""UXa 6,/Wl'J no :wall" ,,'lO""U~l+ ~ ",wq RfhP)(I,J "US ,.-:h,V .Slll 1'''WJ 'Je'!'"~~ns 
'In,;u ' !'l.L -It pu~ r mwe_lm 'gl~ ~.!r_~!,iJ .. moq fit "il lUO"'IR 1'11'" 'If, pm' " UlUn],\.o 
UI~ cunlhll.) ,."'()~ f"6 1" ?J" """",'P ,,,.,., (\,[8 ;).m~!d U! P~.(['l(r,!P ' ''i ".l\1oq ~ l 1" u~"" 
I~(I ~ ~6i !J.dYH, JO uO\jqnE;).H[n llmJ 1JlU~1" "'Il '_'IJ!ULj",.!,)jlll ',01"£",. liO,,"", llL ""qL.,[O •• p 
S~ HR-,{c)Od' pHU (,-~uV jl!lHW1"''' Ot9 1 11\:<lH """l -ll"" '" HI .~nolj t(, ~oJ ueltlqllOlH 
~,"M Ot91- Il'J,J<[ ~11TT11 ~1 UOO_1I111H" u~ ' .''''D t 1 '!0J p~Wq110UT '~J.'",uol\ 'pmJ"<! .;~ D-t '" 
.!,lAO P"'"'''"'' '"'I" """ UU'dUUd pm' f, .]l uV ~l!"" PJ1"'I" ,)U L ,Jl.(;XJUOlU JO UOl," ,'"UX;) (idJU\: 
'papaHp ss." Wl Oj a,,'los S( I ~ ,,~ IXJ pu~ "m,lOj ua~om.'z 
~(l1 ~6 ~ql U1 ""," '~J.'0 nuow ~'!' "i\ P~",~"jx, &11'<1'< ~'!' n~ ",Illn,! ~l ' V ,(~ pu~ (, <uun' j"" 
V I ~ .)"n~ !.'i) ' F'AJj (idl\:}\! llU!"" ' j" lOU "1I ,m Plh!PUL J II,! ," ' ( t UmU jl);' 'V (8 Cl.!c_ll'd l UO!",atux Cl 
(i,Il\l\: U! uOL"'ldl;).!UIl %t~ " "" C_",) "Cl,!pllol flfl -.'i UUd pm' ,,"~uV 'l.!;)"U! W,,"~O(ll.\z 
~A1jmU~< ,' .I (j',l ')'!1 pu~ W",I~ "!P ,',!l 1ll0") U;);'" "'l U',;, 'V -().Jl!,o "! ulJT1"qn,)U, JO ',lr,o,! 
" .I~\J" e,munp t u"".J P~l~jo<l -~l·"'()umU lULU) P~l""lqo wr,lp~w p~unnrpuo0.J" "dj'm ~ 
o'qds"llO(ll_,z ",!'j (llOJj paUl\1',qo BanjK' ":lUl"AS a'11 JO UOl:W,U",,,,,,dal ol,!d~W S 8' va: "llljl,{ 
""'''''P 81 ~ =" -~Ol) , d, 'AA-.!IOOd P"" ,_.iu',' ,{~,~ P""'''"' 
'n." uW",; " (" "'" " 11{."'~'''o, ",,",U' U[011oq - 'Of~'"~' 1"-'1"00 ' 1"'-" 0'"'-" "",m <10,]. .,"~,.10,",', "'",",U'-'''-''"''' 
.u!~:"" "'''UT I ,i ' r ""I' " "',"o,,]x,, 6,ml\: ',111" '{11U""'I'''~' >ou op Afl--..mH,] p,m c-~uV "\I (",mop 
~) • ~ U ' ''ilJ ~ d. ",. "'''''1(0) ",t~ ,i' "'''''!'''! 0, "c", ,,,,d.o 1;,T1~J~ , ,.n<o gg ,o/ '-)(l. ! PU" , '!m.' 'il'_" ' ,n-'OOUOU[ 
, 0 ,uOw,.' ,!, ~ "",,."eel""' ti, H~ ,;!~l" ouO 2u~ ,'q """" '"'"' """ .. lUI. ndI\H "" ,,,""oJ\; L ~ u nt'J 
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and ohM Ang-2 and I'IlGI'-B B .,in'ply accelarale thi' proce8; In both " 'ea,,,,<i and ullcrea led 
,,,n' ples. olle graaual inerea"" III aCl ive ..... 1l\lP~j (H~l.lh) wa, very "milal' (Fi ~ lu-e :HIl, ~el 
ill,,,rt), 
3.1.3 !malysi§ of ~I M 1'2 ""pression 
AlthDu~h opillioll" l'emiUll di v'ia"a reg"rdill ~ th~ ncelll or l\lMP2 ~xpre"io" by mo;wcy te;, 
Sigllit1('anc MMP2 ""I"" ""D~ h,,, )~'''n ""ported In " n"l11)~'r Df differenl p"per • . Sl,,'h ". 
(ihr-Or 200_3j, 
differe"(i,,,ioll a nd act-ivatioll. it is po . sible that aiffcrin~ nwchod oIDgi'" of l11Dnl.'yle 
i""I" lioll muld inl1uenc~ '/,ThiP2 expre"sion 
:1.4.:1.1 An_aly ~i" of RNA txprts§jon 
~;r 
~ . .... ... ... .. 
- - - - 21~ b, • 
LWl" 3 ~" ~"'=''" MoW. "P"'« ;' ''' .. :><\ )l k,,.,d_hJi 
m""''')': ',"i:h Alei 2 on ; P!lGF_n~. T0" . " ; n __ ,~~ "'l l:. 
M_I-1I'2 y.'J' 1'Cy. 12.-!; "~j, "',,'<'''' ;"_"cci,, ,2 12 b" ). M}U'2 
"'r"" .. i"" by m"",,"yl0. :tc)1-"..! ",i," r nnF_TITI 110", ~), 
~" ."_" II , " , ~I '" " ' 'OmOi,, ":i,~ 01 h-ot.h {Ior_, '.j Jd ,,~ 
.Yionoc),,:."> i_"D ],,,ed h" de' Hiry centrif,,~al i on "n<i fihmlleciill adhesion (2,1} flid ,e ('re l~ 
.YL.Vll'2 (}'igu"" :,2, hn~ 1), Tl·."lment- wi,h PDC]7_TlTl "naiDl' An ~ -2 did not _, ignif ic" ncly 
alTed 1>11>11'2 l"odudion (F j ~ lu'e 3~) Decal"e of Ih" rI· laci,· .. ly IDW ~ LLali'y of 'he 1'CR. Ihi, 
Te"ult ",ao confirml·d h y geb"" <y mo ~raphy, 
ln cont.ra"' to (h ~ hi ghly re~ula,"d .Yll>U'9 "x:rlr,, " , io~, ~lMP2 eX]li'e<sion was not 
_,ig~ifi""" ll,Y allel'ec! Lv lhe addit ion of Ang_2, PDC]7_BR. Or a comh illalioOl of holh grow-:.h 
rado",<. Incere".;;l!!ly, ho w"""r, "II "nI P2 <ie l~cl~a waS in the 62 kDa ;H,t i .. " form , In 


















aA .a.a An illn;' of P roteill Expr .. . . j(>Il ill Cd) LHilln 
kD,:, ,"""'",,,n in oombei",,,-'" ",ed,um 
"m],.:-, 0",";",," Iwm m"":""~" 
"~a""l with Al:~_2 «cd PDGI'·nn 
(wl""",.'1",,,, ~J ,]wwcd tJ,., C'X,""""''' 
die! not "ilk< ,,,,ni],,",,tl,. lmm ,,,"teol 
""m""-" (colu",n.'j"",- 1) 
p> 0 .05 6 ex,,-";"""" '" ""h,,"t. 11 
""""J 
MMP2 octiv~tWlJ h". beel! ,h""Jj to be medialed b,- comple.. fOnllation wl,h :\IT1_MMP ~nd 
TJ:\IP~ olJ the cdl memhm"e (K"""," iOlHJ), ThHefore. becau"" 01 t h ~ llpr" g\1 1 ~ti on nf "ITt· 
MMP ,ii'"ll",.d ill 3.~_ 4, Ie wa" ,hoU Rhi po"ible lhat mOl'e M}II"2 oOllld h" IXl\1l1 d tn t h" c~ll 
"u,{~ c~ ill "ccivaii(", colIlplexes W J, ll MT1-M.\1r _ cen ly8 at.,," pl-epa,'('d a" d~t.a lI ~d i n 2..~ 1.4 
were a nHl) s~d llSi ll~ ge)atln "),mag-rap hy (2 .. 3.3.1) . 
No MMP~ eX I}re,"Wll wa" delecled ill 'he cellly"ai~8 allaly"eo. ll8in~ g~ l atin "ymag-mph,.. 
The lane" in which t_he cd l Iysat_e" w~re nm exhihited hIgh i~V('l " nf "tr~~ki n ~ ~lld 
backl:l'ollnd. which Sllg ~e"te r, th a t t_h~ techn;qll~ wa" not "\1;ted for onoiYT.ing cdi iy,ol~'. 
Summan 
PDGF-BB. and the eXpr~,,"iDn of' the ~2kDa zymogen form was ,i~n if\cant ly ; l1c"ea".,.J in 











I:lXlwth f'''·'',r, W", l~"", "Hg-g-eSling ~iLha tho' the .~L~11'!J upreglll"llon "ccn in res)}o'»e Lo 
Ang.2 and PJ)GF-I:lI:l wa s not '"'' ",'Sllit 0" increaileJ lIlOl\(x:)'te uct1vnion. or thal MMI'!) 
~xp r~"'lOn reach~" a plaLeall in di'Te1'enlialillR lIWno")'~' wh1ch .\ng_~ and PDGF-fln 
ac"C~lenl~. 
\1M1'2 ~xprcs8iun Wail no' illllLLencd l)y Ang 2 amll'lJG)<'-BB ~~pr~ilsioll. although ","Lr"" 
t .. wm~ r~p:)l"" ill th~ lite,'alure, ,\[\1P'2 expre"ion hy mon (){:y'~' W3< not~rl in ))10"' dunors. 
lJ~ilpi\e Hpr~g-ulaliull "f ,1.-IT1·jI,'lMP ~Xpre""lOn (:l .. ~.4) n~ "hang~, m MM I'2 ~xpl'{'<"iun W~l,{, 
no L~J 
<)'mography 
3.5 Ana!.· , i. of I'o.~ihle 1{ ~"ep1.Ors rO!, An2"_2 and PDGF_BB Sign.aling 
When AnS'-2 waS ,-irst Ji'c""~red, it wa , thoHg-hl to lw a rrowth !""t.--.r ",'"ul(:ted to "igna llllg 
through lh~ endolheli"l cell-'j>~t'ific l"<:eptul' Ti~-2 (Mai«",p' e rr~ 1997) Inc",a,mgly, ,ec~nt 
"ejJ~rto haw llllked Tie -2 expr~;siolllo olhet c~ll type, (ail di<cHsS('d m 1.4.21, H" w(' ll a< 
oLLS'geslillg that ,\ ~g--2 i< able tu "i~llal ill cdls lucki ng th c 'J'ie_ 2 ,e"epto,. 
,\ nuwher ~l' indq}('nd~nt. inve,tlga tio n" have rep~rtecl Tie-2 expre""ion 0" l1On-~llduthelial 
ccllo, in cluding nClltmphi l. (!-"'mi~ux 2()(1,'i) rr.lLr,,1 precur><lr cells (iurial'C- :!003). and 
~ncl~thelial progenitor cell. IEPC,) IS,,!o Hlfl 5) TllJeed. Shahrara et a l (Shahrara 2002) 
descrine(L ll<ing immllno"tuining. that Ti~·2 wa, nj>r~".~d in sYl10vial lis>ue lining- cdlo. 
rr.,,,,,.oph ,,ges, anu S:\-!C III bOlh "rthrilic and C"OlllWl paliellts. Otkr contraclictory rcport". 
howe"e,', pwpuse oppo,in~ ,'eo ultil, reportill~ l1() Tic-2 cxp''{'osion on nelltrophil" (Fiedler 
2(00). ThcS(' stlldieil Sllg-gCSt rhot Ti~-2 expn"sion i" n~t yet ' ll lly llnJer"t(x>d 
Rec~ndy, An~-2 ha> beell ohowerl to b~ able lu si~llal in tk akenC(' ~l' 'l'i~·2. hhrn"b"t.< 
have ;",en 'hown to adhN~ to Ang_2 rhrough i~tcgrin ct, (Curl"on 20111). while ""rdiac and 
skdetal myuc,"t;c" adhere thmug-h inte~rin s ~" 1M., und P1 (liallahricJa 2()05,1. Ang_2 ha. a1", 
he~n imp li "atecl in tumou r progre,,<ion. whe,.., tu mOll ' "ell> b"k Tie·2 Hpre".io" (EIOh 211111: 
Guo 21~),'i; flu 21~)5) (,ee "eclion 1.4.24.) , The8~ "tudi~" inJical~ thaI At,S'-:!, thrQu~h illl~grill 











Tr.,.ep;rin·mediate,1 iJig'nab pIa}, an important ~ole in "'i:ulmir.~ mar.y leukocyte fundi"l" 
(Yurochko 1992; Reye,-Reye, 211()~). Ir. mnno"yk, and macropha~eiJ. the p, suhi'amily "re 
involved in eell-cell il:teracliol". "ell mi grntinn anJ pha~ocyto,i", The ~I ,uhi'amily , oll the 
other haled, "'''llrol ,'"lhe,ion to excrncell"hr ma',l'ix pl'oleir.s, ,uch liS i'ibnll al:d the 
al~ ivacion nf ge r.,," ir.volved ill inlhimmation iRey~"·Reye, ~oo~, ClarK 200m When l-.ound 
co th"i~ r.atmnlli~and". hoth typeiJ ,,[ il:tegrin, "div"te man)' "gnaling pathway" ir.duct ir.~ 
Ra" },L\P Kinn,,', ,",\K, Sl'c. R"c. Rho al:d PI-J·K IEliceiri ~()()1). Tn adJi1ion. many r",,,"ll 
in",,"cigntinniJ hnve ctemor.,tratect that cell adhe']()]J l'''''epcnrs. ,u"h '" inepim. ar.d growth 
f w"nr ~eceptor __ net ,,"npera tivdy i n ctetel'minil:~ eell ,i~'na linl( IEli""id ~I)()J). The ~(""'pto,, 
known 1n ideract wi"h inkgrin< ir.ducte 1'1lGFR p lind uPAR (Plol'l,er 1!)\J5; SlUlJberg 1\J~)fi, 
Plu<ko1a 200:J; Plmkotn 2004), 
PDCFR·ll expre"",on h", heer. r.nceJ on mnn",)'te __ durin!: 1h" differ"ntiation into 
nwcl..,plw~,,", with low "xpre«ion durin g the early nctil'ation (Kn'tteK 2(01), nr.d a <trong 
,i~r.,,1 ill fully·differentiated nwcroplw~e, (lnnha 199:1: Kuma!:ai 2(01), whik Pf)C,_flH 
acti"n or. mor.ocy"'" has prcviOl"ly Lwer. documentect (Si e!:hahn 1 900; Ji:rnof,<nn 1 fl9Ii)' 
PDCF-DDiPDCFR-li have pl'eViol"]Y been shown to intel'M't with a numhel' of diffel'ent 
illtel(l'ill' (Schnellel 1997), "uci:J ", ir.tepil: ~, lind ",po, Ahl"n e., al ,howed tha" ir. 
fibrob la"I • . PDOF-BB lIwduhte" the membl'''lle mobility of~, inte~l'in", therehy moctula"in!: 
K- and pr"tein "il:.",e C IPKCi-del,el:dellt manller (Ahlell ~1)(I41. PDGF-BB h"iJ a liJ" ,een he 
"imulale 1I:-uJlegrin-medi"ted adhe,iol: ,,"d .pre'Hlil:l( il: S)lC, il:" PKC-depenctenl mar.nel' 
(K..lppen ~(HIII). PDGFIl-p hE abo been ,een lo '''",JoCiale with vm-io", integ-rin" ir.cludinl( 
""P" and "he en~"~emer. L , of the ir.te!:rin ir. Nlll ·matrix ir."eraclior.' hn< been ,,~, Cn increa«' 
I he re<por.,e of t.he growch f"c1n~ ~eceptn]" 1n ch"ir lig" r.d , (Sdnelkl' I ~)!l7i 
The ex l,erimel:t, ill thiiJ '''''tiOl: pl'ovide "n inti,,] ar.alyiJi, of the r"""ptom uiJect hy '\n~-2 nn d 
PDGF-BB to si~nal ir. monocyte" 
.1.~.2 Analy" i~ ofTjp _2 Exp!'e .. i"n in Enti!'e bol"ted M"nocyle POlJula'ion 
While Tie·~ expl'e",,,)]: ha, reNlnlly been reported or. a numhel' of different cdl type, (Koh 
2(HI2; Lemieux 200.')), Tie-2 expreiJeion on mono"y.," i. ,till "n i"u(' unJer di,cu",iol:. 
Recently tho,' have heer. ,ugg,'<1ion, that Tie·2 i, e::,:pl'e"ed 01: " mLllOl'itv "i' hl,,,,ct 











ci'Tllbting EPC "xpr,,".,in~ Tie_2 (.-\nRhelinu 2CKI2), al,hollgh there i, no delinl\i;'~ upinion on 
wh,, : EPC, ar~ - )XXlrlr differentiated enduthelial preelll'"Ol" oj'" ngiu "la.<t "rp" nr .,i Tr.il "" :" 
ud nit 1l10nocl't~" with the a hility to ll'ansdifj'"r"nila leo 
">oth ){l'-PCR ami. flow eytom~try, 
• 
. ' , '" 
"Mly.i •. '1\", ",I ,"", ... "t, '1M,," Jl.T·Pf:~ "" hpj. 
I\u"om ""I " p""nt> TTPJl.T hT· rCh f1 '" 'PJ of T;'· 
, 0'1"""'''' """"oW "'", Ti, ·' w~, "x 00"''''" in 
1';,,,;,1.,,, W.N " " " .. " """~tiy. '''ntml no"" OJ 
""0 TT~VF.r",. ",iei". '''"''01 n."" ,;;. All ""'pl" 
w." run in ,,,"j,,,,,,,;on wi" TT,p,,,."";n •. ~''''''ne 
O:",,.O:,,-,,'il>o,,'I,,.,,,,I,,..,,,, (H~r.,.) ... ,on"ol 
hclJ"'''epi,,~ P'"' R U,ing 1\,,-.- 'y,o", ,,,., '1';'·2 
Wh en the expre>Sj()n of Tie-2 un lllonu"yles w". "n"ly""u hy nT-PCn (a. delaileu in 2.4). no 
,ignifieunt Tie-2 exprH,ion WU" noted in the whole nlOnOC}'t~ )Xtp"lution llnder th~ 
experimental coneiilion" Figme 34A j. a re~l'e,enla,jve gelu!' lhe RT-PCR re,ult". The to~ 
picl"r~ is of t-Iw Tie-2 peR, und tlw oottom of the PCR of 'he HI'Rl' hou,ekeepinR wntrol 
il'ealed with PDGF-Illl (Figul''' H4A, lanp ~), Ang·2 (,'igur" H4A, l"n(' :1) or" "nm")]n"linn of 
ixtth Rrowtll factors (Fi!:LLl'e 34A. lane 4) ,huwed any Tie-2 eX~l'e.'lUn, In Ol'der lu confirm 
11","e negali"" "".<uII,. fiorohlu"lil " .. ere u,en a" a ne~at-i"-e control (Fig"re 3+,,\, I"n~ 5), unei 











A, i" iil I"'il,ibl ~ 'hat mR}'-A ~xpre"lOn rr:"~[ not ~c"urM "I )' ,..·fl'n ,he ecMdy '''' t~ I, .. otein 
le,'~J " Tie-~ expre"ion m mtH" ,,"" .('._ "' n" nloo ""al)',en ",ing T,e ~ now c,' tomel .-." Onc~ 
agaHl HSVEC were LL ",d a.'" p<"itiw cont.roJ. wlnl ~ human cterrr_"J fib"J bl~,b ",e,'~ ll,ed "._ 
n n"l:o tl w mnnoJ. l'igu,--., ,--.,p .. ~,*nt" ~n ~wra~e »1" l f rom chree indClx'nden r eXl~ 'rlm('n to (3 
donoY,) As cnn I", "".., n, whil~ %';'0 of ~ndocheh" l eell_ were p"citiv(' for 1'i(' -2 (h gur<' 3Hl. 
hl~di. lin~.I. mO"'~: ,'·l~. (}'i ~lll'e :\ ~B, J." ._lwd lin(') and flhrohla 'lil (Fig-ul'~ _'1.111, ~ey line) 
ct iilpl~}'e-d no ct'ocHMble exp"", iu n_ Th~_e n--ul", logether wirh "ho«' ohtain~d using RT-
peR " LL ~g~" ,.h"1 ,.h~ mtHHJ(,yt.~._ i,,,iawd h~[ ctenlill)' ,,~nlrifugn:ion in ,he.., ~xperi rr_ ~m. 
W~l'~ a Tie-2-negali"~ edl popllla,.ion 
Although t.he",' fi nding , nn' in roonttadictlOn wi, h Iho.., ofVenneri et a l (Vennerl ~11I17l. il i, 
po"ih l ~ ,h~t tlw di,simiial' i"olalion pr< x:edur~ could ""count for Ihe,",' chff('renrx's In th~i .. 
swd", Vennel'l el "1 LL,ed ma gnd i,' l","d._ 10 p'"i"i,'('ly anct ne~ntn'e l )' sde,·t for c~rt"in c~JI 
p"pLLl"cion. 1'he._e ~nrichmenl pr()(;edUH'" the,--.C'loN mi~h, h ~ \'~ h~~n abl~ 10 ,eled Ih~ Ti~-
2· ""mo('yle o whiroh mny haw Ix,<'n loet durin~ ,h~ i,olation proceJ.l1Te de,,:ribed Hl ~_11 
I"lln.hermo!\., th e' anal)',eo ofu1'AR, .'.-11'1-1'.11>11' ~nd 1>11>11'9 Hpl'e,,,,,n In ,'e'p'Jn,e 10 Ang-2 
and J'llG}'-BB de&Crihoed alx"·e (Seclion 3,3) "lron gl." ML ~ge"l lha l the numher of "ell, 
n""<'il'Rty to I'roduc~ ,h~ l'~lnt.i, ~ inc"""",," In prote in expr~ _'HJn oh._erved wOlllJ. nr~x'.-"ibl.(' 
a lar~er J1"r"~n'a~~ oi' 'he p<,puialion '·0 l~., ""t.iv"ted t· han '.he l",rc('nt.~g" of 1'i('_2_1><)i;;I; \'" 
,'elb de,,,rihd h~[ \' en n~rl 
A, Je",;ribed In "":li() n 1. ,1. 1.1, the l'DGli-BB liga nd i, ahle '" hi nd 1.0 " 11 I.hn'e l'TJCF 
"",~pt<)YS (l'IlGI" R-@, -"~" nnd -~·ri) wh ich ~ii1~r llli'u.nccion mainly l hmu~h their eXpre""Km 
patt~rn' (Funa 2003) _ ,\s 1'1lGFRri exp,.., ,,ion W~" P"""j()u"Iv "~p'>rt.d on nl!")(J("" .~, in ,·h" 
(KumagaI 2001 I, 1t ",a" ""I,d"d for fll rt Iwr 11H',,"t-i:::ation, 
An "naly,i, of n:H.NA ('xt.l'a,·t",] fron: mon",'y\(-' "reat.cd wit h ,\ng-2 and 1'llC;}'-BB l'e,,~alect 
lha I l'DG FR-I! expre",ion ""'''' LL P"'~llla ted in Ihe pH'",.,nC(' of A n ~_2 "n d P Dt": 1"_ n n. and a l eo 
mod~l'atd" in 'he pr~""nc~ of ,\n,,;-2 ~lone (FigLLre 3(;), Cel b tl'ealed wilh PD t": I'-Dn "lone , 











..,-. ,..",~~ I 
----, co"",I. w;,h PDcr·TlTl wi,h A".·:l, ,no ~';,h heth ,\".·2 "'c. rnGF·~~ ,",,,,,,~,,,I , . n _:; 
Till. ,'e,,,] t s"g~eGt.s not on ly t lwt I'VG I'R-E> I' In str\l men ta l m I'Ve; 1'_fIfI ;;ignn lin ~ , hut n 100 
ti'"l Ang-2 I" m,il''''''ent,,] m r""'lht"llllg l'llGII-DD ",gna]lll ~ b,- Upl~~u]aung the l'llGr 
PXP"!'''510n u.in~ " I'DCFR'il F.JJS,'\ kit obtnmpa fro", nKon Sy;;"·",,, '" a">-<'ctib!'o in 2.:L; 
(\-lll),,,,I" ' (2 .:, 51 t~ken '" 15 hour; J'n>cJ cell' L -", ~'ed "jth Aog-~ (50;) n~/mli 01' l'DGF-BD 
i2() n~iml) wpre \1>"'] fnr Ihi, f~!JS.'\ . 
The re"\l]t, dIsp layed bdDW hn-rh!'l' '\lg~e't t·hat. the pr"".,n,." 0" ,'\ng_2 il< [Jill''! '"'u"''' "n 
upl'eguia,ull or mono""'~ e"pl'~OSlllll ,,~ PDG F.H ·1i (hgur~ 3'" oohnnn s 3 and 4], ai; . u gg!'sl!' O 
by 'he R'l'-PCR nna]y,i,. LPlllllh~ addu·ioll or An~-2. (in the pres~n"e o~ an,,"'1C!' of I'TJU II · 
EE) a hlW, bui detec"ab]e PDGFR·1i 8ignal wa, de~r]" on,en;ed in t,h!' cell Iy",,'" ,, "mpl'" 
Lnlike lh~ PCR anah·,i, (2,5 ,3.1) howe"e,', the level o~ PDG'·.H-~ expl'e""iDn wn;; O('"n to l~· 
















p[}( lrn_ I\ l\LT~,\ ,", I,.,,, of men,,,,"' 
cell bote , "ho~,-,j dm udrcal," " 'il. 
"oJu '"" 1)." 'h"" ''''"'e'ti w,tI, l'llG f 
~I) {3D ,~iml. co].,,,,,, 21 "»ph"'" '" 
,h","-ah" f";t 'H I' """",~, Wo,'" 
'\~·2 w'"' add"d. h' ~·I" U. l'itb" ",_.",-
(",iume> :<,1 '" in l'"oi"m , i"n w,'.h rnGf· 
1)1) (""ium,_ .;). l'DGI'H _pl'.p""',n wa, 
3.5.·j.1 Analysjs of ,'X'lfct~d inte!:rip Ex pre« jQU Oil 1tlopoc) its V < jUl!" 
TmmunO(Tt.("'h~mi~tl'Y (ICC) 
, hat ' \llf:"- 2 was si..-na ling- through al,olh~r ,y~e of r~ce~,or, An il'creasinr:- 1lU III ~r of 1'~porc8 
III mder to 
inv e'ti~ale lhe IJo.<sibilily that All~-:! wa" l"lemcli"g' wi lh wonocyle, throug-h a we mb er of 
th~ il,r<l grin fan1;ly, a p re liminary study of il'tegrill ",, [}res-ion wai3 ,,'mnuoied USil'~ the 











J.,,;, '!'"k 'P"~ma nox dWll,bel' ,I ide" WHe u"~cl fnr growLn~' Ih" "ell,. lherehy ('ireu mwn tinv ;.he 
nece",i;.y of conting ,h~ ,licl~, wI,h " prolein ,u('h a, fihronedin, a, i, ne(',,,,,,,ry lor gb", 
"lid~", Fur,h~rlnor". 'h" '''In''''"hl" ,'hnmjx"" " llowed the c~lls 10 b~ incuil"ted wi,h AnR-2 
"nd PDGF-nn dindl), on ;.h" ,Iiue, Aftel' th~ incub"tion, the c~ll" w~"" fix~d with i"~-,,,,ld 
mctlwnol and stained with tIl<' an\ ihodi~" [rOlr, lh" In l"~Tin ria,.i". ki ' '" ,iL,.,'rih",1 in 
2,".1,1. 
Of all th~ an ,ihodi~" u",d. onl,' :he "lltihnuy ;.0 int.cgrin II, (~igur<.' 37) gn"e a oonvincing-
"ig-nal in nil cdl n'ea: lr.enl", Th~ "miix>dies to ;m"Rrin> a-fl. (Repre""n:" l;,'" "hoven in figur" 
38) nnd ~ ga"~ very IDW sivnal8, whj]~ the olh,'l' lv:o "lluh,><ii,," showed nn ,ign,,1 ,,( "IL 
Th" pi,'l.ure, ohU,ineu h), tlunr<.'",~,nl lr.inm')c,py ,ug-g-e,tcd th,,\ \h~ ~'; imeRlin WaS loclili"ecl 
on the ,~,II "urfa"" around the ool'del" of att"cllln~nt '0 ,h~ "lid~, III OJ'd~r lo fLLr:h,," 
invc"tivate t.hi' Ob"el"'atinn, the "lid~, W~re re-hHrr,ined u"inR confocal rr,i'To,eopy 'Lnlih 
n,gulal' rr,i"j'()""OI'Y \",)l1lIYU<' • . nnly light frc.lr. ;.he fo"','ed point con;.l'ihu'e, to the final 
irr,"~" in" ('{mh',,1 'y,l"m. which allow, hivh-re"olucic.n pi"tures !loom n well-defined optic,,1 
"",t-ion to he pl'odu'~'(L 'C.inR a 63x wlitel'-imll,e,'sion I~ns on the conlocal micrc.lCop~. the 
,Iides were opticnlly ,ec:ioned a' 1.5 ~ll' .,.,r """,ion, """u!t;ng in HI ",,:cion, pel' field o[ 
FiRm,," :19 "nd 40 ,,, .~ rePIe,,,lll,,liw opl.i",,1 ,l,, ('b l"h,n "f lr.om,,'y,." •. Fi~ll"" :19 <hnw' 
umn,,,:,,d Innno";'l~', whil ~ fi~ure 41l "hnw<" ,"]1 ';.imuial.L>,1 "~lh Ang.2 "nu 'PTJCF· l-1H .'1< 
""n h" "1,,,,~ly "een ;,,,h ol,l](',,1 "",,,b, lh" ill:,,~";n~, i, d""rly iLx,,,li,,,,1 on I.h" ,,,II ,mf",'". 
"nd i, ,,,., ~,i";. ,,,1 with h,,,l "uh",ion, nn ehe inl.erfa"" helw~en the eenubr lr.L:mhrnne allu 
Lh" growlh ,urf""" "nd in th~ m"rr,hmllnLL ' proj"(',ion, (Fig"", ,, :19 "nu 41l. d ,,,,r ,m""",) II 
wa, al.o no,ed ,h"t a siRn,,1 Wei" ohlliin~d in :h~ l"'rinLLd~al l'~~'ion (FiRLLre, 3fJ and 40 
do;.led nn'{Jwn fly anal)',inV Ihe optical sections, it wn" decided Ihat Ihi ' ,i~nal wa, 
p"";lll]('I""r, "llU " h~"W" ,h](': of 'h L: l'"rlr.L:" hili"" in n of lh L: ,,,II m"m hr" nL: duri n~ <" lr.pl" 
pl'~p'Ealion (re r><>llal mrr,mLLlu"a:i"n, ./dl" Li7, .. lin ,I er ,,1e l'W e, D~pt Anlitomy & C~ll 
ni"lo~y, CrT. R8A) 
Report, in Ihe literanm, ,uvg-e,t "hat Wlr.C gl'{JW;.ll lactor, ah'r the memhrane dislrihu;.ion 
nf int.L:grin, on ,,,II ,u~f"('L:'. :hu. ab,";ng- ;.he ,ivnalinv of :h" illtL:vrin,. 'PTJCT'.HH, fo~ 
exaln l,I ~. h,,, pl'~,'ioLL"I,· b",n Ob'''l'Hd u, rr,ndub", Ino:lilily of Ih in"'Fin, in fLhj'()bla"l" 











stud y of h lll)1nn mo~oc}').es Mali,,"-Homan el al (M nt.in._Hnmnn 20():') "Uf';~e>;ed th '" the 'hli] 
and noli ! del'en<lent llpNgul" linn oj' .\ 'lTl-1I11l1P wa; mure <lepe c_J e nt on ic_c"gri~ l'~c~ptQr 
occupnc_cy, r oth~l' ,han ,,~gregati on. 
)e ac_aly'''<l ll" ng 1)1lCrn",opy, ~o ch"n~es in di"rlLhution ", ere de"""t.ed ""ing t.h,' 
1)1lCTn,cnpy fneilitie. nvnihhk ,\lternau" e me;h,.J, ",ere lh ere[ore LLt.il iz"J ic_ 'm]"r t o 
3.5, 1.2 InhibitioJl of C andjdale lniegr in.Emi<·tinni nil" 
T!lle to til" kv"l" nf ""p)~,,"io n .«"'n t.hrnugh ICC, it seemed lihly ula, im~gTin lie w,," a 
cnnJid nW fnT ,\ ng_ 2 si g~ nli nR. Th,. h ypoth~;;is ¥.'", ,€, led by adapting' lhe '~ru m-[",e fibrin 
----
, 
i "" , 
"., _~"~"'M' • 
I' o""''',- -i,,),,'i- i'''' " 
jW\T 'll 6 .. ,,,lew' 10 .. vi ilnd-'I'lXW-l:!l:!_ 
.",d,,,,,,.,, , 
'"0"",.,,, fil,, ;n im·" ion (.-oh,m n 21 to 
dn)p l<) \'0"",,1 b~" ,,,»1um,, 11. I" ,he 
a!:"'-coc. vi ,~2 "n" 1'll UJo IJIJ tJ ... 
"n ';·""".I' "'" '"'' ,i"n 'I",,"-), all, ,,, 
1.",,1,, " mone"," lil"", in".,ion (coin ,"n 
,<, ", ~ "_",, ,,_ 2 ox,,,imon,, in 
\ " enn lx, ","c_ fTOl)1 fil:llre 4 1 obnve. t.he fll~Ct.ioM J inhi hition of tl", rY, ic_le ~rin fOl)1il,\' 
removed t he OlpregulatiDn oj' fibrin in" a'llJll ca u,ed by AnR-2 and PDGI -BE. lntere;li~ gly. 
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i:J..II.:.t..,l'li. l'rt. "". ,,"- nU'ft",,,,1 fro., ,,_'U .... ,1 .... (1) '" oull". . 










3,;;A,3 iUUlUlnOH€ciuilaliou of :\ng-~ with I.lI.t(~grin p, 
In lInler w .':'u-'h~l' cee,1 ch~ h)'p'lCh.i" of in!,,!;rin f', "" Ilw r''''''ptor for A~~ 2 i~ "'O"''',I'!!''', 
cell In''''' ' fro", c"n , 1,..·,,(,," ,,~th .-\n;:-2 Wet" ""o)&ct.ed 10 illLlnn nop:r.,cipn,atiDn with a n 
,,~t.il~)"y for in(!' gri n II, (Al",om, C:ambring~ , ah;J~7). '\8 MtaIl~d '" ,,,,,tiDn 2,~,2 , ",,11 !y"at&, 
w~re mm,,1 "nth th& monodo"u! a"tih.,dy fllr human Jllt~~Tin p,,, n"d t-h~ ""tih.,dy 
p""eipi tat"a u""g 8"ph:,",,,,, C beorh, l'ol1owin;: precipitatio n , r.lJ!' ,"p~rn":anr,' wer~ 
analy""d by SIJS 1'AC1'- (2,.,.2) ond a~t",ct",d fM 1·he pr~"~nce of Ang-2 "'in;: a polyclo,wl 
o"hbocty (2_3.2)_ 
Fig·.Jr" 42 h<,low i, 0 ",'pres~ntatiw ilnlllunohlot of the ilnlllun·opr&cipiwtion ~esu!t·s, Th ~ 
amih.,dy l()~ i"t-~~~i" p, ,liJ indeed ""-~l'~C1~jc"le wilh lh~ ,~rm"bina~c An~-2 i~ mo",,"}',e 
ce111Y.l<le" 1<, sh",,'n by a bl<nd (Fi~lu'e 411\_ ian" J) coj'j'e ,ponuj~g in ,,<~ (60 kfJa) 10 Ih,· 
A~g-2 " ,amlanl (ri~ul'e 42.'1._ Ian!' 4) Thi, Ang_2 bana wa, al"",,' in ,am~i,,, I j'eal~d wilh 
!'ith"r i~t"gri~ If, "~Iil~)dy a"d "'pharo"" c: b""d, (~'igu"" 42A bn" 21 or wich ibg-2 amI 
""I'.,oro"" c: l)('Ml" (,'igu",' 42.-\, lo~& 31 
A 
n 
Fl~"" j2. :",,;) ",.j""",,,,,,,,,,,,,,,] ,;,",,> _~';" ",t'g,;n r' ;r 
m"",,,",e ,·, Ill- ,,", A, (hJ w"' .Ic'k,"," ·.'"h ""co_hum." 
'\n"_' (f<; 1.0,) E, ~""'" ""1 ,;,_""",,," ·.,tI, ""[;_hun,,n 
" ._ ,_.,,,,,~" (85 "D'J Lon' j ,",,,,,,,,,,, h~ ~ "rt,'H"" ~ C(,ll 
i","". "'ocod ~d, ;'_"',,,,, n', "",'oo.iy "mi "Vh",'''''''' G 
" •• d., 1,,,,,· "OW'."',,', ,,"'pl.. ""1>",, ,'\ n"_ c t ..... t,a 
Aitlw11gh Il,,, b,,~d at (;(-i kfJa i~ the 'I<mple Iri ~u,e 4~, iane 1) ",~" ~elat.j ,'&ly low,,, s'";n,,I, it 
wa, ch~ ,1ll!Y ba"J ~~e'~n!Rd in th" .amp!"" a"d CDn~"pDnd~d 00 th .. Ang--2 ""'llf1:ml (l'1gllr<' 
42, bn" 4) ,'urlh"rmo"", Iwo ,,,,,,,u"')rr,,cipitaG()~ conli'oi. were i'lln lu en", lr~ Iha, the 
,..·mit wa, valid_ 
i",munoI'""eiI'it:!t"J (FigLLi'!' 42_ 1:,n!' 2) Ji,1 not have a band at (if; l fJ a , ",'~;:est';n~ that the 
I<nGb.,dy W'" "," ,I~ceciin~ I< nlllhe, ce11ly.al~ p:r"lein, ~\D"[,hernlDr~ , ,ample, of c~1J ly",t&, 











al.,o did not I",,'" " bal:d at 66 lVa. ",LI:I:~,tin~ dwt Al:g-2 only p r~ipitar.e,,: il: r.h~ 
immllllopr~tipi'mion pn)wl'ol in the pre"'nc<> lil' 'ephaI,,"e G be"d,_ 
\V h~n th~ blot was etripP<"d al:d r~- el et~lHI tor inlegrin ~, (8~ klln), n bnnd was p r~.ent i l: 
' he t wu "aInple , tli whlL,h 'he It "lllihouy w"., ad2ed (Fi.~lll'e 4~n. la!:~ , 1 ,m": ~), Th;, 
Lmliil'lIled lhat the ,e~hal'o"e G head" were VUjjill~ 2lmll the anlib uci,' Cl,g~" her wilh it" 
E~a!:d, Till" l'e, ul,. tc)~ethel' wI,h the Illhihlliun " tudy re po-Jr,ed "\.><Jve (J . ~ , -1.2) 'tnJl:~ly 
"ug~e"," , hat III hUInall Inu!:,,!,,,',e,. -"ll: g-~ 'Ig!:a b"y b1Il2jjl~ CD lIlte .~l'inll, Due lo llnj)el'l'e<:l 
a l:tib"dy . tril'l'ill ~ 2uri!:~ the revrohin~ "f th" memh"H: e. the Ang-2 ",andani " I" lbie H: 
'Figll'" ~2.'\ (la nl' ~j. wa, .t ill vi,ihk ill 'FiguTi' ~2 1-l (La,,' ~j. a nd the <ig!:,,] ul the lIlte~j'jr_ 1'1 , 
W,I, low"r lh'l ll it wou ld h'I"" I)('('n on 'I n"w hi"" 
3.~.ti Summary 
[!: ,111" ",(;oili!: 'he j)()" ,ibie ,,,,,,eV tc!l'o [or A!:.~- 2 and I'DGF- BB on nll!nocY''''. WH~ 
im·""ig'll .. d Tlw 'Im,],',i, "I Ti,,·3 "xpr ,,,.i lOl1 lOr_ m"'1( ~:yt". by RT-'PCR ,m211uw c,'l ul11e ,ry 
''«v~n l~d t-hal -,1),,: "r "xp;>ri m~r.La I tondi"io n" mOllocO"",., did 110l "xl"· ... " t hi, re""ptr)!' While 
lhbe """ u]" ar~ in "ul::rn ditoion tli lith~r rec",m repurl. (V ~l:neri 2007), it i , po.,ihl" thi., 
"J'~ld be Mco lll:r.e,,: for nO' ,,:iileril:g monotyt~ ieolation mNho(:o llOgy 'Fnrlh",·mlOr". il 'e"llH·d 
',Hllikely 'hac 'he i"l'ge lIl<:,'ea,e" H: the expl'e"iun 01 varioll. prot~ills ill r",'plOl1",' CD 
tl'ea'l11en: "'l lh All ~-~ alld 'PDGl'-BB "uulel be acmllnl ed for by " h~ p"n' .. n t." g(' of 'l'i,,_3 
V" , itiw Inonucvte" ii!: ""la liull lo the ",Iwle j)()puintioll) p,,«yiously Nporte (:_ Th".«' ,Llt" 
lur' h .. r CDlll'il'lIl 'h,,' Allg- ~ i" nu l re,,'ricle d Cl' Tie- ~ " il:lla lilll:, 
AI1~-~ ha' ,'~C'ently ""en shown to . i~nal throu gh a r_llmlwr "f dil'!.'l'''ll' lllle~nll'. Oll " 
,'ari~ly 01 ,,:i/kn'"t ce ll tTP ':< (Carl",r_ 3(~11; f:wh 3(~ ) 1 Da li"hmi" 2()()5; Guo 200~: Hu 
300(;) 1'h" ""P""", iOll lil' " n u nber lil' dill"rent u '.egl'u:" wa, u:yeetl g"tl~: "" mor_(~'y"'. 
-"r_d .. ,· ('x]wrim"ntal m n2i,iun"_ IInlIlUlll)\n"wd,elIli",<l ana l"",," r~v~al~d " w,'y high , ignal 
lor i lll e~rin I)" a :"1:0"'1: l~ulocyt~-op<"C'iljc ime grin (Din 3(~ )iI) Wh .. ll 'he I'llllLocion lil 'hi ' 
.nt~p'in was illhi"i1<·d in mor_D"y"''; , it w".' lOb., .. rve d 'hal the hel~h,,,n~d librin i l:vasiY~l1 " "" 
,*,~n in r ""pon",' tlO .-\n~-2 an2 'PDGF-BB wa, lo ,l. ", hil e th~ tibrin invasior_ of conlrol !'('Ii. 
ll,«at~d wi th Ih" ar_~. i hodO' w," ullaff",-"ed Whe!: an iInlIlll lll) IJl'tnplation of int('gl;1: r" w," 
p" rfor m"d '-\l1g 3 wa, 2el~ ,,'e2 i!: the pull-duw n ~"J(l'~ct, mnlirming that ,\r_g_2 ni r_d , lo t.h e 












l'DCl'R_p "xpr"";OLl WUS ;~,",,", ; go"'o "s;ng RT_I'CR ono f: U.8A IndhOflo logie" h t:.olh 
inV"stigntio n, it wo, ob"",'ved that Ang-2 ufJre~ul ale-d \lw e"fJre,"iun ot' 1'11GYll-p, wh ile 
I'VGI'-BB had no ell'eet, In ""reSlin~ly, while (he RT-peR " LLg~"'ied a ""l'y luI" baseliLle level 
u[ PDGFR-I: expre"wn L~ l2nCl'ea'eJ aLld PDCI'-nn ""aleJ celk ,'p<" lls I,-{) m lhp ELlS,\ 
inrlicol.,,1 "n "~pr<'''Lnn 01 l'DGI<'R- P pmlPin on these cell' Thi, 8u~~e8te t hat one of ihe 
m"choni,m, t hrollgh which .-\n(:_2 interacte with I'VG}'-B B i. [.0 enhance (or p<J.eihly 
i"itiMe} l'DGHI-IlIl'n",;"r iption ond tro n,lotion, 
3.6 Investigatjon into the .'Jature ofAng-2ante!!rjn S" Signaling 
:UO,1 
,\1"",1",,,, of ,·1", 11, ;ntpgr; n fn m; I)' m'" Ih" rlo",;nn,,;n g i nlegr; n" "xpr""",,rl 0" I ell :·<f"'Y"'". nml 
they pla,- a ll'ajor role in lel:kocyte cell -cell a"d cell-lnall'ix adhe.ions during i" flo nllnn:ion 
a nd oihe1' imll'u"e re'ponilee (Al'naouc lS911: Vib 200(1), They a le-<> cont-rihl:te tn dwmotoxis, 
aJhe,ion "'. eyluki"e -acci,'ated endochelil:ln a"d ita""""doiheliallnigra:ion of nlO"OCy:e., n, 
;"Iegr;", 0"" ";poli"g r<~"plors, b", th"y nr" 01.", '.orgets rd. 0"0 or" fll~(~,lOLlHlly nib ,,,,I 
by, intracelh:lar eignal., 
",~naliLl ~, l wu lype, oj' s i ~nali"~ by fl' inle gri n , ,lioulJ De r"'-"~jJl"ed: tranemiseion of .i~nal" 
;T'" the cdl lol low;"g b;no;Llg nf hgnl1f1, or cOllnl"r _,', ,,,,,pI.Ol',' t.n thp inlpgl'i Ll> ("oLLc,<iJe-d' 
,,,ch n' ,,1',-\ R (5i mon 1 9%ii . n nrl reglliolinn of "he OVifl;" y on 0 m"lo,- mn Ii () Ll of 1 nl"gr; LlS !,y 
.i~nals (:e,wrated by ot her 'W'''p',Ol'< wi"hin the cell n n"irle_ollt."I, ""ch 0' 0 "';'-otin g "i gn 0 1s 
On" n' Ih" ;~lio1 """nt" ;n 11, iLlt."grin media,."rl ,;p,']i~g i" ih" ad,val;uLl u[ variul2, llUn-
l'ec<'ptor tyro,i~" k i"o""", "",h n< m."l1!."'" of th " srC' a~o I<',\K !amil;" ,_ The prec;", 
m(~,ho"i,m' !'Y WhlC'h 11, ;lll"gri~" ;~l;lliiie Ihe 'iLOlival;un u! Ihe", l~'l'U' j lle ki"a"", howe ver, 
'ir" uLlknuwLl (O ib 21~)Oi_ Ell(:agemem oj' the I" i"i egl'i". Oll leukO<'yte. is a leo o"" ncint."rl 
wllh a ,iplJ'icaLlc a lleraliull ui' the celh:bl' cyco,ke lecon, lea cli"g :0 cell ep1'eooing onrl 
loromoiio", This involves th" o{'ti,-nt io" nf Ih" ;;mol l GTI'_h; nrl ing prot,,;n,< Ra" ami RhoA 
(llih 31)00; I.nllflon"o 30f12j 
I'DCI' ami PDGFR have pl'evllJu,ly Uee~ refJ{)j~ed 10 i"teraci with i"te~rin, 0" the c,,11 
,ul'face }'Ul' exa lnple , i" fibl'oh la.(s, i" coopel'acion with i"te~ri n" l'TlGl-'-Hfl w"r" ,,""" to 
~l'(lcluoe a markef!' tran"i""t oc!ivotinn n' t.he ,:Rl( "10.,, 0' ,\/'-\1')( 0,f iya mul{) lm)(i) 
h:rtlwrll'we, th" growth foclor "",."plor wa" ;t.",11 ;~dLLC'e,1 "', a~~l'"gale lJ'aLl"e~ll~' by 










in!.~grin_,nar,,,a 1"",,1, In " prn,,,,,, ""qlliri ng hnth "ggregati(l~ and ')(cCllp"n"y or i:l"' ~lin 
","~p!.or,_ SllggC"ting "yn"~gi,m I",!.wee ~ i~!.~grin" and grmvth I"Cti,"" tJ'igSl'I'l:lg 'YI,,,ine 
pho,phorylation of P DC F' "'''''']1.0r8 f,M i yn mn.o 1 ~%; i'und hcrg 1 ~fK;)_ it wa" als,o ,ug'g,,"wd 
that h!.cgrin-growt, ll fact,or ')~1cr!!y migh t, ~j1cra,~ r,hrOllgh r,he dnwn,o."" "", df,,,,,, nf 
i:l"'S'l'ln, "nd lJI ,)(Ccup ied Sl'owch f"cwl' J'""e~wl''' In i-"l additi"e or s"ner~i"uc {Mi,'nme,to 
J \)\l(ij 
b chi, """lion lh" 1'0,SLble ",",,,,,a,ion of the An~-1-a",0"ialed ;ntegrin pc wi.h "Pill( ",no 
illVeslis,~ted_ Furlhel'Il'lJr~ 'he llpJ'eS'ul"l;on of prDce", ,,s ob,en-oo h rc"~"se to trcau"""" 
wi,h An~'-1 "nd PDGF-BB was ulv e"',I~a ',ed with l'egai'ds CO in'ercrin ~" inhihi.io" , Y;"ally, 
"ltemp" Wel'e rnade '.0 ,dent,iJ}, a 'Igm,ji:lg p",hwa,,' thrD,,~h which A,,~-2 a"d P D(;Y-J:\J:\ 
W"J''' llpn'S'lua li:lg rno:"",y'e I ib l'lnol)-"," 
:1.6.2 lnun\lnopl,tcipitfltjo)) or \lPAR '"' Hh In( "!!fin B, 
ilJlegJ'in ~"I:' ,,,,d uPAR ha,'e ~l'e,'io;"",' i-"le:l ,jwwn '" t,mn n tunctionn l ""it on ",nnoe}"le 
cdl" (S,mon ] 9f)(ij 'Ios"chel' dIe," h,,,'e been ,how" to mcdin.~ rompicmcnta ry fu nct,i()~, a LHI 
~l'ornol" llw degJ'ada',ion ol'Iibl'l:l(~~e"l, a' ",ell a, conferrin~ adhe.iw prop.:rti~8 n~ th" cello 
(Simoll ]\1%; Silrill ]\1\16) A" uPAR expJ'e,"ion waS see" :0 h~ "pr€gula.~,1 in m()~'><:)''''' 
lre"le<! wilh An~'-1 "lld PDGF-BB (J_J,J.1j , it "'''S deci.-ko ,h"t tk imm\n10pr~('ipit.a""" 
ob:,,,in,,d ablJ"" 1:,-~,4_HJ wnuld be l~,ed to im'esligate dIe je"e] of "P.\R nsoneintion with 
;",~~ in (» i" the pr~8e~ce of Ang_2 
B 
:) 
Fi,,'H' 43, ,,1\'.1\ "'_"'''''"'''''<0';'''< ''',0 ,,"'j , h iel ,,,in II 
A ,, ""\1\ ;",,",,,,,,hlot, H_ 1m. ";,, I;' ;,"_,""nob;'x 
',·'p",.",t, ,be'''-'''nt.o;n;~e ", jj iy,",., l,'.d..J wilh ;nlc'~ri" ~, 
O)"ih,,", '"" ,"":,.re,,, G l",",_ J."". ~ """-.. ~" ,"m,h 
""""""nR ,be" ",i, """" ~'il'_ .. ~_''''''''' G \>CA, L,"", ~ 
,'C'p,,"'.'nl. ",,,,,h w;'I>."" ,\n1" t~,."," wid, "".,,';n I" 
"",;c.-,dy "oo ... 'p''''~'''c G """ct., H -" 
'\' can j~, """ll in 'he 1"~J'e"enl"l ive tj~ure (~'i~"re ,1m. in botll "a"'ple,o 1",,,,.,,,1 wi,h 'he 
":lliho{!>' en L:lte~rJ" Po. "P!\R cxpr~3S1nn ,va' d".,,,'Ie<! hy llPAR imIl"L:lGblor,tin~, 
bt~re".;"~l)', in nil -,he ",mpk, "n"l)-,o"a {n ~ :lj, 'he uPAR ,i~llalln 'he .ampic !-rented with 











hdweero the lwo l'ecepCor,. 
3.6 . .3 
1'1'0-.\1.\11'9 expl""ion in th" 'IH1'-1 ll,onocyt" 0,,11 li r." h ad lm''';'lll"ly h"ell ,),w,,,,o [(J be 
dep~Ld e ni on ul'Nul'AR "xpl"'sinn C ... knshlkov 2004). I l WO' lh"",fore ~x,,"ihle chat lhe 
Ang--211' DG F-J:lJ:l-d"p"Ld"nt "P""gll la tio01 of ]l,IMPll WOll Id h" me,ila ted hy uPAIL Jrodeed. i he 
" .,"ocia lion of uP Aft with int"gl'in p, ,](';,crihe ,1 a l)(Jv" 01..'1.".1). '" well '" the All~- ~ m~dia,ed 
!'I", "xp",,"inn nf M\fP9 WO" analy"" ,1 ,r. :.he conditi(Jr.d mediurr, oj' celb ll..,ated wi , h tll~ 
function-blnckiq: uP AI{ a ntih0<!l' (,,'" sen ior. ~A. I . I I. Fro",. :.he re"t!" ~)l'e,enced 111 rig ur~ 
46 Jl '" oLe-iou; Ih,lt ' he on,i-uPAH au-iLndl' (Figllr" 44. colllmn, :: ,,,od 4) lo",el'~d \-[\IP9 





• ,., ," ."' 
"" ,".,~ 
; , 
UJwtt...H,. Ir.hjb" irn of "PAR 
~ "'''Y'''''' Arg.~-'P!)r; r. Dn. 
JnI'>l j.,WJ UV'~fu:.u"" ,f \\,\P'I n ... 
"ddio~'" of" r.,,~-licr ir:, ih;';" r "PAll 
"",'bo'.' lu~I'''' U _\\.\\:"' ,"P""""o 
" VI'", i]1 ,,,mpl .. "'ith (co]"mn 1; '" 
""l hv.lC (1'01<,"']1 :Ji Aop' ,n<1 pnrd'· 
Illl in rom""i",r. ",,," lh, ,ur.~·ul, 
'v " 0.[(; flo 
"""1"" ..... '" ~"lh "Ii ,th,,' """'-''''"i 











The large ue<Or<'a",' ;n MMl'9 eXp"'esoion when uPAR Illnclioning W;" lnhib"",1 "1'1",,,r, 1o 
fmche-' confirm "n" Hlen" 'he re""i,,, 01' Men,l:ukov '" "I (lIknshikov 2()()4). "'n""ling not 
only ihai ihe expte"'lOn of .!.Thrp9 i" highly regulat.ed by Ihe plasminogen.ipla8min 'Y.,,,,m. 
blll al", lh"i .!.ThlP9 ex"re'"ion in ,,"_ono.-'}'Ies was seen to be int ima",!." connec",t! wi,h uPAll 
activity, anu mo,t MI>Il'9 expre>sion \\.,,, lo,i m the "re • ...,H:e "1',, uPAR Illndion-inhih.ting 
antibody expre>sion Ill"o 1 ~}%j Il J" imel'",\in ~ W n"t." Ihat. t k '-\ng_2IPTJC F_ 1-11-: . d""end,-nt 
upregnlaiion or :\[\n~) wa" lo, i wkn llP.-\f{ "ctivily wa" inh ihit.eu_ Tk'e dat.a ,Irongly 
.ugW'" " link klw,','n the "\ng_2IPD C]7_1-:1-: uependent up-",~ulation 01 uJ'AH. the An~-2-
dq-.enuent m"",'a,"'d asso<:i ,,,ion of uJ'AR wi:h in l.e ~n p" an" Ihe ob8el'.-ed An g- 2/PIlG .~. BB-
dependent upre~ulation of .~L~il"l. 
In order w investigate :he role 01 in L.<grin ri, in MMI'~j e"pte8. ion, I".onoc-"l~' Wel'e i,>cubated 
wiih a Iunction-inhibiling mlegl'in rL "nliL<HI~[ wilh 01' wllh'JUl An~-~ "n,; I'DGF-DD AILe' 
1" hour" t.1l<' "ond; lioneu n",d;um was an aly.,e" tor :\nU'fl exp-'e"io n b" ~eja,in zy mography. 
The in hil}icion of in "'I',in jk ,.,. move" th~ An~-::/l'D GF -DD-"ependen l llpre ~(\ll"tion or MMI'~) 
exptes"ion (a" tepoJ'l ed m :U_:1.2). ,,,,d "nJu~hl the le,'el or .!.ThlPI' e"pl'e"'lOn "own l" 'he 
,,,mil'o] level, (Fi~un' 4 ~. ""luI".'" I "n" 4). ht""-,,Iingly. t.he a,;,;ilion ,,[ lhe 1'lllldi,m-
mhiLiling "nLih<HI~[ l<J lllllte" Let! "ell, ,; Ld not "ff""l t k level of ",,'TMPH eXI'H,.,ion (Fig"l'" 46 


















' .. _ _ _ w " ; 
,,,," ~ 
""", .1",-,, 0' ).j\U'ft """,,,,>On A 
d,n.om"," ,",I,.;, ,'., '..1111'« 
.mm"nohk,,.. """,I.d 'n" th. 
'~ >I""'''' t~ .~n"_','l'D{Tf'_TlTl t .... ''''''nt 
(,oi"m" 2) .. ;. , " t ,,;r.e"nU,. "itmoo loy 
'"timoy'" mte"in , , (coh,mn -O J_ Tn tb.> 
,MoO« "I A,..._~ .,," PfJ<;F_IlIl, th€ 
(2o'no,-" , 
1'h"",, n'<u )", ,<)~('j h 'T with tn",,", T<'pnrt('rl 1n .~ _ 6 _2 ~nd 3.6.3. <trongiy s llgg,w",,1 that thp 
uprpglllnt lon of.M~ T 1'9 hy c\ t\r,-2 "nM J'Ll G F-l:\ IJ was dcp enrl pr. t or. ;r.ter,rir. rc, "t)~ i t\fluencd 
h)'its with " PAR, 
3.6.5 ~lTh\l!lll' Jl xpr~ssion jn Resp()nse to 1!l\E'c in lh Inhibition 
In on,er to determine the involrem~m of inw~in Ih in .MTI-.MMl' e"pr~" sion, clOno<'yte" we,.., 
lllwbaled with a function-inhibitinR lllwgin~, amib<Xly. Wh~n the celllyoaws obtained lrom 
th~"e cdl' Wier<' anal)'",'cl by I>I'l' I- I>IMl' ;clmunohlorting. It. w~s ob""'ncl t.h~t. thp 
uI'r<>gu iation in I>l'fI ·MI>lP ('~I'n',slon ln n"l'on,p to Ang_2 ond PDGF·nn (Fi gure 46. 
",lumn 2. ~s ~lso r"l'orw cl in 3.3.4) was significa ntl y cl"(,"('~,,,d in "ampi,," whi"h hod h""n 
lreateJ will, the an,iixJ[iy (F igure 4 (i . ('olum n 4\ anJ Ihal lhe le,'~l or .'I1'fl-.'IlMP eXpre".lOn 













"."" ... "",.~ ~"u,,, ",."., .. ,. .. ",~ 
'K'_'" 
(cd"",,, 1·) ~'" .. mm'C'" h~ '_'_ ' .. Ioi'_',,, 01 
a ",u:c«," ;"hr"i'i n ~ '""h1y ,,, in"""" 
~, . k '_he P'""""". G' AnJ" '0' prnif-
~~ the ~,bl>t.i<H' Gi i",, ~,in fJ, W,i"",,_ 'I 
1,,,",,,i MT:_M.\ll' ""'""'''''' ,e ,'On'_,ol 
"'"N"""" ,,, "',"_'_wl w,il, *p < '.1.05_ " 
~ 1· "".ri " " "" io "i"];,,.,,, " "",,,,,,). 
The", data "ugi:ested that i01legi n r, is i nVfllv"d 111 ~,h (· LLI','e~llla lioll of :\lTl-ld./l,U' ~xprcs;;io" 
by hum~jj mOlJ(K'Y'"" jjj re'pUll'" to Ang--2 an cl I' DC; ~'_ f1 f1 
~.ti.ti Analysjs of Pos.; b Ip Signa liug P ath "''1x.~.f()!' Ang-~IPDGF BB Act jon 
lL wa, hoped that a pr~liminary ",udy of Ih ,' llllmcellular palhways im,ojwd in ,\ng_ 
2/rDGF-BB-depcnr:~nt llpr~gllht.i()n of fibrinolysis clJuld be oollductccl u;;ing lnhihilo?< 
knOWll to illhibit prevlously "lentif",,: ;nkgr;Il'llpr<'gLLl~cd palhway", ,u,-h as MM'K. 1'1-3-1\ 
\~~t~ made to i'm-ther 11l,,:,,;·,ta I1ll Ih" "ig nalin~ pmhways ,lll'ou!:h which I'J)G~'-f-H-l an ,: .-\ng-
2 WHe ,-all"'ng 'h,' o;,,,,"vecC upr"gulm;oll ill fiilri01oly"is m mfl''''''}'',''"_ A Ilum;>er u[ 
inhibitors were emp]o)",d in coll)unciioll with 'he ,,,rum-lree Ebri01 lllVa<ifln a"<ay til a,,,,,, 
fihr;ll im'a"iOll. 
3.6.6.1 l'h!!l>J,hoinQ_jtiuf J-Kju".€ (l'I $ Iiin~s~) 
l'I';,-killa, " i, a lipid kina "",, tha' phfl,phoryl~i"" pho"phollJO"itir:~" at the 3- p,,,i!.10n of th,' 
ilj()",lol rill!: (D lb 2000), l'J-3-><Jna'e appear< 10 l,,' invulved;ll llUmerous a")Xci, oll~uhwyle 
aI,tivi ty. i nlO]l](,;ng II, illle~l'l n , igllalill~ i01 polymorpho,,, 1 d~a" 111,,11 roph ils (Lo[grell l~~:l; Diil 











clustering of p, integ-rins ind uced ~h(),~horyl"li()n ,md "ct.iv,lt,\()n ()f prol"in kina," DlAke. a 
aa,"" [r"" In "'r ~"t of PI -3-kina,," (I " fgnn I f);I3 ; Ax ehilon 21)(l(l, DJ h 21)(l(l)_ It, hail al ,, ~ heen 
, hown th"" ty"nin" -Jlh~;;Jlh~rybtNll'",:e pw,.". "ueh as I'DGf l'eCeptDr3, can hind 10 p"':; a nd 
in('r~as" , he catalyti c' acti"ity of 1'1-3-kinx5e (Vanhae,ebFO eck 18~7), Worlmannin "" 
kno"ll in hi bilor of the 1'1-3-kinase (Pr"ger 2004). anrl hae il, ,,:ce ,,,ful ly be~n "",, rI In " 
nu mber of differenl i" 0' fro "uri i", 
When worlm'lllnin w" , "dded to 'he fibrin inva",m """y (~_3 . 1. 3). n() ch"nge in fibrin 
inva , i()n """il ,een b"t.,,-een Ang.2,tn"le<1 ilamJl I ~il "ith or wilh~"" wOl·tm"nnin_ 1'h"",, 
n""lts il "gg~'1 t.hal Ih" PI-B-kinase pmhway is no l ilwolvcd in Ihe incr ea." in mOllG"yl~ 
fibri n ilwa, io n "nd fib rinoly"i , Ihal OCCUl'S in l'espo n"e 10 trea ' ment with An!:-2 and l'DGF-
BE. The"" ,'e, ul " COl'l'e"pond with pre"iou" ill\'e"l~"lions which ' u~~ e",ed Lhal p, imegrins 
do not .ign"llhrull gh PI ·3_K (R"ye.-R"ye , 2002), 1'he ,~ e"I'Nim~ntil. h ()w~ver, were l imi t.~J 
hj-" Ih" ab",nce ~f a 1'000iliw ('~ntrol. il"~g-~ilti ng t.hat f"n.her inw, tiga li ()n, ""~lIIJ be 
n""e,,,ary in ord"r [() deu'rmi n e the role of 1'1-3-K in Ang-- 211'DG F- BB "ig-na li n~ conchl 8ivd y, 
3.0.6.2 Mitogen-Ani--ared Protein Kinase (MArK) and p5~ 
Ang_2 aJh"8ion tAl inkgrin, In In:VRr "ml fibr"b];'!.> via n,~ , ~c l ivat.e, FAK "nd RmJ:\-L\.PK 
(Carlson 2(01), The )I"I .. \I'Kill fl.K (eN'l'acellulal' 'i~nal-l'eg"lmed kinase) pathway i8 a ,ignal 
tr"nsdHeti ~n pathway that- ooHpJeilllltrlieelh .la l' N"po n,,", to th" hmct ing of r,rOl\'t h foetor> t.~ 
cell surfuce r",optM", II phy" ani mpol'ton I role in a Va l'l ot-v of pal hop h ysi ol~gi cal re'l'~n'e,. 
and has nee" "ur,r,e"ted to be im'olnct in many pn>ce,"~" eonsid~l'~d crm cal u-. t.h~ 
inQamrnatorT re"pon"e and ti,"ue ,emo ct eling- (Gri"wold l~+{j , Uncten,ooo 21)(l(l) 
SlJ2H~0r,3 ha' previo",ly k~n ,hown t.u be a p()t~nt.. ,nhibi t.Ol' of ]l3il ';lAP k ina s~_ 1'3H 
mito~"n."cci v" ," d lH"Oce in kin",,,. ar" a ch" of lllilag ~lH,cti,'ated prolein kinase , which are 
N',pon",v~ to ,I .... " ",irn uli, il \lc h as evtokines, UV irradimion, hea, ,b ~ck anct ~sm~hc 8h""k , 
anct are in"olv~d in c~11 different18 t (()n "nd "PO]lt,oil lil_ S1l2~\H )(; :j hail l>{'en ,u(oc""fu ll ; u, "d 
'I! vi tm to inhibit t he :\L\I' kin""" pathw"y jn mOIlc"."},i", ai C'onc"ll lnH,ion, "I' 10 H)(I ,,:\j 
(Underwood ~OOO), A" SB23;lO~3 ha" lin lD ,~ ~! 44 nJ\1. it wa" d ",:ided Ihat for t.h~8e 
inhibit-ion expel'iments. it- would be u"ed at 1(10 n.\'L 
""'hen Sn~3811~ 3 ,,-'" "dded lo th e fibrin inv,,,ian '''"''Y (2-.~_ 1 ) II wa, obsen'ed lhal rna"l 01 
L-he manoc)'i " nb rin 1ll.-"s>On w"" ab alish ed. in both lhe 1\ng--211'DGF-Bll-conlaining- well" 











1D mon(l<'yt" fibrin lm'a.<ion, " wa, not po",b1<' to det.ermine whether lhe ~athway I<'a, lJJ 
any way invo lved In ";h~ ,\ ng_~iPDG F _nn _d"),,,ndpnt "pr"g" btion offi1mrwl ;' ,i.<_ 
,\pig,'mn "p"t"Ht lllhibitor of the J,,';J pathway (Huang- 19%) "as also "(I(I ~d t,n the fihrin 
lllVal;wn aSJlays, .""nilnlily t.n th " "Po" lts nbUlln('d from Sll~:l!)II(i:l exp~rirnents, whell 
apig-enlll (Sig-ma , St~inh~im. -\31 .. 5) ""no ndd('d to th" "''''-'' the im'",ion b"th Ih~ LLnt,r"at~d 
c",II ,,~, """ I I~,, tho", "r~nt~d with Ang_2 ond PDGl' nn w~~ >everel), clll'~ailed, 
Ba",d on th~se ohservacionil, it wail apl",r('nr that the pathwa;-', dJO,en for im' ~" J~alion 
were vital for cellular functioni ng in ar~as nth~r than ,\ng.2iPDnF-BB ,timulatiolJ. 
Th"rdore, In order to " ILLcidate lhe level of involwmem nf the ~lem~nt.' "f ,,,,e h pachw"y, 
mdhodol"gi(', ull"v"il:oblp i'"r llll' ",,,,ardJ wOLLld need w he ~m~lny~(1. Jt is possihle rhat 
t he U'e of sifll\Ail w rarg-er sP"<'ifie el~ments nf th~ p"thway mi~hl proviue ,'alLLable dala, 
FLLrthermoN. u,in~ anal' rechnolo~y. ir mi~hr he pnssibk rn invp.,tigalp the LLPJ'(,gul:o·.ion of 
\'al'IOU, ~Ie m~nb of the path"" ay. in I'es>",n,*, to " _ng-2 a11(1 I'D(; F-Bn tr"" tm "nt._ 
In thi8 Sfflion, rh~ i)1vnlvem~nr nfmt"grm Ii, m thp ,\ng 2iPDCF-BB-medialed LLpI'eg-ulation 
"f mOlw"-,,,,' fibrlll"ll'," wa, furlher ;nve"ig-ated, hrilt.lr. rhrOl 'gh lmlnl mopr('cipital Lon it 
w".< ob.,erved lhat, Ul a~reemell\. with pre'~ous I'~ports (.", men 199m, in"'g~in 11, wa.< 
"""~'Lat~d wllh LLPAR undel' e"pel'llllental conditionil 
"l"(,l'\'al;oll thaI An~-2 and PDGJ'-BB upI'~g-LLlared "I'M{ HpreSSlOn (3,B B_1) c"n h,,,,tp, 
,"'ntainin~ A n~-2 ' ho werl hi~hH" mOllnt s nf uP M{ nilsocint~rI WIth thp mtl' ~rin_ 
H"l1or\s m th" ht.",'at",,, hav(' ,hown t.hat M"'I'f) eXIJl"S","" In 1ll0nocyteimMmphnges is 
d,,)~'nd(' nl on LLi'AR (Ran J 995) _ Whe II "l'AR e"pl'e,sion wa. i 11 hi hit~rI hy funct IOn.illhihiiin~ 
"nllh"dy it W'" "be rv"d lhat lh~ An~-~iPIX;F-BB-M""ndent "PT<'gll I a tion of M M~) ',:l_"_~) 
w",lo.'1. Thi; ,trung-Iy I;llg-~~ilt~rl rhnt "I'Afl is involv,,,1 in th" ,\n~ -~/i'DGF-BB-de""ndelll 
U))l'(·gub tion of "''''1-'9_ Furthermore Au~-'l/I'DGF-BB - .lepelld"nl Ill'regul"tion of S1S11'fJ 
wa, remo,'ed by lhe inhihirion n!'illle~rin p" 
In hihitinn of inwgrin Ilc ,,1"(1 rl'mowd th" All~-2/PDG F- BB-de""ndent uprepdation of MT 1 -
M MP, f","h"r confirmin~ i \., role ill as th~ Ang-2 I '~ceptol for the "ng_~i l'DC F _Illl_ mNlialed 











Inl~,.,,"tJn~ly, ",helJ Ih~ '\ll~-2/ilJe~;;rin p:_ jmm"nopr<~'ipitation w,,, "c.aly<~d by 1'DGFR-~ 
immllc.oblotli ng. c.o PDGFR-p Hpre"iliolJ wao dH~Cl~d in any of t.h " 'ampl"., (oata nol 
ilhowr.). Thi& .'"gg"""O t.h"t. o~,pi'.~ ""pO"'., ic. th~ lil~""tlL)'~ ul I'DGj<'R-~ a'wciHlin~ "'ilh 
illC~~rilJ ' ulJ 1 h~ cell il ",-t'a,,' (M iy" mot.o 1 HH6: 811r.ab~rg 1 ~f)(il llc.d~" e,q"'",lll~lltal "olldi,i(Jl'" 
th"r<' w", r.o physical I nle""cli(Jc. kl weelJ l' DG FR -~ alJd ilJI~~rir. p" 
'\It"mpl , w,,,.,, m"a~ 10 ,uenlify Ihe ilJlracdblar pa,hway throURh "'hich '\n~-2 ano PDGF-
BB si;:!luko lnhbition of the I'I·:;-E pachway ",ieh w(JrlmalJr.il1 did nOT, "If,:"", monoeyre 
Ulva,Wl1 il1lo fibrir. with or wi,hout ,\n~·2 and 1'DGF-BB The ilJhiiJition of t.h" )l.l,\PK 
p"lhway by SB23906·3 ,,'U' ineDr."lu,ivp, how~v~" a, lJlOC.O"y'~ [ib"lJ i,l\·ailiUlJ ilJ Oo,h ,\n;;-
2iPDCF-BB-',."al~u awl ulJ:""ul~d ",ll& "',,s aboli"h"a. \Vhil~ this dellloc.slraeeu that :h~ 
.\,1.-\PK pathw"y i" jc. l~g raj to llU''lllal mOllOcyl" fil.rin 1r.Va.<1on. no eonelll"lOc." as W il" 
ilJvolv~nwlJ' Ul A]1~_2.iPfJGF_nn 'i~nalin~ ",,,ld be ~lllCidal~d. jlJ Ul'd~r CO ~ain dari:y ir.t.(l 
,hi,. ie w(J"ld ~ """"il'a ry r.o pmI' loy m"t hooo]ogi~s olhe r Ihan Iho,,~ "vailable for t hi' "wdy, 
:1.7 Extcp~j<,m of find ings It) Vitro 
:1.7.1 Intl'oductjon 
Th" ,~,.,,,ll" )'('pott.ea in lh~ pr~vH"." sec,iUlJ ' olr<JlJ~ly ""g-1(,,'1. T,I", invoh-emH.t o[ An~·2 and 
)'IlGF_BB in moc.,~:,·l~ fiLrlnol)"",", how~vH, th~ ~x p el'impnr.al d,,,igr.' ar~ "naLl~ lo ac.sw~" 
in divi d "a 1 r"gula l.loc. of specific d~lll~lleil u[ ,h~ fibrillo.lylic "y.,I"m, .'" ~g~"', du,1 d,~ mc)'eas~ 
ilJ fi b'~nol y.,i, i, a ' p"cifie occu),rence, i, Wei" ""C"""~''Y '" foorl h~" c(Jdinn that t I", i c.e,. .. ","~ in 
fibri no]ysi" was nul an el"'ll~lll (Jf" g-loiJul il"'",,a",' in proleo],·.,i,. Tc. o),der '" do ,hiil. t-h~ 
fib),in inva"i(Jc. ex>*rjm~lllil ,,'He ",'pp" l,," u,ing (J,~)wlh F"cl(Jr·R~,llw"d :','lael'ig-d (l;j'-R 
liLrildo1:('n), hur, i, mmp<)""a of" number (J[ (Jthe)' ECM pl'ut~ilJ&, inc"",""o in',,,ion I.y Ang-
~/PTJf:F.BIl'lr~a'ed lI1OlJ(J~yt e, w(Juld ou;;1:",1 a mor(' global llpr~glllL<liolJ (Jf l,roe""lYili". 
ra,he)' ,h'il1" &p~cilic lll<"-.-as" in fil"~noly.,i". 
MallY of eh~ ilJ"'p~n fam1ly fllr.<:lion" ar~ l'educ.ualJe Iwt"'~~ ll inoi,~all"l mC'mbe,.". and a 
lluml",r of aifff,rpc.1 inlegrin" c"c. billU Ihe ,alJl<' .ligana <}Iyne, 1!J~)2; Rue~~ 2[)fHI. 
TI",r"for,\ al'.ho"gh Ilo Jlll e~",ll ~XIH'~Oil ioll i, l'~o:rictpd to l('"k, ~:yl~' (DiL 2(00), it iil poosibl e 
th" l An~· 2 ~"'y oig-lJ"\ t hrou;;h ow' of th" OIh"r integ)'in" (In c.ull-leakocytic ~eUi\, I r. ora,," t{) 











i~ lim,' rDCFJ' - i', - e xpre",i" ~ cell 1)'l'e" Lllvohed 111 ",'ollnd healin~ - e l1doth ~], n l ,.,, 11 < 
,, '~ ooth )~"" ('l,, " ~ll, al1d Cihrobl"_",,, _ 
det ermine w hether T,he ,'"suit., d~"orLb~d ahm-,' Wi"'" 'pe<:"'" _,p""j[ic. ule "enLln-free fib,in 
Jl1\'a swn a",",- (2 .2_7) wn ., ,'('p " ~t." d ",i~g )~ono('ytL" i,oia l"d In!lll male Wi"ta l' rab and 
bab'~)ll", 
:U , ~ In Vi If]} Anah- sis Qr Am:-2- fmrll' PGf I-HJ.-M" n i ,,/.(' n C FH hI ;,U;rig~ I Lysis 
}lolTir.el 18 n ""~m('r",ally_"v,,iiabl e ",l ubl" baseMellt memDTan~ extrAct from Ih" 
F.ngdbrdh-H"lm-Swanl tumDur th at r.ei s at room "'nllp"ra lm',' 10 Corm a gell ulll e 
GY'()wth facwr R~d ll".,d (CFR) "''''cr igd. as lL" ed Jll lhe l'"jjowm~ exp~rim~ ~t. , difli,," Yi"')' 
lic-,l" fro~ Mall'l~el (Ta '" le LiBl in oo)~})<J<it.jol1, but i, gl'owth I" ''''>r depl eted (Ta','l~ 1,,;\), 
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.\latrir:el has previously OOell u sed in a ,'ariely 0; studies in\'{jlvillg mOllocyte, (Whilt~ 2001), 
alLhour:h studies l!sin ~ GH{ .\.jatrigd are Ie," COlllmOll (a, thc pn><iuc' i , m latively \l€w), 
Gm :'Ilatrige l ,,,,, choden as a s uitable nnn-i'ib rm s ubstr"Le in "n elTort to tedt whelkr the 
upr,,~ulMion 0" :'ih ri n d"gr" dalinn ""'.l,'pd hy An J;. 2 and pnCF· DD wa" a1.-o "ppn m oth"r 
'otms 0' pmleolysis, Th~ldote, the "" tu m-,'r"" illvasiun as>ay (2.3,2.1) was t~P<'aw cl, 
I",we,'er. the fibtill clot was replace<! wit h a GFR Matn~el c)ul of s;ml lar dime:lSioll', Cells 
were seeded un "'p a, befure, a lld lhe experiment Incubated at ~J7-C 
Thr"" donor,. all In tripli('ale, h Ol d minima l ('dl.. in t he hottnm ,'omvarlm"nt oi ,,11 
Irpat nwnW all"r twn d"", nf inmnalion and nn , igni;icant. diffpr"n('p hdwppn til<' 
tr<>a' mcn LS a"!pr four day. of incuhation (dat.a no' ,hown), Thc incuna'ion time < nc"" •• ary 
for cdl~ lu p€nfJIta'e tlli> GHI ,\-iatrigd wa" llotaoly lun~r)f thall l,)r fibrill (1+ day, VCt'Ud 19 
hours), however. j ud ~llg by t efere llced ill the Iilerat ure, thi, JS not ullexpe-cted ((S h1pley 
1996) 5 dap fur a ll 8fLlll layer; (Zhu 2i)()5) 14 hu ur," i'nr" ';,run )"yd') As shown in ,abl" 
15A abnve_ GFR :'IlatrEgel due" nol cnnbun vla"minog'e n Thp "b,'"n('p ni' an ""tr ,,,',,llula r 
,upply of pl,, 'mEnn~pn mu ld account for lh" ,low invs"ion of mon!X,y"'" intn I.h" CFR 
\j"'rig,, l cloL. in. vilro 
Thc"" ob~~rvatiom a ppear 10 .ugge.t tha! the e,fcct ,~ell dmillr: mDllDCl't~ expoSUl ~ w Ang-2 
and PDGF-BB I S pmbably lim,ted '" iibrlnflly,i,', and i, nnl. lib, 1)- to be pari ui'" g"neral 
prol"olytic llpregul",inn . , .. , lh" unlre"ted monocy",,,, howe,'"r, pendrat~d lh " :'Ilal ri g,,1 
"ery in~fficient.l)-, it i" nnlpr"".ibl" tn draw any ,,,,,,,lu,ion,, fro m t.h",' " "xp"rim"nt" Further 
"xperiment,. u"ing indivi,;ual Er"f prol"in, wou ld h" nee,,,,,,,,), to dd"rmin" ll" , na t ur (' oi' 
this ob'ervauoll 
3.7.:; In Vitr" AllalHi_ of the Efrect of Ang· 2 ;md PDGF·OO Ull FjbriIlU)Hj. ill 
Qth.,,- Ctll hp~s 
III order to illV~stil'.'ate whLJIlli>r A llr:-2 and J'VGlI-BB aliect~cl th" fibrinolytic mechani.m~ of 
other cell type , lnvo)veU ln wnu nd h"almi!, t.h" fih rt n lnva ,ion '''''''y de"'r1n"d ill ~ .R. L1 wa," 
r"p""wd U,illg' F.r,_ Gbmbla,t, and "mnnlh mu,de cells (S!>.Ir,j (obtaine d as cle8<ribed in 
2,fj ,2) , As mellcion ed above. it wa. thou~h, pos> ible that in the ab.rmce of ~2 int~grin., .-\n~- 2 
mir:ht i3i~llal th rou gh on" of the other l nt~grin s , 
previously h""n "'·p'".wd to ~xpre",' PTJCFR. p (ero ,h)- I!J!m, Tada ~IIO:!; Kiyan ~()05). 
F"rlh"rmDr~, whll" f:r, are kn nwn ", expre,", Tie·2 (\hi "" npi"rrr' 1997\ tI",y have "I "" 











thrnH,ht )lO"-,ihle ihal the Atl~-~iPDGF-BB mnea"e In i'ilmnoly,i, ,een in ",oI\ocyte< mig" ht 
• , , 
'. i , 
1" 
,~" .. " ,., ', ..... ' ~ " ... ~ ,.c>" " ..... ~ 'r,,,,,, 
", ... _ .." .. _-
ll.!.:Jllill.","Io.,,, ,dIe, J. ,udA rl~ 
'm·"I",;.;" "'"~ __ .\,,., 2 ''' ... -''--'''','''''_ 
,n' (;) d>pl."',,. "",if".,,, dih"'m~ 
I",tw<x." f,k,'. imo,,,,,," ;" th, "",em', 
"oJ <) . I' > O.lIO ,,= S c~"'"'i",,''''' in 
,nvku 
Th~ Tran""el!, conr.nming th., fihrin clot anu the "'~ueu cells W~l'" incHba\~d for ('ith""1.h,'('" 
nr r~"'r ~")'" ""I'or" any fib"in lnva,i'ln WI" lIh ""l'ved D,,~ lu t he InTg"H <i"" of tl",,,,, thr"~ 
""'1" '01.1"" cell lyp~", fibrin i n,-"siun "a, qllan\i1kd hy collnhng ihe ('ell, appearmg lIl) \h ~ 
011 the figure "ix"'~ Wi);,"" ~7}, 
Afler [liur daIs of illcllhaliull, noi l h,,,' r, ho o,l(lmhe l i.~ 1 rel l.. (hoth llSVEC ~"d MVr.C) ,n ,he. 
c(lmrol ,,'el l, nO)' r.ho,,, h'ealen w1lh Ang-~ were "HU to iJl>'"de \h" f ihrin dnL Upon 
f1bTinol)-:. ic octi"ir.}" Aflel' lhl'e~ ua\'", l'ihrobla", l",d no'. ;n"oo,.,o, the fihrin dlll, and no cells 
wcr" pr",enl on 'he j),emb""n~, How''''cr, nn t.1l<' fourth day lIf lncuba,;ou ""lis weTe 
lIh"'l'veu '-<) hav~ u,igTawd cheough thc clot, alt.hnugh ihe auuiliou of Ang-2 <i;d not ,ccm t.n 
make a signitlcaut rom r;h',lhnn til thc 'peed of migra lion a nu lhHo t h~ fio,'i "'ol)'t ic o"r.i"ir.}" 
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1H'!1"1'''! ,pc" ""j P"I(~J(1 
,,~"" (PI() '~lu(JCU ~) '-' ''_' __ '_''''',\\ "l"w "",'-41 w"', !",oIY "41 ~11" 'U ~ .~-(;) ""llpun<i OC[~."_~J 
i;u 'UOllCUIr\~U"'X" q;Jno.np O~UlU1uO "~," ooolq mu ')}OO[y ~loqA' mOlJ IT;; Ul OOOP>fJ.p 
,~ P~l~I""! "H.", "'l·;;,YlUOlli ~Ij'l ""-'~ ."04 "H.wu.dx~ .'~Ijl ill '(YSlI '.1:)11 ;_'.!.~.mS' 
Vl"ll 'Xli"'!"'" '''','-''I\"U UOLje"LUl\Ll."n,,) I "uG"""I} I"CLLlUU Jlll ,;0 UJJlc\" " 'P CLLW.; "d,ll00<1O LU 
'jUj0'3' ".HlPl~"'"' .'UUlU 'l U~ " ill"'.J ~lq"ur"lq~ !'oorq JO '"mnw, _''OJ ~ql ,0 "m""'fI 
!';}jA'WU0t1l poom ,,<1aqdP~J w'!I ilu!s.1 5\"_'11>1h/ rver. 
J.Jil.JO ~dH[CUlUOJ 
"Ol41!! IUlUlU\, ''ll pua ""'lll"U1i)~) qo.I""'~H AH;:I.lll8.1o lUolllllU,j 80 ~\P 'n"", Eu uo.,o"o<1" 
pu~ ~'nLlllUlOJ e)lqp jUlUmU .L:Jrl "'11 Eu p"pl.,O,]ct 8~Ullepm;j eq. 0) ;jmplO)H p~pnm[oJ 
eHA' ~~O," l~U!LU" lIV ''' 11m ".! 'lamLl<\ "'P .10 lOO,m e w H lp OUU "" POP"I"" 010,," "Uoo''''y 
" 1'4,\\ "1"0,\\ <>l1d W "'y'"W! n L p~"n JoG 01 <Md,,, ,'J\!l J"[l"~ u,,,oll~ ".I"." "''''ll -U'''''l[m" 
~,~," "H,1~ct- 111;""1.)11' 0,"1 1I1()J, .~l(;"mo].~ p~ld1I1~' ~n<,"~ 1I0T'l~lnct(}fl ~'1l ,0 "ml"~, 
""imIn ~ ;P~~PlIT m -"?''"rt, "~To~{l> 1011 ~," ," p~-"",qo 'lJ"J.J~ "']1 11''11 ,ea;j;jn, Plno,." ' II '" 
lumm" mOlJ ' lima< "AT11S0J: '811~J l"mmH >flITS" p",~OO~,l "'" PI"O'l" f'<:~,"" 1I0"R"'1 lIUUl,; 
"'l' 11''1') P'P""O ""," l' -"""' U1 8~1.'oollom llO fTfT -_~ DO,I plI" ;;-~lIy .10 1>a;J' ''1 1 ~ll!I"'" a<ol"fT 
l!fl'f:)"it!UI!UV'UO \-l H-.~'D(]d-'PU'" :-.-;!u V JO P')JJ:~ "'1'1 JO S\"_{ l"u \' i'~nT "I tTl: 
',',1~'8~"'11 "'! PIn",,, '~1'<:"""""1 ~lll'8~,l(IX'-lll,l~",lll '9 ~'qlO ~ll"'10A1I1 
SlIm1 ~~l1"""m .10'1'1111 pllU 'lll.Glinm 'D "'11 ;jlll",o,ldxe "II'" .10 'I'WU'pU~ 4" " "! 10 'e",_'.J(!U(JU,L 
01 ""Ollm .1 l101"R"'1 UUG,l,; luepu"d"o-;;-;juv "'ll lUll, ""'I"!" ""(JP"""I' "I",!''')(\ "! 11 
'.lIo11'PlIOO l"ll1oWIHdx, "lIl Hpllll P"P"Jj~ lOu ""," U(J!"'AU! U!"U!i ""I'l(J.'-'l!j pu" JI,(::;' -,J!l 
''<:I1"no" "d_'l II ' " Iia ''"''J'' j(JU .<>op ',UdlUUO"LAUd llu!W' I" "'1' Jl U!l"UI !~()JddR .1I(Jll lplIm OJ)!" 
U1 J~pUll '"-llu,\:, 0, ""uu(b~" III u~"" U"I"~"u\ ul.!aLJ Ut ,,"Jt'"""Ul "'1l1ULfl ,"o~~n' ellne,,-, OG,1Y.L 
'"II"' .10 ,'"'I lU llU ~4'j "' ""'_'U! _'['lu [ ., !j!uff!, "1 Wd,,, 1"11 l"P Ull1rp~1U 
""nl[11.1 ~~l 01 I:-~uy ,0 lIOTPP1''' "Y1 J",'~,"''''l '~ll0.T plI" """,nil ".<:u~ 'P"" uo ' ~ U""'lU,LdW 
~Y1 110 )11"' , ,:<\ 01",," 'll'~) 'U"1l"U1UUl ,;0 "up uno;"", ""-1' U,L"-'j jOI:J U !"'l!j '"l' U! "1'1'"'' ,,- 'I 
















D01M "" '; ~"" /1", ·2 ""U I'PI;)' lIB 
.'u",. ~ nm! !'ma'_IIII">,,"'n,"_ "im"I,,," 
moncev," 
f,h,;n,: " i, 
'p < U (>;. n - ~ "1,,,,,-,. n1, '" ,,,,,'.'OlO 
increa,~ in flbrin inv".ion w'" ""ell in the pre,ence of (hllman) "\llg_2 lind Pf)CF_fll-l (475% 
mere""" P 'cO.(15) which ""'" not present in any of t.he other r."!atm""!", (Figme -18) The 
lnore,,,'" In fihrin In\-.U10ll III the p",~ence of the, " two growth factor" wa , con"dcrohly 
larger lh~ll that ob,erve J whellthe e~perimenl wa, COllt!LLcl~d LL,ing human mononte ' 
llahoon hloud wa, generously provided b)' the Cardio·ThnT"clc ._urger}' department (l:"CT. 
So\lth AI'rica) front hahoon s . which had been obtained hy the departn1en\ ror an ethic" " y 
approved "Iud)' "f cardlO. ,mpl"nt.,,_ ,\"de from Vir."m ln Band Ivnm(><", t.h,' ),,,O<xm._ w('r" 
nt.he""', ,,,, me(ll"at~m _ trp e M the tim~ of hlOO<1 dr.Wllllg Bi<x"l Wa" drawn trnm th" fnT('''",11 














, .,., . , , . 
• • I I 
bhrillo ln" dbt (,/ ""'lmg hahoon 
"'0""',.,,",. "'iV-) A!!J<:; ~nu j'llGl' Ill:! 
An. 2 " '" fDUI' iiI! ," , .b", "" ""_cl",,,1 
A" demOll"tra\~d ill the figure above (Figure 4~), Ang-~ ,,,,d PDGF-DD "gnific"nlly incn'''",j 
~xpeliment" WO" fal' above that ,"ell in other , [}ecie, (~40% verm, 47ti% for rat, and 200% 
[lJrh llm"n,), 
the pre",,,,"" or J\llR-2 lmd 1'1lGF-BB. The,e ",,,;ull, "Uf:-i:"",,,d lhat ..\111(-2 and l'DGF-BB 
'j}~cifi"all)' ll]Jr~g"l~tc fihlillOly,i , in mO"(>(')'tes. and do not aired other ]Jroteolyh<; 
lllc"hani,m •. however furt.hCl' inv~,tigation.' wou ld :ex: nc"">sar), 10 <;onfi,'m the ohs~rv~tion 
FllthNmorc. hy <;omp"ring fihrin inv" , io)) l}('lw~en monocyte " "nd othe~ w()una-rel"",,! cell 
eyp"'_ ,uch a. ('n{\ochdi,, ) cdb, ,m(x)lh mu .• d" "(,n, and fib"obl",\" ,ugg'",ted 'h"l ('ilher 
lhe lL~11,gLL1"!ion of filJl'inolysi, In the IJl'e,enee of Ang-~ and PDG F -BB ,een in mon"")'t e, did 
llO' tl'an,late to other <;ell types, or tlla ! thi. lLPl'egulation wa, restricted 10 <;ell !.ypc. 
~xpre."ing :ooth pnGFR-li ond integ:rin r,-
Whell 'he e[t'ec!, of Ang-2 alld 1'1lGF-l:\l:\ lJn monoe}""s wel'e inve"il(ated in othel' 'llecie" 
OnCe again it was not.ed that Anl(-2 and 1'1lGF-Bl:\ in combination caused a significant 











su~~"s,,,d 'hac 'h" """Lln"" elled 01 An~-~ "nd I'DGF-DD "n ~l"nn,yl " [ibnn"ly"" W"" nu' 
H ol-", Cl", -, peci[ic pheno",e n@, f'unhel'lI""''' , ,I wa, noled lhat th e inc rease in Iiurill 
in"" .. "", varied l.", lween 'he . peei,, " (~()()'.; III human" _1(j5% In mt-s and ,'·10% in hnL oon s), 
Whde no i",m"",,"e ",,- planation Can be ollel'ed [01' lill" "L .. ervMion, it i. po"ih l€ thm th e 
<'IfN'.' of , hoe growth [a"tor, diff,.'r "llghtl" h"t.w(~m ;;l)("'i,,~_ 
~.R [n Fir", Analysis '!fMo<l~) 
3.1:1.1 
:\-\u,t "" "ilea a,say, haw Yel'Y r~dUi:tiulli"t readuul". and. whik )Xlwo-ful, or" limlt.l.''' f", m,-, 
in 'he ,I",;,,. 01 oomp!~x oc llular inkm"uon l1h~llOtneno. r-.-l ()jJr. in. "il", o<,oY' hm"pvcr_ a,",' 
either nol Qllamitati" e Or th~y an, re3:rieler. to e nd)Xlint readout' thot "0 not ollow an 
apIH'ecl",io n 01 th e dynamic 3-dim~miolla! spatioteml1oral Olx!Cl' of ongiogcni" pro,",""," 
(Au~ll,lin 2U01), Deeall"e of th~3(' limiwrioll', it- i, "ometim~s r.iffi,',,11 10 tran, lo'." '.'1. " ,1m 
dala into in l'i«) ,'",uiL._ 
Th" in c'n" me",,,1 lJeili"",r. 10 teo, thl' in "itro At\ ~-2/PDGF-BB-r.ep~nd""t- in"rL,a"" 111 
tnon(,,')",' mva ;; lOn inc<, fibl'in repur 'e" al'>uH w,," adape~r. fr()m one In"'~o,dy u ""d 
"",'c, ';; ,f"ll), b)' "olka~U('s III Ihe lab. In hi3 PhD Ih" . i3 (lh' Chl'ist-inn Schmid t. , eVRlJ, reT_ 
RSi\. 2(07), Dr Sd,,,,rC,t inve_'i~,,'ed the imm01ili"at-ion of grow lh fai'lo", on 0 h"ponn . 
mo k d polYllrl',honl' (hPLj dIs, '''' a novel ",ethud fur ~ruwth lacror dcliv~l'Y ':~ "':"0_ flul't." 
110" r"vl'r~ibk na'ur(.' 01 'he ~l'owth laclul'-h.pal'ill brnr.illg, :h~ gl'Ow,h bct."", 1'rodually 
" iff";;ed in,o th e ,u]',.oundin~ al'''a, C"USlll~ cellllla,- infiicmtioll into 110" di .. :_ Af",r a 
prede,el'mJner. "moullt 01 eime , rh~ disI: wa , l'Xl1lonl,;d and Ii", kvd of cellulaI' rnlhlx lllt" 
th" di, e determill(.''' l1,' ing ,mm11n(")'t "'hl'mi,I1',, Tl the eXp eI'l",elllS ",pole.er. b.,low, the 
holh An1'-2 ond I'DGF-DD were 1""TI(, )" II "ed un the hre r.isc, following pl,," . 'ol_ d,'v(' l"p("l 
b" Dr C-hrislian ScluIllde and lh' Keil Da"i~" (CVltl:, UCT RSA) Tl",_e di_,," wel'", lhen 
en"' l>.<ul,,,,,o. ill a fibl~ll ~el nnd im11 Iant ('d ""I1<'ll t anl'",,,l,, in mall' Wi""r ral·3, 
The hl'l: r.i"c, w~re 01,.-, 1>r<;violl,ly im,,, " tig,,,,;d a" a CalTiel' fur l'ecnmhinnlll adeno-
a"o<:int~d virll"" (,.-\,\V', hy Dr Clmslian g,h""o.l. In th~s e ~xperitnent.' th" r.-\,\\' wa, 
load"d "",, ,l,e l,PI: disc, in .. ir." n maU'X, "uch a& fihl'in, pol""lhyl"n" ~l)'c-ol (PEG;, an" 
"oll,,~en, It wn" luund thnl in~idc Ihe;;e mo'ril:p;;, 110" rAilV muk be l'elarned ill3ide th~ r.iSf' 
ilt ,·jil'O lor up '.0 41'- ho"",_ It wo, al<" ",;e n 'h,,' in the I'l'esence ui' "erum, tlw rA,\\' ,'pt.om,," 











,,,uld I., 1m'" ,n ,n:"" ", "n aitnnati" e mpth~d of ~~wlh fadur delivery with the tl'amduceu 
mfiltrating cv ll , provid 1ng on nh ern",i"" """,,"Ce of' t eComhUlant ~ Iuw'h [ad"l" lo 'he u Lr<d 
lo"'ling of gmwt.h I'",tor protei nil mru th e heparin-"oal"d ui.<", Dup t" ell(' ""n>'td"r"hl" 
qunnlit ipil uf !:wwlh faewr prutein" ne~ded [ur ill vic''! analy"" u.<illg thp hPU m,,~d. u,mg 
rAAV , wa.< lll"p,ligatp,1 'IS a v,,,hl,, ,,It.erno,,,-e tilr the cipli1;ery of An!:-Z ond I'U(jF-BB;n 
I!IV'! 
3.8.2 ]" ~Ti l rQ Analysis of H~pal' jn.Co;, tpd Po Iyu r('th~ llP ni ~,," 
l'l'"viUllil rc ""arch rondnded by U,. Neil Da" le, anu Dr Chrisciall Schmidl (f'VRU UCT. 
HI';,\) "howed t hat I'[)UF-BB t>ound wilh h i ~h alfinicy c" 'hp h('~ann ar.d !).'i'), of 
,,,rumbinalll PllUF-BB a dded to a he~"-r l r. di,,, l'('mai , ,,·,1 I.,unu lor aft."r a wcpk of 
ineuhaliull ill PBS, Ai. IW prev, ,, u,, dxla p_"'''NI on thp hin,ling "ffinity of Allg_2 "'( hpp"rin. 
elu< ;o,x, 1nw,lig'alpd in vir,,, '" dp,,,rih,,d "I.",,, (~ . 7 . 2) An g_ ~ wo< <llilpellded 1n I' llI'; nt" 
mncpnt.rati~n ~f I I' giml ami inCllho,.,d w,,· h thc h l'l: el i",," uvel'llj~ln at 'I'C _ The di,c , We"~ 
,hen wa,heu 3 time, wi,h PBS and in"uhalcd IOJ' ar.o,hpl' 41< houl" 1n PllS at 4°C_ Th" .->.ng ~ 
j'en"Hnin~ Lll lh" U"''' an~j' 'hc ill"uhat. Lon w,,, "llli.~,1 m III m,\,j lI n for half an hOllr " t r"om 
lpmpprat.lln'_ Thp,~ .<amplp, WNP U,pn in'"", ,Iri"". an,l nn"ly,~~ hy ,i lver_".a1l1illg (~_3 .4) _ 
A, "huwtl b~luw (Figul''' 00), after "i~"l'''u' w,,-,lung anu In,,ul,,,,iull . upl~",,,h lp amuuncs "f 
,\n!:-2 (at>om 100 Ilg) remaillecl in the di,,, after 41< hu ul", 
3.8.3 
" ,--,~ 
;"",I",,;"n I" ..... 1 ","",,,,,n,, ;i(~"'" ,A"p'. 1.."",,,;, hl,n" "," 
bn , ;; c"nt,,", . luti"" hm hl'l' ",,-,, 
SUb-CUta!l{'OU5 Implaptation ofGrowih Factor-earn-in;:- Hepal'in Dj~n 
1'1", h l' l: e.i . ,., w"rp P"'P"rL'" witb Ang_2 all~ I'TlGF_HH ail e.~s("'· i ~~ ill se,tion 2 7.1 Tb~ 
gl'"wth [aelor-""r.tallling hPU u i",," W~I'C thPll ,,,,,,t~u w ith 4 mgiml f ihl'in (~_7_H)_ Thp fihl'in 
"oalin~ uf the hPU di;c, wail analy,,,ct thruu~h '''allnitl!: eleetroll micrus"upy (wi,h the kinu 
help ~f .\1s );azlia l';amrxli~l1, CVIlU CCT), and hig-h-r~ilUlutiutl phu w!:wp h} (wit b the kind 
hPlp of '\Ir ,ioh"nn Egpl ",,,. CVRU l :C'f)_ Althoug b t. he fihrin was ",'en to il '" v~ry well 
"roulHl thp (li"", (JIlg'UI'C ~l). mar.ipulatillg ehp di.,,,, prm·"a Co hp a ", 'riou, tl"w in th" 
~xpe"imental de,i!:t!, alld a Ilumb"r u[ Iihrill layer' wel'e damageu uUl'in ~ the ,ul.:utalleou, 












t ;1" '" ~ 1 •.• ',\>.o,,'Wf'W IiI 'U 4"u. A. <0. "" ~M .. buth ,\ (l~., .<OJ B ,JIn). II., r,b .... ""'"to .. 11K. J...: lom"-..,! 
"" ""<~. "''''w I~. ""."0' ,he...,.f....., '" I"" M'IJ "'''' (; 'fid D .." ,"p .,,," """' . ",,,,,.f ,I>" d..., .... 'cd ~"h 
r" "" .,," .\t."'<~ K',Ii, a"II,,", Ill... r .. ,u", ...... <. ~ u. h .. h_n .... I.',,"" ~lw'"....."hy 
Wh,'n th,. di .. ,," .... "r~ L'xpt"MU,d afu.r ~ doro (~. u"..,ril:><'ct 2,7,.';), thp s'"~ of th.. llhnn 1I1)'e1'!l 











w~ re ",,"lion",l ami 'lnal ..... d with haemau,,,-yhn and ~osi n, t'eHular infllt.ratcs ~ et.lct('o in the 
fibrlD w~re fur ther a na ly""d by JiLl-1 
immunohiswcn~mi"try ( 2, 7~) m oroer t" Tdent.,(,' t.he p"",e nj<l ge m"not'},t.limacr"pha~es ill 
I,he mfiltrali' > Tk extreme \'a ria biht,y lxtw~~n j,he "17.~' of t.h~ fibrm "apsuie, of (he 
sompk •. hvW~VOT, mao e 'Illy ".nelusions ,mpo>sibk alld it ,,'as c'Onc luded t.hot wlth"ul 
,\e"eiopment f>cyonrl th~ <('ope "flhi. t.he",", thi~ m "Il''' mo,lel was not mton,,"j,,"" , 
3,8.4 Developru"nt of REcomhinant Ad~llfr"A""()cjl!ted Viru~es 
As mellt.~ln e d ill 3_,7, fA,.',V VlrHWS WCI"(' devcloJXd in oTd"T t" pmvide all alli'rnatiw tu 
dired growth factor lo a ,lin~ inu, the nl'lI 01<c< .... r.-\.\V C"Trying t.h e g~n" for green 
fl"or~"''''nt. pfOt-"JIl (OFP) was 'le,'elope~ as ~ POSit.1W wntTol for lev"l of inf"di"it}, both ,It 
uitm and in I. .".~ A, . hown \"'\"'" (Fi~Ul'~ 02). both Ang-2-carr)'in~ . and GFP.""rrying-
r.-\.\V. w"r~ wer~ .","",,,full}' m"nufadllred and snowll to be infectiv .. in vilm as 
determin"cl hy Ang-2 Imm"lloblottin~ (Figure 52A) and GFI' fluor~<c .. nt micl'f)~"op}' (Fi~1.lTe 
52Bl_ lJnf"nunatei}- ~tudie;; t'omludeo by Dr Cnri,tian Schmidt ,howed that while the 
~-iru,,, s muW be adequately immobiliz~d on t.he hl'U oi.c< in ,;ilm, the"" result. ,,)\lId not. lx 
reprocl",,,,d In ''(C U, a nd wry littk infcctl" ity could b<:' det"ct.d in th" ti""U~ ~urr"ulldin~ t.he 
oi,,". a. clet" m,n" cl by OFP expl'~""ioll 
A 
,,,,,,,,1,,,,,,1 CHO ccU' '0 ~'''" '''''' A""_",, ,;Im. I..no 
1 i." ."",~j. of «"oJi"o",," m"lium /ro ,n ,,.n.d,,,,,," 
CHO cd!.' 1.>", " ,. , !l<JOl"" ",nd"o of " In. _i, 
I."" " i . , ., ,,,,, ", of conO","",-·" ,,,,,,I,,,,,, from oo"t",] 
CllO ,,]!.. B. ,:,,\ V_G]'T c",,,.,, "''''''"'''''" (,llO t.n 
"nodu",' UH' in ,II" C.lh c"P''''''''' n FP ("m",) 











,\ limitation which ~reduded many other i~ 1.';1'0 ~:!1fJel'imeLlal nlOdeb was eh" n"e,1 10 
<luac:iIy mOL""d e inIiltrat ;or. a I a very en d y "tage of wound healiLg () n,' of Ihe ,,,I vancag"" 
of u,ing the J"~ l: di,cs wns that the suLwbn"'LL' p,,,;I'Gr.ing Gf the di<"o iL the rnt ' made 
fnr v~ry wLv~r.ient implantat io" ""'] explaL blinn 
On~ of :he ma,lor shurlC'()jjuL~" of th,' fi h ri"-coat ~d hP l: di,c r"od~1 wa, the dimcullv 
experl('ncd h,' Ih" ,urg""" during implnnt a:ioc: a ul ex~Jantal;o" or Ihe ,IE"', dLLe co tlw 
,oftre,," of t he fibrin ~e ls 
creat ing n hal'fliel' ami rllGl'e dumble geL lieeralur" "xi,t, 10 ", ~g"" , t hat th" ,,,,,,,,,,,,Iralio,, of 
fibl'in ~o""ntiajjy aITe,," ll", rau' or Inol"'''yl" mi gmlH'" into Ih,' g"]' (C,a"o 19R(;)_ 11 i, 
lik" ly te,) t hnt t h" fragi li t)- of th e fihri n also ""nlfibutec1 to tile exll'~me variability ""en in the 
fihrin iayen after the implantation 
The po;siL ilily oI cranoIe'''lllg Inor.<X:yl", wilh " ,R:-li\ i" o"l"r ,<, inh iL.l PDGFR-IJ "nd':or IJ, 
;nt"l~rin" (,," , h" r" '~ptn r" fnr p\)c:p_nn nr.d ,\ng-2) wae a i,,, i""",,,ga,,,], "r.d , nm e 
l'el'el'ence, in the li "" 'n\Ul'~ '-e)Xll" wcce"sl'ulll'Uul'ections of n;Gne,.;yte, \lei ng Ih" \)0'1\\ 1' 
lipusoma I lran,rection l 'ea~ent available lrom RGChe (Roche, 11811117700 I) (h ",n~LW~" 
1991\), }I>lll)- other r "porl" ta. wd '" p,'r;(!1la l eOInr"LLnical;on' wlth val-iou. ochel' 
re ""n rche", "r.d r"p') Iww"v,'r ,ug~,,", Ihal lrandecliL~ leukO<.l'le, is a [}!'Oee" of 
,'n11 <"k r "hl" ,liffic11lty ,Ill" '" lh,,;r JJlIU"" "hilit.)' I" d,'grad" j'ur"l ~" Dl\A and R:-IA. Thi'leel 
-') th~ d""i<ion ,.hal w;,h"\lt "Xl"n.-"-,, ,r. I}it,." eharacl"rlza li" r., aL)' in t 'it<! im eotigatiou 
carrieel 0111 l1 <i r. g t-,'''nsf",.tion m,,,ho,lo]ng:,- would pr"du"" p,>c,'n'lall), c"nnictin~ l'e"uit " ami 












Further Discussion and Conclusions 
The work of this thesis explores. the cooperative stimulation of Ang·2 and PDGF·BB on 
peripheral blood monocytes. When administered together in vitro, Ang-2 and PDGF.BB 
together stimulate an upregulation in fibrin: invasion and fibrinolysis, which was . absent 
when either growth factor is applied singly. Upon investigation, it was observed that the 
increase in invasive phenotype was due to the upregulation of elements of both the 
plasminogen/plasmin and the MMP systems. 
While both Ang-2 and PDGF-BB have been reported to act cooperatively with other growth 
factors (Hanahan 1997; Maisonpierre 1997; Etoh 2001; Lobov 2002; Russo 2002; Fiedler 
2006), the interaction of these two is a novel observation. Ang-2 is released from the Weibel-
Palade bodies of endothelial cells in response to a number of different factors (Fiedler 2004; 
Fiedler 2006), such as thrombin (Huang 2002), while one of the sources of PDGF-BB is 
known to be the a-granules of platelets, and is released during platelet degranulation 
(Heldin 1999). These two release mechanisms suggest a clear conjunction in the delivery of 
these two growth factors during fibrin clot formation, and the intiation of repair. This 
congruence of events also occurs during pathological remodeling situations, such as 
myocardial infarction (Frangogiannis 2006). 
Increased fibrin invasion by monocytes in response to Ang-2 and PDGF-BB could be 
inhibited by protease inhibitors of both major fibrinolytic systems. While monocytes have 
been previously reported to express many elements of ·these systems (as discussed in 1.3.2) 
(Loscalzo 1996; Bar-Or 2003; Pierleoni 2003), these studies show that in response to Ang-2 
and PDGF-BB, two membrane-bound proteins involved in pericellular fibrinolysis (Ellis 
1997; Hiraoka 1998), uPAR and MT1-MMP, were upregulated. The inhibition studies 
conducted for both uPA and its receptor uPAR further suggested their involvement in the 
Ang-2IPDGF-BB-dependent fibrin invasion. Upon examination it was noted that monocytes 
migrated through the fibrin prior to completing lysis of the clot, further suggesting that 
pericellular lysis was central to the increased fibrinolysis. Indeed, tPA, MMP3 and MMP7 -











expressed significantly in the cells under experimental conditions, further suggesting a 
pericellular fibrinolytic response. 
Both uPAR and MT1-MMP have previously been shown to be involved in the recruitment of 
monocytes to sites of inflammation (Estreicher 1990; Matias-Roman 2005). It is intriguing to 
note that MT1-MMP was found to be necessary for proper extravasation of monocytes 
through TNF-a-activatedendothelium. This suggests that Ang-2 plays a central role in 
directing the recruitment of monocytes to a site of vascular disturbance through not only 
regulating adhesion to the endothelium (Fiedler 2006), but also enabling the cell to move 
through the endothelial layer and invade the underlying matrix. Indeed, assessing thlY 
effects of Ang-2 and PDGF-BB on monocyte extravasation would potentially be an 
interesting avenue of investigation for future research. 
Although the role of MMP9 in fibrinolytic activity is not as established as those of the above 
proteins, recent studies have shown MMP9 to degrade fibrin in vitro (Hiraoka 1998), while 
increased fibrin deposits have been observed in MMP9-null mice (Lelonght 2001; Lambert 
2003). MMP9 has also been shown to affect leukocyte trafficking during inflammation 
(McQuibban 2000; Wetzler 2000; Menshikov 2004; Greenlee 2006), and is known to be 
important for leukocyte invasion, during which it is associated with integrin ~2 (Stefanidakis 
2006). It is also important to note that MMP9 has recently been proposed as an element of 
the angiogenic switch (Bergers 2000; Nozawa 2006), being highly influential in the release of 
growth factors from ECM sequestration. Therefore, the up regulation of MMP9 expression 
indicates increased induction of vessel ingrowth during wound healing. 
While Tie-2 expression has previously been reported on cells of hematopoietic lineage, such 
as neutrophils and endothelial precursor cells (Ikeda 2004; De Palma 2005; Lemieux 2005; 
Modarai 2005), no Tie-2 expression was found in monocytes under any of the conditions 
studied in these experiments. Recent reports have suggested that Tie-2 is expressed by a 
subset of monocytes (Venneri 2007), however, no data was found to support this observation. 
It is possible that differing isolation and culture techniques may explain these divergent 
results. 
Ang-2 has previously been found to interact with a number of cell types via mechanisms 
other than Tie-2 binding. Indeed, the highly conserved COOH-terminal fibrinogen-like 
domain of the angiopoietins implies a functional association with the integrin receptor family 















found to bind to surfaces coated with Ang-2 (Carlson 2001; Dallabrida 2005), and this 
adhesion was mediated by integrins av, as, fh, and ~3. Alternative evidence from cancer 
studies shows that Ang-2 is able to induce the expression of MMP2, MTI-MMP and laminin-
V in Tie-2-deficient glioma cells, of which MMP2 was seen to be mediated by Ang-2 via 
interaction with integrin av~l through the focal adhesion kinase pathway (Hu 2006). Ang-2 
binding to monocytes was investigated by immunoprecipitation, and Ang-2 was found to be 
associated to integrin ~2, a leukocyte-specific integrin (nib 2000; Grisar 2001). When an 
integrin fJ2 function-inhibiting antibody was added to the fibrin invasion assay. it was seen 
that the inhibition of integrin fJ2 function removed the Ang-2IPDGF-BB-dependent 
upregulation of fibrin invasion. This strongly suggested that the immunopreciptation results 
reflected a functional association between Ang-2 and integrin fJ2. Although integrin fJ2 has 
been previously identified as being involved in a number of different fibrinolytic mechanisms 
(as discussed in 1.3.2), when the function-inhibiting antibody was added to the control cells, 
no effect was observed. This suggested that this interaction was specific to integrin ~2 and 
Ang-2. Furthermore, the Ang-2IPDGF-BB-dependent upregulation of MT1-MMP and MMP9 
was seen to be lost during integrin fJ2 inhibition. Further research is needed, however, to 
identify the a-integrin to which integrin ~2 is associated under these circumstances, and 
therefore to further link this research in with the body of literature on integrins and 
monocyte/macrophages. 
Further analysis of the integrin ~2 immunoprecipitates revealed that uPAR was also 
associated to the integrin. While the formation of a uPAR/integrin fJ2 functional unit had 
previously been described (Simon 1996; Sitrin 1996), it was observed that in the presence of 
Ang-2, increased amounts of uPAR were associated with integrin f:}2. This, in conjunction 
with the Ang-2IPDGF-BB-dependent up regulation of uPAR expression also reported in this 
study, suggests that Ang-2 binding to integrin f32 in the presence of PDGF-BB not only causes 
an up regulation of uPAR, but also that the upregulated uPAR is physically associated with 
the Ang-2-binding integrin. The removal of Ang-2IPDGF-BB-dependent up regulation of 
MMP9 expression by inhibition of uPAR function further suggested that uPAR is integral to 
the Ang-2IPDGF-BB signaling. 
Monocytes have previously been reported to respond to PDGF-BB, and a number of studies 
have reported the expression of PDGFR-~ (Krettek 2001). Both RT-PCR and PDGFR-~ 
EIJSA analyses of PDGFR-fJ expression showed an increase in receptor expression during 












one of the ways in which Ang-2 and PDGF-BB interact to up regulate monocyte fibrinolysis is 
through the Ang-2-dependent initiation of PDGFR-~ expression on the cell surface. 
Both PDGF-BB and PDGFR-j:) have been reported to interact with integrins. PDGFR-j:) 
associates with activated insulin and integrin aaj:)l, thus potentiating the biological activity of 
PDGF in fibroblasts (Schneller 1997). PDGF-BB, on the other hand, has been found to 
influence the clustering of integrin j:)1 in SMC (Ahlen 2004), as well as inducing MMP9 
production in SMC simultaneously exposed to an integrinav~3 ligand (Bendeck 2000). 
However when the integrin ~2 inimunoprecipitate was analysed by PDGFR-j:) 
immunoblotting, no association was found between the two receptors. 
Figure 53 is a schematic diagram of the proposed interactions between the elements studied 
in this thesis, based on experimental results. The invasion assays showed that Ang-2 and 
PDGF-Bl} cooperatively stimulated monocyte fibrinolysis, while the inhibitor-containing 
invasion assays suggested that elements of both the plasminogen/plasmin (uPAR and uPA) 
and MMP fibrinolytic systems were involved. The involvement of both uPAR and uPA in the 
observed up regulation of monocyte fibrinolysis also suggested an increase in the conversion 
of plasminogen to plasmin. 
Immunoprecipitation and function inhibition suggested a physical and functional link 
between Ang-2, integrin !J2. Futher immunoprecipitation of integrin ~2 with uPAR. as well as 
the Ang-2-dependent upregulation of this association extended the previously reported 
association of integrin f:l2 with uPAR (Simon 1996) to include the observed Ang-2IPDGF-BB-
dependent up regulation of uPAR seen by immunoblotting. Previous investigations 
(Menshikov 2002; Menshikov 2004) have shown that MMP9 expression in monocytes is 
dependent on uPAR, and indeed, in this study, this was shown to occur under these 
experimental conditions. It therefore seemed probable that Ang-2 binding to integrin P2, via 
uPAR was responsible for the observed upregulation of MMP9. Integrin fl2 binding to Ang-2 
was also shown to upregulate the expression of PDGFR-fl, suggesting one of the ways in 
which Ang-2 and PDGF-BB act cooperatively in monocytes. Ang-2 and PDGF-BB together 
were shown to upregulate the expression of MT1-MMP, although the manner in which this 











FiIYn 53. Schematic di@gram of proposed 
interpretation of in vitro findings. Straight 
arrows indicate effect, curved arrows indicate 
upregulation. 
Previous investigations have reported the activation of both the MAPKp42144 and the AKT 
pathways through the interaction of Ang-2 with integrins (Carlson 2001; Dallabrida 2005). 
Furthermore, in fibroblasts it has been noted that PDGF-BB produced a marked, transient 
activation of the ERK class of MAPK when integrins were both aggregated and occupied by a 
ligand (Miyamoto 1996). A brief investigation into signaling pathways did not provide 
conclusive data, due to inappropriate methodologies. The inhibition of the PI-3-K pathway 
did not affect Ang-2IPDGF-BB-dependent upregulation of fibrin invasion, suggesting that 
this intracellular pathway was not involved in the reported phenomenon, although further 
investigations would need to be conducted before this could be established conclusively. 
As all the proteolytic elements described above have been previously implicated as markers 
of activation of monocytes to macrophages (Pierleoni 2003), it would be necessary to 
determine whether Ang-2 and PDGF-BB increased specific elements of the fibrinolytic 
pathways. Interestingly, when monocyte invasion into Matrigel in response to Ang-2 and 
PDGF-BB was quantified it was noted that the growth factors did not enhance the invasion 
of cells into ECM substrates. Unfortunately, as monocyte invasion into Matrigel was not 
pronounced in the control samples, it was not possible to draw conclusions from these 
experiments, although they did seem to suggest that Ang-2 and PDGF-BB did not mediate a 
broad-spectrum invasive profile, and did not seem to point towards heightened activation. 
Further experiments would need to be conducted using a variety of purified ECM substrates, 
in order to pinpoint the influence of Ang-2 and PDGF-BB on monocyte proteolysis. 











mobility, lysosomal enzyme activity and cytocidal capacity (Ross 2002) it might be useful to 
examine these aspects of activation in terms of treatment with Ang-2 and PDGF-BB. 
When the fibrin invasion assays were repeated using peripheral blood monocytes from both 
rat and baboons, it was seen that the increase in invasion in response to Ang-2 and PDGF-
BB remained similar, showing that this phenomenon is not a species-specific trait. 
Furthermore, despite references suggesting that the functions of integrins are in part 
redundant (Hynes 1992; Ruegg 2004), increased fibrinolysis in response to Ang-2 and PDGF-
BB was not seen in SCMs, ECs, or fibroblasts - all of which express PDGFR-fl, but not 
integrin f:l2. It remains to be investigated whether other f:l2-expressing leukocytes respond to 
Ang-2 and PDGF-BB in a similar manner to monocytes. 
It is worth reiterating that Ang-2 appears to function in an interconnected manner with 
other growth factors (Hanahan 1997; Fiedler 2006). It has previously been shown to 
stimulate angiogenesis in conjunction with VEGF (Maisonpierre 1997; Lobov 2002), 
inflammatory cell adhesion in conjunction with TNF-a (Fiedler 2006), and now, increased 
monocyte proteolytic invasion through PDGF-BB. This suggests that Ang-2 is a key 
regulator of wound healing, enabling other necessary growth factors to elicit their required 
response. The specific interaction between Ang-2 and integrin fl2 further strengthens the 
proposal that Ang-2 is a pro-inflammatory mediator of the initial steps of inflammation and 
pathological angiogenesis (Fiedler 2004; Lemieux 2005; Roviezzo 2005; Fiedler 2006; Imhof 
2006). Indeed, mice deficient in Ang-2 could not elicit an inflammatory response to immune 
challenge, a response restored by the administration of recombinant Ang-2 (Fiedler 2006). 
The identification of Ang-2 and PDGF-BB as factors that may be involved in the intitial 
recruitment of monocytes to a wound site suggests that they could prove to be useful, clinical 
targets in the drive towards reduction of scarring during tissue repair. Given the increasing 
importance of scar prevention in regenerative medicine, together with the recent realization 
that the presence of macrophages throughout the duration of the wound-healing response 
may not be required, suggests that manipulation of their recruitment may prove increasingly 
important for engineered tissue regeneration (Martin 2003; Duffield 2005). 
Furthermore, MMP inhibitors have been actively tested in tumour therapy over the last few 
years, but their potential in inflammatory diseases has just started to be explored (Matias-
Roman 2005). Understanding how MMPs are involved in inflammation, and what triggers 











variety of conditions. In addition, the recent observation that integrin fh-deficient mice 
exhibit blunted inflammatory responses (Pluskota 2003) could also produce a viable avenue 
of therapeutic intervention, in which the selective inhibition of integrin ~2 might provide a 
means to controlling aspects of inflammation. 
Previous in vitro Ang-2 experiments have yielded many variable results, highlighting the 
difficulty of drawing conclusions from anyone system (Jones 2003). Nevertheless, this 
thesis, together with a rapidly growing body of evidence support the involvement of Ang-2 in 
many aspects of wound healing, and highlights the importance of understanding the roles of 
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